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Human immunodeficiency virus type-1 (HIV-1) initiates infection by direct fusion of the
virus membrane with the plasma membrane of the target cell. This fusion event is a
multi-step process mediated by the envelope (Env) surface subunit gp120 and the
transmembrane subunit gp41 which anchors gp120 into the viral membrane. First the
surface subunit gp120 binds to the primary receptor CD4. This interaction promotes actin
cytoskeletal rearrangements in the target membrane that bring the chemokine coreceptor,
CCR5 or CXCR4, into close proximity for binding and induces conformational changes
in gp120 that allow it to couple to the coreceptor. Formation of the gp120-CD4coreceptor complex triggers conformational changes in the transmembrane gp41 subunit
that allows gp41 to insert into the target cell membrane, allowing lipid mixing or
hemifusion, and pore formation. Previous studies from our lab have shown that
reorganization of the actin cytoskeletal network is required for multiple steps in HIV-1
fusion. Additional data from our lab show that HIV-1 Env induced activation of Rac is
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critical for HIV-1-mediated membrane fusion. HIV-1 Env activates multiple signaling
pathways that could potentially lead to Rac activation. In an effort to determine which
signaling molecules were required both upstream and downstream of Rac activation, we
utilized small interfering RNAs (siRNAs) and various small-molecule inhibitors to
disrupt signaling pathways activated by HIV-1 Env through CD4 and coreceptors.
Published data from our lab demonstrated that the Gαq pathway, activated by CCR5, is
required for Env-mediated Rac activation and fusion. Further studies have shown that the
downstream effectors of Rac that promote fusion are components of the Wave2 signaling
complex and at least some of these signaling components are required at a posthemifusion step. Other studies from our lab and other labs, with mutant CD4 constructs,
have shown that signaling through CD4 is also playing a role in membrane fusion, most
likely at the step of forming the gp120-CD4-coreceptor complex. These results suggest a
model in which gp120 signaling though CD4 promotes gp120 binding to and signaling
through the coreceptor, which is necessary for full fusion and release of the viral
nucleocapsid into the cell’s cytosol.

iii

ACKNOWLEDGEMENTS

I would like to thank my thesis advisor Lee Ratner for his mentorship, support
and guidance throughout my graduate career.

I would like to thank the members of my thesis committee, all of whom have
provided helpful suggestions and good scientific advice. I would like to thank John
Atkinson for serving as the chair of my committee. I would also like to thank the
members of my committee for their thoughtful comments and for always being positive
mentors and role models.

I would like to thank the members of the Ratner lab, both past: Ajay, Suzanne,
Leon, Lisa, Emilia, Aneeza, and present: Nancy, Gunjan, Xiaogang, John, Dan, Anna,
Esa, and Intelly for their friendship, their patience, and their guidance. Without them I
don’t think I could have graduated.

I have been extremely lucky to have an awesome group of friends, who have
supported me throughout graduate school and given me many wonderful memories:
Suzanne Brady, Tracy Nicholson, Regina Rowe, Nancy Campbell, Van Pineda, Amanda
Troillett, Silvia Kang, Phil and Tracy Czarnec, Jamie, Matthew, all the lovely OTs and all
the other wonderful people I have met along the way.

iv

I would like to give a special thanks to my boys: Ajay Bhatia, Andy Prantner
(you will always be my #1), Victor Villalobos and Damien Fair, I miss you guys so much
and I am so grateful for all the amazing fun and trouble we got ourselves into.

I would also like to thank my friends from home who have supported me every
step of the way: Patty, Melia, Jamie, Pardis, Beatriz, Imelda, Oliver, Rachelle, Dina and
Vidhya.

I want to give a special thanks to Nikhil Daga and the Daga family. Thank you for
your many years of love and support, my life would not be the same without you.

Most importantly, I would like to thank my family, especially my parents Ray and
Pam, I don’t think I can ever say how grateful I am to have them in my life, my brother
Ryan, who has always been there for me no matter what, and my amazingly wonderful
niece Cheyanne, the world became a better place the day you were born and you will
forever be my inspiration.

Finally, I also have to thank my entire family both past and present for their
unconditional love and support.

v

TABLE OF CONTENTS
Title Page………………………………………………………………….i
Abstract……………………………………………………………………ii
Acknowledgements………………………………………………………..iv
Table of Contents………………………………………………………….vi
List of Tables and Figure…………………………………………………vii
Chapter 1…………………………………………………………………...1
Introduction
Chapter 2…………………………………………………………………..30
Antiviral Activity of a Rac GEF inhibitor Characterized with a Sensitive
HIV/SIV Fusion Assay
Chapter 3…………………………………………………………………...51
HIV Envelope Induction of the Gαq Signaling Cascade
Is Required for Virus Entry
Chapter 4………………………………………………………………….107
Role of Abl Kinase and the Wave2 Signaling Complex in HIV-1 Entry at a
Post-Hemifusion Step
Chapter 5…………………………………………………………………140
Discussion and Conclusion
References………………………………………………………………..162
vi

LIST OF TABLES AND FIGURES
Chapter 1

Page

Fig. 1: Intermediate Steps of HIV-1 Fusion

12

Fig. 2: Signaling Effectors Activated by G-protein-coupled receptors

25

Chapter 2
Table 1: Panel of Isolates Tested with Virus-Dependent Fusion and
Magi Assay

37

Fig. 1: Comparison of Env-dependent and virus-dependent fusion assays,
using an Env packaging-defective mutant proviral clone (L12E)

43

Fig. 2: Virus-dependent fusion assay results are comparable to levels of
infection of HeLa.CD4.CCR5 cells containing and LTR-lacZ reporter
using viruses with Env V3 mutations

44

Fig. 3: Virus dependent fusion assay and infection results with HIV-2
and SIVmne

45

Fig. 4: Inhibition of virus-dependent fusion with antibodies or peptide inhibitors 46
Fig. 5: Dose dependent inhibition of R5-Env dependent fusion or
infection of U87.CD4.CCR5 cells using a Rac GEF inhibitor

49

Fig. 6: Constitutively active RacV12 overcomes the effects of the
Rac GEF inhibitor

50

Chapter 3
Table 1: Summary of studies with inhibitors

80

Fig. 1: Model of signal transduction pathway elicited by Env interaction
with CCR5 required for Rac activation and membrane fusion

86

Fig. 2: Env-mediated Rac activation and cell-cell fusion are PTXinsensitive and PKA independent

88

Fig. 3: Gαq downregulation with siRNA reduces Env-mediated cell-cell fusion

90

Fig. 4: PLBβ is required for Env-mediated fusion upstream of Rac

92

vii

Fig. 5: Intracelluar Ca2+ release is required ofr Env-mediated fusion upstream
and downstream of Rac

94

Fig. 6: PKC is required for Env-mediated fusion upstream of Rac

96

Fig. 7: Env-induced fusion and Rac activation are dependent on Pyk2

98

Fig. 8: Ras is required for Env-mediated fusion upstream and downstream
of Rac

100

Fig. 9: Effect of inhibitors on virus-dependent cell fusion with HIV-1 R5
virus and infection of TZM-BL cells with HIV-1 R5 virus or A-MLVpseudotyped or VSV-G- pseudotyped HIV-1 virus

102

Fig. 10: Gαq inhibitors do not affect surface expression and localization
of CD4 and CCR5 GFP

104

Fig. 11: Pretreatment with inhibitors results in specific effects on
target molecules

106

Chapter 4
Fig. 1: Downregulation of Wave2 signaling complex with siRNA reduces
HIV-1 Env-mediated cell-cell fusion and infection

126

Fig. 2: Abl kinase is required upstream and dowstream of Rac

128

Fig. 3: Infection with HIV-1 particles but not particles pseudotyped with
A-MLV Env or VSV-G is dependent on Abl and the Wave2 signaling complex

129

Fig. 4: Abl kinase inhibitors block virus-dependent fusion and infection
at a post-hemifusion step

131

Fig. S1: Abl is activated by HIV-1 Env and pretreatment with inhibitors
and siRNA results in specific effects on target molecule

133

Fig. S2: Abl kinase inhibitors decrease Env-induced fusion, virusdependent fusion and infection of TZM-BL cells with R5 and X4 virus
in a concentration dependent manner

135

Fig. S3: Abl kinase inhibitors do not affect surface expression and
localization of CD4 and CCR5.GFP

137

Fig. S4: Abl kinase inhibitors block fusion at a post-hemifusion step

138

SI Table 1: Quantification of cell-cell hemifusion assay

139

viii

Chapter 5
Fig. 1: Mutations in the ICL2, ICL3 and a deletion in the C-terminus of
CCR5.GFP prevent its surface expression

146

Fig. 2: Deletion of CD4 C-terminus attenuates Env-dependent fusion and
Rac activation and virus-dependent fusion

157

ix

Chapter 1

Introduction
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HIV AND AIDS
Human immunodeficiency virus (HIV), a complex retrovirus and the etiologic agent of
acquired immunodeficiency syndrome (AIDS), has infected more than sixty million
people worldwide since its discovery in the early 1980s. AIDS was first identified in the
United States (US) in 1981. Clinicians in New York and California noted an unusual
clustering of rare diseases such as Kaposi sarcoma and other opportunistic infections in
young homosexual men. It soon became apparent that there was a common
immunological deficit in cell-mediated immunity, resulting from a loss of circulating
CD4+ T cells in these patients. In 1983, a research team in France published data
indicating an association between a retrovirus and AIDS. At the time there were two
known retroviruses, human T-lymphotrophic virus (HTLV)-1 and HTLV-II that were
recognized as viruses known to preferentially infect CD4+ T cells. The transmission
pattern among individuals with HTLV was similar to that seen among AIDS patients. In
1984 the French group and researchers at the National Institutes of Health (NIH) led by
Robert C. Gallo published evidence that the virus known as HIV was the cause of AIDS
(1).
The discovery of HIV as the agent that causes AIDS led to intense research in the
field of molecular virology that is still ongoing (1). This research has led to the
development of potent antiretroviral drugs, 30 of which are currently approved by the
Food and Drug Administration (FDA) to treat people infected with HIV. These drugs are
prescribed in combination in a treatment known as highly active antiretroviral therapy
(HAART). This treatment, although effective at suppressing the virus does not cure the
infection so it must be maintained for life, and prolonged use often results in significant
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toxicity. Any interruption in treatment results in the rapid rebound of replicating virus
which can lead to drug resistance. An increase in heart disease, diabetes, liver disease,
and many forms of cancer has also been observed in aging HIV-infected patients who are
receiving treatment (2). Due to the high cost of HAART therapy and the lack of an
adequate delivery method, it is not available in developing countries where it is most
needed. According to the 2008 UNAIDS/WHO report, there are 33 million people
estimated to be currently living with HIV/AIDS worldwide, with 22 million residing in
sub-Saharan Africa. Out of the 9.7 million people in immediate need of life-saving AIDS
drugs, only 2.99 million (31%) are receiving the drugs. This information clearly shows
that current treatment strategies are not sufficient and that understanding the molecular
biology of HIV and its relationship with the host is imperative to further progress in drug
discovery, vaccine development and prevention methods.

HIV GENES AND THEIR PROTEIN PRODUCTS

Lentiviruses are a separate genus of the family Retroviridae. They include equine
infectious anemia virus, visna/maedi virus, caprine arthritis-encephalitis virus, bovine
immunodeficiency virus, feline immunodeficiency virus, simian immunodeficiency virus
(SIV), and HIV. There are two types of HIV, HIV-1 and HIV-2. HIV-1 is found globally,
whereas HIV-2 is found predominantly in West Africa. HIV-2 has a longer clinical
latency period than HIV-1 and a lower morbidity rate. HIV-1 and HIV-2 have 40-60%
genomic similarity and are thought to have evolved from SIV. Lentiviruses possess a
relatively large genome, with more genes than other retroviruses. Lentiviral genomes
encode the three structural proteins common to all retroviruses, Gag, Pol, and Env, as
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well as many additional auxiliary proteins. The gag gene encodes the 55kD Gag
polyprotein precursor, and due to a ribosomal frameshift event, the 160kD Gag-Pol
polyprotein that is cleaved to produce viral protease (PR), integrase (IN), and reverse
transcriptase (RT). RT transcribes viral DNA from the viral RNA genome, IN catalyzes
integration of viral DNA into the host chromosome, and during maturation of virus
particles, PR cleaves the Gag polyprotein into matrix (MA), capsid (CA), and
nucleocapsid (NC). The product of the env gene is a monomeric glycoprotein precursor
(gp160) that is processed into the gp120 surface subunit and the gp41 transmembrane
subunit (2-4).

The auxiliary proteins, transcriptional activator (Tat) and regulator of viral gene
expression (Rev), perform regulatory functions necessary for viral replication in vitro and
in vivo. The negative effector (Nef), viral infectivity factor (Vif), viral protein R (Vpr),
and viral protein U (Vpu), are not essential for viral replication in vitro, and are known as
the accessory proteins. Tat and Rev are translated early in infection from multiply spliced
RNA, so that they may function to stimulate transcription and facilitate mRNA export,
respectively. The accessory protein Nef is also translated early from multiply spliced
RNA, so that it may induce signaling pathways that enhance viral replication. Nef
promotes the production and release of more infectious virions by activating T cells,
activating expression of FasL which induces apoptosis in cytotoxic T cells that express
Fas, and by downregulating expression of CD4 and major histocompatibility complex
(MHC) class I molecules on the cell surface. Nef also inhibits apoptosis in the infected
cell by inhibiting p53 and by blocking Fas and TNFR death signaling pathways (2, 3).
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The rest of the accessory proteins, Vif, Vpr, Vpx, and Vpu are translated late in
infection from singly spliced mRNAs. Vif is required early in infection to stabilize the
reverse transciption complex (2, 3). Vpr is associated with the nucleocapsid of the virion
and has multiple functions in the cell. Vpr promotes G2 cell cycle arrest, plays a role in
reverse transcription, promotes entry of viral DNA into the nucleus, regulates apoptosis
and transactivates the HIV-LTR (5). The HIV-2 and SIV genomes encode the accessory
protein Vpx in addition to Vpr. Similar to Vpr, Vpx is associated with the nucleocapsid
and is essential for replication of SIV and HIV-2 in non-dividing macrophages. However
the role of Vpx in the HIV-1 life cycle is less clear. The current hypothesis for the role of
Vpx is that it interacts with a ubiquitin ligase complex to inactivate a restrictive host
factor in macrophages (6). The final accessory protein Vpu is unique to HIV-1 and
SIVCPZ and is involved in viral release and degradation of CD4 (2, 3).

HIV-1 LIFE CYCLE

HIV-1 entry is mediated by the envelope (Env) glycoproteins gp120 and gp41.
Entry is a multistep process that begins with binding of gp120 on the virion surface to the
receptor CD4 on the surface of the target cell. This gp120-CD4 interaction induces
conformational changes in the gp120/gp41 complex that expose coreceptor binding
regions of gp120 and regions of gp41 necessary for insertion into the membrane. Next,
one of two chemokine coreceptors, CCR5 or CXCR4, is localized to the binding site and
gp120 binds the coreceptor, leading to dissociation of gp120 and gp41. Subsequently the
fusion peptide gp41 is inserted into the target membrane leading to establishment of the
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fusion pore and pore expansion (4, 7). The process by which HIV-1 virions enter the host
cell will be discussed in great detail below.

Once fusion occurs and the NC is released inside the cell, viral uncoating occurs,
revealing the reverse transcription complex. This complex includes the diploid viral
positive sense RNA genome, tRNAlys primer, RT, IN, MA, NC, Vpr and various host
proteins. Phosphorylated MA then facilitates docking of this complex on actin
microfilaments which is necessary for DNA synthesis. Completion of reverse
transcription results in double stranded DNA that assembles with IN, MA, Vpr, RT, and
host proteins to form the preintegration complex (PIC), which is then transported on
microtubules to the nucleus. The PIC has a 28nm radius making it approximately the
same size as a ribosome and making it twice the size of the center aqueous channel in the
nuclear pore, indicating that nuclear import is not a simple process. Many of the proteins
in the PIC have nuclear targeting signals, so these proteins could be functioning in a
cooperative manner to facilitate import or they could be playing unique roles based on the
target cell. Once the PIC is inside the nucleus, integration of viral DNA into the host
chromosome is mediated by IN, and this establishes a functional provirus. Alternatively,
the ends of the viral DNA may be joined to form 2-LTR circles, the virus may undergo
homologous recombination resulting in a single LTR circle, or the viral DNA may autointegrate into itself. None of these processes result in production of infectious virus;
however these circular forms may be transcriptionally active leading to production of Tat
and Nef (2, 3).
Once the viral DNA is integrated, it is transcribed into proviral mRNAs, and the
mRNA is transported to the cytoplasm. Transcription of viral DNA into mRNA is a
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multi-step process involving both host and viral proteins. First, the host-cell transcription
machinery transcribes short nonpolyadenylated transcripts that form an RNA stem loop
called the transactivation response (TAR) element. In association with the cellular protein
cyclin T1, the viral protein Tat binds TAR and recruits cyclin-dependent kinase 9 (Cdk9)
and other activating host proteins to the HIV LTR, where they form the positive
transcription-elongation factor b (P-TEFb) complex. The P-TEFb complex positively
regulates the host RNA polymerase II, allowing efficient elongation of the viral genome.
During the transcription process, more than a dozen specific transcripts are generated.
Some of these transcripts are unspliced or singly sliced and they stay in the nucleus,
whereas the multiply spliced transcripts that encode Nef, Tat, and Rev are transported
into the cytoplasm early in infection (2, 3).
Once transcribed, the small shuttling protein Rev binds to the Rev response
element (RRE) in the env gene and in association with host proteins exports the unspliced
and singly spliced transcripts from the nucleus to the cytoplasm (2, 3). The singly spliced
transcripts encode the structural and accessory proteins Env, Vif, Vpr, and Vpu, whereas
the unspliced transcripts encode the viral RNA genome, Gag-Pol mRNA, and premRNA. Once in the cytoplasm Gag and Gag-Pol polyprotein precursors are translated by
cytoplasmic ribosomes, Env mRNA is translated by ribosomes bound to the endoplasmic
reticulum (ER), and full-length RNA molecules become encapsidated as progeny viral
genomes. Gag and Gag-pol precursors are transported to the plasma membrane by
multivesicular bodies, whereas the Env proteins are transported through the Golgi
apparatus where they are glycosylated and cleaved to form the mature gp120 + gp41
complex, and delivered to the plasma membrane. At the plasma membrane myristoylated
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Gag associates tightly with the inner leaflet of the membrane, oligomerizes with
additional Gag molecules, and recruits Env gp120 and gp41 proteins as trimers to the site
of assembly. Also recruited to the site of assembly are two copies of the viral RNA
genome, Vpr, and Nef which are then encapsidated. Formation of the immature HIV
capsid requires approximately 1,500 Gag polyproteins. The host protein human ATPbinding protein HP68 acts a molecular chaperone for Gag, mediating conformational
changes in Gag necessary for the assembly of HIV capsid. Once assembled at the plasma
membrane the virions bud from the surface of the cell. This process involves the host-cell
budding machinery and is directed by Gag. At this point the immature virion is
noninfectious; maturation requires that PR cleave Gag and Gag-Pol, at which point Gag
molecules rearrange to form mature infectious virus which involves condensation of the
virion cores (2, 3).
HIV-1 ENTRY
HIV-1 enters cells by fusion at the plasma membrane and endocytosis, and it is
thought that only fusion at the plasma membrane leads to productive infection (2).
However, a recent study has shown that complete HIV-1 fusion can occur in endosomes
resulting in efficient infection (8). Fusion at both the plasma membrane and in endosomes
is mediated by the Env glycoproteins expressed on virions and CD4 and coreceptors
expressed on the target cell surface. On the virion gp120 is organized into trimeric spikes
that associate noncovalently with trimeric gp41 which anchors gp120 into the viral
membrane (4). HIV-1 fusion is a complicated process that is dependent on actin
cytoskeleton rearrangements in the target cell and multiple conformational changes in
Env. The initial attachment of the mature virion to the target cell is due to the interaction
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of positively charged regions on Env with negatively charged heparan sulfate
proteoglycans. This attachment brings gp120 into close proximity to the primary receptor
CD4 (4, 9). Gp120 then binds to CD4 and this engagement induces conformational
changes in the gp120/gp41complex and actin cytoskeleton rearrangements in the target
cell. Multiple regions of gp120 undergo conformational changes upon binding to CD4.
One set of conformational changes results in exposure of the coreceptor binding domain
on gp120. This domain includes conserved epitopes near or within the bridging sheet and
the V3 loop. CD4 binding has been implicated in promoting exposure of the bridging
sheet by moving the V2 loop. Additional conformational changes occur in the C1-C4/5
regions of gp120 that are occluded due to gp41 interactions. CD4 binding also promotes
conformational changes in gp41 that induce formation and exposure of the gp41 prehairpin intermediate (4). The actin cytoskeleton rearrangements induced in the target cell
by CD4 binding promotes recruitment of chemokine receptors CXCR4 or CCR5,
cholesterol, ganglioside GM1, adhesion molecules, and GPI-anchored proteins to contact
sites (10, 11). Once the coreceptor binding site on gp120 is exposed and the coreceptor is
in close proximity gp120 can bind to coreceptor. Binding of gp120 to the coreceptor
induces signaling through the coreceptor that results in actin cytoskeleton rearrangements
necessary for fusion. Binding to the coreceptor also induces additional conformational
changes in gp41 and subsequent insertion of the hydrophobic N-terminus of gp41 into the
target membrane (4, 12).
To follow gp41 progression through intermediate conformations, the
formation/exposure of novel gp41 epitopes has been assessed by antibody reactivity or by
binding measurment of gp41-derived peptides that are complementary to the heptad
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repeat region (HR) 1 and HR2 domains of gp41 (7, 13-21). Intermediate conformations
where HR domains are exposed after binding to CD4 and coreceptor and prior to sixhelix bundle (6HB) formation are referred to as pre-bundles (7). During fusion gp41 folds
into three intermediate prebundle conformations that mediate different steps of membrane
fusion before folding into a stable 6HB as depicted in Figure 1. The first gp41 early
prebundle forms after gp120 binding to CD4. Further conformational changes in gp120
and gp41 occur after binding to coreceptors which result in dissociation of gp120 and
gp41. At this stage HR1 and HR2 of gp41 are exposed. Additional folding of gp41 results
in formation of a second bridging prebundle that inserts itself into the target cell’s plasma
membrane and further folding of gp41 into the fusogenic intermediate results in
hemifusion (lipid mixing). The energy from the final folding of gp41 into the 6HB
conformation is thought to facilitate pore formation and enlargement while the 6HB,
which forms after pore formation, is though to prevent pore closure. In the 6HB
conformation the HR2 domains are packed in antiparallel orientation against the trimeric
HR1 coiled coil and this interaction forms a thermodynamically stable 6HB structure (7,
22, 23). The actin cytoskeleton rearrangements induced by Env signaling via coreceptor
in cooperation with folding of multiple gp41 intermediates into 6HBs mediates the pore
formation and enlargement necessary to allow delivery of the nucleocapsid to the
cytoplasm (7).
The initial steps of Env binding to and forming ternary complexes with CD4 and
coreceptor can occur at blocked temperatures (below 18°C when membrane fusion does
not occur) without promoting hemifusion or fusion. HR1 and HR2 domains of gp41 are
also exposed after receptor binding at blocked temperatures. The formation of the Env-
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CD4-coreceptor complexes and the intermediate gp41 conformations at this lower
temperature is referred to as temperature arrested stage (TAS). The next stage of lipid
mixing which occurs at optimal temperature can be blocked by lyso-lipids that inhibit
fusion by disfavoring monolayer bending. This arrested stage is termed lipid-arrested
stage (LAS) and is used to identify the gp41 intermediate structure that forms directly
before membrane merger (7). At this stage the gp41-derived peptides inhibit fusion
demonstrating that the 6HB has not yet formed. The gp41 conformations formed at
optimal temperature but prior to membrane merger (LAS) directly engage the target
membrane and gp41 folding into 6HB is completed after but not before pore formation
(7). Based on these observations it is thought that gp41 pre-bundles can form small
nascent fusion pores and 6HBs play a role in stabilizing and possibly expanding the pore.
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Fig. 1.

Model of intermediate steps of HIV-1 Env-induced fusion progressing

through early, bridging, and fusogenic prebundles toward 6-helix bundles that form
after opening of the fusion pore adapted from Melikyan 2008 (7). As mentioned in
the text actin cytoskeletal rearrangements are necessary in the target cell first to localize
the coreceptor to the site of gp120-CD4 binding and then again at a post-binding step
most likely to facilitate pore formation and enlargement.
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THE ACTIN CYTOSKELETON AND HIV-1 ENTRY
In the case of HIV-induced membrane fusion as well as other types of membrane
fusion, actin remodeling is probably required for at least 3 steps in the membrane fusion
process (12, 24). The actin filament capping drug that interferes with actin assembly,
Cytochalasin D (CD), inhibits Env-CD4-coreceptor complex formation (25) but has little
to no effect on fusion post-binding (12, 25). Jasplakinolide (JP), an actin filament
stabilizing drug and Lactrunculin A (LA), a monomer sequestering drug both inhibit
HIV-1 induced membrane fusion at a post-binding step (12).
Rho GTPases are involved in multiple cell signaling pathways leading to
cytoskeleton rearrangements, cell adhesion, cell polarity, endocytosis, vesicle trafficking,
progression through the cell cycle, differentiation, oncogenesis, and gene transcription
(26, 27). Rho GTPases are regulated by three groups of proteins, guanine nucleotide
exchange factors (GEFs), which increase exchange of GDP for GTP, GTPase activating
proteins (GAPs), which stimulate intrinsic GTPase activity, and guanine nucleotide
dissociation inhibitors (GDIs), which inhibit the dissociation of GDP from GTPases (2730). Membrane fusion is mediated by Rho GTPase activation of multiple downstream
effector complexes involved in cytoskeletal rearrangement (24). There are three main
subfamilies of Rho GTPases, each controlling a signal transduction pathway connecting
membrane receptors to assembly and disassembly of the actin cytoskeleton. Members of
the Rho subfamily stimulate myosin based contractility resulting in stress fibers and focal
adhesions. The Rac subfamily stimulates lamellipodia and membrane ruffles and the
Cdc42 subfamily stimulates the formation of filopodia (27, 29, 31, 32).
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Upon incubation with HIV-1 R5 Env expressing cells, target cells expressing CD4
and CCR5 underwent changes to the membrane structure resulting in membrane ruffles,
lamellipodia and filapodia extensions, indicating activation of Rac and Cdc42 in target
cells (12). However, only the downstream effects of Rac are required for Env-induced
membrane fusion, as expression of dominant negative (DN) Rac completely abolished
fusion but DN Cdc42 had no effect. On the other hand, expression of DN Rho, in target
cells caused a 40% reduction in syncytium formation and cell fusion as measured by dye
transfer, but no stress fibers were observed in cells incubated with HIV R5 Env
expressing cells (12). In addition, both Rac and Rho have been shown to be activated in
target cells incubated with HIV R5 Env expressing cells or with HIV-1, respectively (12,
33).
The study demonstrating Env-mediated RhoA activation also showed a 50%
reduction in single cycle infection and cell-cell fusion with cells expressing DN RhoA
(33). A more recent study described a role for Env-mediated filamin-A association with
CD4 and coreceptor in Env-CD4-coreceptor complex formation. Interaction of filamin-A
with CD4 and coreceptor induces phosphorylation and inactivation of cofilin through a
RhoA and ROCK dependent mechanism (11). The activation of Rac and Rho by HIVEnv and the inhibition of fusion by blocking this activation is evidence that HIV-1
induced signaling to Rho GTPases is required for fusion. However, the studies with CD,
LA and JP demonstrated that actin cytoskeleton rearrangement is necessary at multiple
steps in the membrane fusion process (12, 25). Therefore it is unclear whether Rac and
Rho are required for the same or different steps in the fusion process.
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Rho activation mediates integrin clustering and promotes actin polymerization,
however the level of actin polymerization in response to Rho is relatively small (27).
Outside of integrin clustering Rho activation has been shown to have a stabilizing effect
on the actin cytoskeleton. Its activation leads to suppression of cofilin, an actin
depolymerizing protein, and enhancement of myosin activity which results in a rigid
cortex (27, 34, 35). On the other hand, Rac is a potent activator of polymerization and has
been shown to activate multiple actin remodeling proteins leading to nucleation of actin
polymerization, and uncapping of actin filaments (35). Stimulation of Rac has also been
shown to actively antagonize Rho resulting in disassembly of stress fibers and focal
adhesions (27, 36).
Rho has also been shown to mediate inactivation of Rac via the filamin-A-binding
Rac GAP, FilGAP. FilGAP antagonizes Rac in response to phosphorylation by the
RhoA-activated ROCK, and the binding of FilGAP to filaminA is thought to position
FilGAP where upstream factors can activate and inactivate it (37). This study and the
2007 Jimenez-Baranda study describing a role for filamin A, RhoA and ROCK in EnvCD4-coreceptor complex formation, suggest that RhoA activation is required at this
initial step. Interestingly another study has shown that the C terminus of gp41 interacts
with and inhibits p115 Rho GEF, suggesting that Rho is turned off and unnecessary for
fusion events after gp41 insertion (38). Therefore it seems likely that Rho is involved in
the initial step of Env-induced fusion (Env-CD4-coreceptor complex formation) before it
is inactivated by the C-terminus of gp41, and active Rac can then mediate later steps in
membrane fusion.
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HIV-1 Env induces multiple signaling pathways through CD4 and the coreceptors
that could potentially lead to Rac activation and actin cytoskeleton reorganization (27, 32,
39-43). Preliminary studies from our lab indicate that Env-induced Rac activation is
mediated by the coreceptor as determined by inhibition of Rac activation with the CCR5
small molecule inhibitor TAK779, and the inability of X4 Env to induce Rac activation in
CCR5 expressing cells (12). Additional studies with cells lacking expression of CD4
indicate that CD4 also plays a role in Env induced Rac activation (preliminary studies in
chapter 5). Also, as described in chapter 2, a small molecule inhibitor (Rac GEF
Inhibitor) that blocks recognition of Rac by Rac GEFs dependent on a specific Rac
tryptophan (Trp56) eliminated Env-dependent fusion (44, 45). The Rac GEFs shown to
be sensitive to this inhibitor are the Rac specific GEF Tiam-1 and the Rac and RhoG
specific GEF Trio (44). Rac can also be activated and stimulated to promote actin
rearrangements by an unconventional Rac GEF DOCK180/Elmo/CrkII/p130Cas
(DOCK180 complex) (28, 39, 46-48). The DOCK180 complex requires cooperation with
multiple proteins to mediate Rac activation including RhoG and Trio, suggesting that this
GEF, in addition to Tiam-1 and Trio, would also be inhibited by the Rac GEF inhibitor
and is possibly required for Env-induced Rac activation and fusion (39).
CHEMOKINE RECEPTORS CXCR4 AND CCR5
Chemokines were first identified as chemoattractant cytokines that regulated
leukocyte trafficking to sites of inflammation. However chemokines are involved in more
than just chemotaxis. Chemokines have been shown to be involved in angiogenesis,
hematopoiesis, embryonic development, and metatasis (40) . Some chemokines and
chemokine receptors are highly specific for each other, but in general chemokine
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receptors can bind to more than one chemokine and chemokines can interact with more
than one receptor (49). CXCR4 and its ligand, stromal cell derived factor (SDF1/CXCL12) are highly specific for one another, whereas CCR5 is associated with four
inflammatory chemokines MIP-1α (CCL3), MIP-1β (CCL4), RANTES (CCL5), and
MCP-2 (CCL8), and each of these chemokines can also associate with other receptors
including CCR1, CCR4,and CCR2B (49, 50).
Activation of CXCR4 by SDF-1 induces several signaling pathways that lead to
chemotaxis, migration, and secretion of angiopoietic factors. CXCR4 is expressed by
many cell types and SDF-1, a member of the alpha family of chemokines, is a potent
lymphocyte chemoattractant but is also constitutively secreted by fibroblasts in bone
marrow, lymph nodes, lung, liver, and muscle. During embryogenesis signaling through
CXCR4 is involved in both hematopoiesis and organogenesis (51). CXCR4 is also
involved in the homing and retention of hematopoietic/lymphopoietic stem cells, pre T
and B lymphocytes in the bone marrow, and the trafficking of these cells to sites of tissue
inflammation and damage. A recent study provides evidence that SDF-1 may also signal
through another chemokine receptor, CXCR7/RDC1, but its role in cell trafficking and
migration remains undefined (51).
CCR5 is expressed on subpoplations of lymphocytes and monocytes/macrophages
in blood, primary and secondary lymphoid organs and in non-inflamed tissues. CCR5 is
also expressed in the central nervous system on astrocytes, neurons, and microglia and in
other tissue on epithelium, endothelium, vascular smooth muscle, and fibroblasts (52).
Unlike CXCR4 the role of CCR5 in vivo is not very well understood. Studies in knockout
mice have shown only minor defects in cell mediated immune responses and individuals
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that lack CCR5 surface expression on their cells due to a 32-base pair deletion in the
CCR5 gene are seemingly healthy. However, recent results show a role for CCR5 in
control of infection by West Nile virus (WNV). WNV is a mosquito-borne flavivirus that
primarily infects birds but can also infect humans. It was first isolated in humans in
Uganda in 1937 and has caused periodic outbreaks of encephalitis in Africa and Asia
since then. The first reported case in North America was in a flamingo in 1999 and by
2005 it had caused 19,369 cases of human symptomatic illness and 782 deaths in the US
alone. Symptoms associated with the virus include mild-flu like illness, and more rarely
meningitis, encephalitis, acute flaccid paralysis, and post-neurologic conditions (53, 54).
In CCR5 knockout mice, infection was uniformly fatal, in constrast to wildtype
mice where the majority of infected mice survived. In humans with the CCR5∆32
homozygous mutation, two association studies were performed with a total of four
cohorts. These studies showed that the majority of CCR5∆32 individuals infected with
WNV became symptomatic. In one of the cohorts homozygous CCR5∆32 was also
associated with death. This study also suggested that CCR5 controls WNV infection by
mediating leukocyte recruitment to the infected central nervous system (53, 55). These
studies with WNV were the first to associate an antimicrobial function with CCR5 in
humans, however in mouse models of infection CCR5 has been implicated in defense
against Trypanosoma cruzi, Toxoplasma gondii, Cryptococcus neoformans, Chlamydia
trachomatis and herpes simplex virus 1 and 2 (54).
CHEMOKINE RECEPTORS AND HIV
Although there are many different chemokine receptors that could potentially act
as coreceptors for HIV, CXCR4 and CCR5 are the receptors preferentially used in the
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human host. CCR5 is used by macrophage-tropic viral isolates (R5 viruses) and CXCR4
is used by T-cell tropic isolates (X4 viruses). Transmission of HIV is mediated by R5
viruses which are present in early stages of the disease, and preferentially infect CCR5expressing macrophages and dendritic cells. R5 viruses are particularly abundant in the
gut-associated lymphoid tissue, one of the primary sites of HIV and SIV replication. X4
viruses are present at later stages of disease progression when virus preferentially infects
CD4+ T cells (2, 56, 57).
The switch from CCR5 to CXCR4 usage by HIV-1 strains late in the infection
course is likely due to selective pressure of endogenous CCR5 chemokines. There is not
always a complete switch meaning that viruses can use both CCR5 and CXCR4, and
patients may harbor R5 viruses, X4 viruses, and dual-tropic (R5X4) viruses that can use
both CCR5 and CXCR4. In a subset of patients, during the terminal stages of disease, R5
and dual-tropic viruses seem to be lost and are replaced by pure X4 viruses. X4 variants
emerge in only about 40-60% of HIV-1 positive individuals. X4 variants are associated
with expanded cell tropism, increased viral replication rate, faster disease progression,
and the onset of AIDS. It is still not clear whether the X4 phenotype is a cause or
consequence of HIV disease progression.
HIV-1 ENTRY INHIBITORS
Currently there are two entry inhibitors, approved by the FDA for treatment of
HIV-1, maraviroc (Selzentry, Pfizer) an antagonist of CCR5, and enfuvirtide (Fuzeon,
Roche) also known as T-20, which competitively binds to HR1 on gp41 preventing
association of HR1 with HR2. The efficacy of enfuvirtide is limited by the delivery route
(subcutaneous injection) and cost. In addition, enfuvirtide is only prescribed in
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combination with HAART because it has also been shown to drive viral evolution and
resistance (9, 58, 59). There are many others entry inhibitors including attachment
inhibitors, co-receptor binding inhibitors, and fusion inhibitors that are currently in
clinical trials (9, 58, 59). The risk with inhibitors that block chemokine receptors and
CD4 is that they could also block natural ligand binding and signaling, inhibiting
essential immune cell functions.
Most coreceptor inhibitors either approved by the FDA or in clinical trials target
CCR5. The CCR5 inhibitors that are in clinical trials or beyond, block binding of CCR5
to its chemokine ligands and block CCR5-mediated signaling events. CCR5 is thought to
be a better drug target than CXCR4 because individuals harboring the naturally occurring
mutation CCR5∆32 have no known health defects due to this deletion. However as
mentioned above, CCR5 has been associated with defense against infection with WNV
and has been implicated in defense against Trypanosoma cruzi, Toxoplasma gondii,
Cryptococcus neoformans, Chlamydia trachomatis and herpes simplex virus 1 and 2 (54).
These results demonstrate that complete blockade of CCR5 could put patients at an
increased risk for numerous infections some of which are potentially fatal. In addition
there is the possibility that treatment with CCR5 antagonists would promote emergence
of X4 viruses, thereby accelerating disease progression.
Development of antagonists of CXCR4 is also complicated due to its role in
multiple processes including cerebral development, embryonic survival and B-cell
lymphopoiesis (51, 60, 61). In addition, investigations with the X4 inhibitor AMD3100
revealed that CXCR4 blockade releases myeloid cells and CD34+ stem cells from the
bone marrow into the blood, and the backup compound AMD-11070 causes abnormal
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liver histology in animals during long term dosing studies (9, 58, 59). These results show
that there are many possible disadvantages to blocking the normal functioning of
coreceptors. In addition, it is well known that the envelope glycoprotein is among one of
the most variable HIV proteins with diverse phenotypes making evolution of entry
inhibitor-resistant viruses likely. Therefore, a better understanding of chemokine
receptor and CD4 signaling, function, and mechanism of action, in response to natural
ligands and in response to infectious diseases is necessary to develop novel approaches to
limiting HIV entry without impairing the normal immune functions of CD4 and
chemokine coreceptors.
CD4 SIGNALING
The primary cellular receptor for HIV-1, CD4, is a component of the molecular
complex that facilitates the interaction of the T cell receptor (TCR) with MHC class II
molecules and is involved in TCR signaling (43, 62). The CD4 molecule is a 58 kDa
transmembrane (TM) glycoprotein that consists of a 370 amino acid containing
extracellular region, a 25 amino acid containing TM region, and a cytoplasmic tail of 38
amino acids. The extracellular region is folded into four distinct domains, D1-D4. CD4 is
post-translationally modified by formation of disulfide bonds that stabilize D1, D2, and
D4, and by N-linked glycosylation of D3 and D4. There is extensive species conservation
of the cytoplasmic tail of CD4, indicating that it is functionally important. In addition to
T lymphocytes, CD4 is expressed on monocytes/macrophages, B cells, and certain
specialized cells of the central nervous system (63). In CD4+ T cells, CD4 plays multiple
roles in response to antigens. The binding site on MHC II for CD4 is distinct from the
binding site for the TCR so CD4 can interact with the MHC class II antigen presenting
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complex (APC) at the same time as the TCR increasing responsiveness to any particular
antigen. Upon binding, CD4 undergoes conformational changes that lead to activation of
the constitutively associated Src tyrosine kinase Lck. Activated Lck phosphorylates
immunoreceptor tyrosine activation motifs (ITAMs) located on accessory chains of the
T-cell receptor complex. Once ITAMs are phosphorylated, they can bind the Syk family
kinase ZAP-70 which is then phosphorylated and activated by Lck. Once activated ZAP70 phosphorylates the linker of activation in T cells (LAT) and SLP-76.
Once these proteins are activated there are three downstream pathways that can be
induced. LAT and SLP-76 bind to and activate Tec kinases, which phosphorylate and
activate phospholipase C-γ (PLC-γ). PLC-γ then cleaves inositol phospholipids to
generate diacylglycerol (DAG) and inositol trisphosphate (IP3). LAT binds to the adaptor
protein GADS, a homolog to Grb2, which then recruits the Ras guanine nucleotide GEF
SOS-1 that then activates Ras. Another GEF, Vav, also binds to SLP-76 and LAT and
this association leads to Rac activation. Ras is also activated downstream of PLC-γ by
the GEF Ras-GRP which is activated by DAG and phorbol esters. Other downstream
effectors of PLC-γ include protein kinase C (PKC) and Calcineurin. Once activated,
PKC, Calcineurin, Ras, and Rac mediate activation of transcription factors that influence
cell proliferation and differentiation and activation of proteins involved in actin
cytoskeleton reorganization (43). Lck is not expressed in non-lymphocytes, but CD4
induces signaling through unknown proteins that lead to Ca+ flux, PLC and
phospatidylinositol-3-kinase (PI3K) activation (64).
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CHEMOKINE RECEPTOR SIGNALING
The chemokine coreceptors belong to a family of seven-transmembrane (TM)spanning-receptors termed G-protein coupled receptors (GPCRs). GPCRs share a
common structural theme that consists of an extracellular amino (N) terminal segment, a
seven TM α-helical segment forming the transmembrane core, three extracellular loops
(ECL) three intracellular loops (ICL) and a carboxy (C) terminal cytoplasmic segment.
Chemokine receptors contain an acidic N terminus, the amino acid sequence
DRYLAIVHA in ICL2, a short basic ICL3, and a cysteine in each of the 4 extracellular
domains (49). GPCRs associate with heterotrimeric (het) G proteins. The GDP bound
inactive form of Gα interacts with Gβγ and the GPCR which upon ligand binding acts as
a GEF and causes dissociation of GDP from Gα. This results in immediate association of
Gα with GTP, which leads to dissociation from Gβγ and activation of downstream
effectors of both Gα and Gβγ. Signaling is ended by hydrolysis of GTP to GDP.
There are four classes of Gα proteins including Gαi, which is sensitive to ADP
ribosylation by pertussis toxin (PTX), Gαs, Gαq, and Gα12/13. Dissociation of Gαi and
Gβγ leads to signaling by both subunits. Gαi signaling results in inhibition of adenylyl
cyclases (ACs) and subsequent inhibition of cAMP production, activation of potassium
(K+) ion channels, inhibition of Ca2+ channels, and activation of phosphodiesterases.
Signaling through the Gβγ subunit associated with Gαi also results in activation of K+ ion
channels, and inhibition of Ca2+ channels. Unlike the Gαi subunit, Gβγ activation can
also stimulate PI3K activation, PLC-β activation, activation of some ACs, and can recruit
Rho and Rac to the plasma membrane. Signaling through Gβγ is usually observed only at
high agonist concentrations. Gαs-mediated signaling results in activation of ACs and
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stimulation of cAMP production, stimulation of c-Src, and activation of the GTPases
activity of tubulin. Gαq-mediated activation of PLC-β, results in production of IP3 and
DAG, which then stimulate intracellular Ca2+ release and PKC activation. The
downstream effectors of the Gα12/13 subunits mediate activation of multiple Rho GEFs,
stimulate E-cadherin and activate a GAP of Ras (65-69). A few of the signaling effectors
of each class are illustrated in figure 2 (49).
While many GPCRs are known to associate with only one class of het G proteins,
some are capable of interacting with several classes of het G proteins. Different agonists
for one receptor and different concentrations of agonist can result in different active
states of the GPCR which are recognized by different G proteins (65). GPCRs are also
capable of signaling independently of het G proteins through interactions with β-arrestin,
a scaffolding protein involved in internalization of GPCRs, or by direct binding with the
PDZ domain of GEFs, and various other binding partners (67, 70).
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Fig. 2. Signaling effectors activated by ligation of G-protein-coupled receptors
adapted from Marinissen and Gutkind 2001 (71).
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HIV-1 SIGNALING THROUGH CD4 AND CORECEPTORS
Our lab and others have shown that HIV-1 Env mediated signaling is necessary
for membrane fusion and entry (12, 25, 33, 72-74). Although multiple signaling
components are known to be activated by HIV-1 Env through the chemokine coreceptors
and through CD4, many of these components are not required for Env-induced fusion.
Multiple studies with soluble CD4 and CD4 tailless have shown that signaling through
CD4 is not essential for Env-induced fusion (75, 76). However these studies were done in
cell lines where CD4 and coreceptor were over-expressed. More recent studies done in
primary cells and cell lines expressing physiologically relevant levels of CD4 and
coreceptor have shown that signaling through CD4 is required to promote formation of
the Env-CD4-coreceptor complex (10, 11, 25, 53, 54, 77).
PTX experiments as well as mutational studies have shown that Env-induced
fusion is independent of signaling pathways mediated by Gαi, and either the conserved
DRY motif in ICL2 or the C terminus of the coreceptors (78-85). Therefore, the receptor
signaling events that mediate fusion are induced by Env, independent of Gαi. CXCR4
and CCR5 are capable of inducing multiple PTX-insensitive pathways either through G
proteins coupled to ICL3 or ICL1, or β-arrestin. Some PTX-insensitive signaling events
that are induced by Env engagement of chemokine coreceptors or CD4 are
phosphorylation and activation of proline-rich tyrosine kinase 2 (pyk2) and p38 MAPK in
both T cells and primary macrophages (41, 78, 86-93). PTX insensitive p38 MAPK has
also been shown to be activated by Env in B cells (94). Env-induced pyk2
phosphorylation is dependent on coreceptor signaling and on extracellular Ca2+ flux (88).
CCR5 and focal adhesion kinase (FAK) phosphorylation in T cells is also PTX
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insensitive and CD4 signaling dependent (89). Furthermore, chemokine mediated PTXsensitive pathways are blocked by Env, but PTX-insensitive signaling to p38MAPK is
not (90, 94-97) suggesting that PTX-insensitive signaling pathways are important for
HIV-1 infection.
The signaling mediators required for the Env-mediated activation of these
pathways are unknown, and it is also unknown whether these pathways lead to Rac
activation and fusion. Various studies have shown that distinct intracellular signals are
elicited by Env stimulation in different cells, by Env engagement of different coreceptors,
and by Env versus the receptors’ natural ligands (49, 92, 98, 99). For example, signaling
through R5 Env but not X4 Env induces elevations of Ca2+ in lymphocytes (100). Neither
CXCL12 nor the natural ligands of CCR5 activate nonselective cation ion channels that
are opened by X4 and R5 Env (98). In addition Env activated Cl- currents more
frequently and Ca2+ activated K currents less frequently than the corresponding
chemokines (98). Futhermore, co-engagement of CD4 along with coreceptors may induce
unique signals not elicited by either receptor alone and/or the presence of CD4 may serve
to enhance signaling through coreceptors or vice versa. In previous literature it has been
shown that CD4 constitutively interacts with CCR5 and this interaction leads to
modulation of signaling via CCR5 (101, 102). CXCR4 has also been shown to interact
with CD4 in the presence and absence of Env, however the physiological role of this
interaction has not been fully determined (60, 103, 104). In addition, signaling through
CD4 via Env or via IL16 has also been shown to inhibit natural ligand mediated
chemotaxis via CXCR4 and CCR5 without altering expression of either receptor (95,
102, 105).
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It is also possible that the necessary signaling for fusion can occur through either
CD4 or coreceptor as both are capable of eliciting similar signaling pathways (49). In fact
unpublished data from the Broder lab demonstrated diminished Env-mediated syncytia in
cells expressing both tailless CD4 and tailless CXCR4 (49). In conclusion, it is possible
that although Env mediated signaling appears to be different for CXCR4 vs. CCR5, there
are similar components activated by both coreceptors that are required for Rac activation
and fusion. As demonstrated in chapter 3, X4 and R5 Env-mediated fusion with primary
cells expressing CXCR4 and CCR5 was dependent on the same pathway. It is also likely
that the interaction of CD4 with CXCR4 or CCR5 is necessary not only to facilitate
binding of Env and exposure of the fusion peptide domain but also to facilitate signaling
distinct from that induced by chemokines. Therefore, Env-induced Rac activation and
subsequent fusion could be dependent on signaling components activated by ligation to
CD4 and CXCR4 or CCR5 that are not activated by chemokines or required for host
coreceptor functions.
CONCLUSION
In conclusion, the current treatment for HIV, HAART, although effective at
suppressing the virus, does not cure the infection, it must be maintained for life, and
prolonged use often results in significant toxicity. Interruption in HAART treatment
results in the rapid rebound of replicating virus which can lead to drug resistance (2). In
addition, due to its high cost, HAART therapy is not available to 31% of the people in
immediate need of these life-saving AIDS drugs. This information clearly shows that
current treatment strategies are not enough and understanding the molecular biology of
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HIV and its relationship with the host is required to make further progress in drug
discovery.
New drug development targets the steps in entry. There are many entry inhibitors
including attachment inhibitors, co-receptor binding inhibitors, and fusion inhibitors that
are currently approved for treatment or in clinical trials (9, 58, 59). The risk with
inhibitors that block chemokine receptors and CD4 is that they could also block natural
ligand binding and signaling, inhibiting essential immune cell functions. In addition, it is
well known that the envelope glycoprotein is among one of the most variable HIV
proteins with diverse phenotypes making evolution of entry inhibitor-resisitant viruses
likely. Therefore, a better understanding of signaling through CD4 and chemokine
receptors in response to natural ligands and in response to HIV-1 Env is necessary to
develop novel approaches to limiting HIV entry without impairing the normal immune
functions of CD4 and chemokine coreceptors.
In chapter 3 we provide evidence that siRNA and inhibitors targeted to Gαq and
its downstream effectors prevent HIV-1 infection of TZM-BL cells as well as Envdependent membrane fusion in U87.CD4.CCR5 cells and PBLs and virus-dependent
membrane fusion of U87.CD4.CCR5 cells. In chapter 4, we show that the Rac mediated
actin cytoskeletal rearrangements necessary for fusion are dependent on Abl and the
Wave2 signaling complex. These results confirm and extend the implication of Racmediated actin cytoskeletal rearrangements in HIV-1 infection, and point to new potential
target molecules of HIV-1 inhibitory drugs. This strategy of using inhibitors that disable
host signaling proteins essential for pathogen survival may have a general efficacy in
developing drugs to combat pathogens that acquire drug resistance.
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Chapter 2

Antiviral Activity of a Rac GEF inhibitor Characterized
with a Sensitive HIV/SIV Fusion Assay
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Abstract
A virus-dependent fusion assay was utilized to examine the activity of a panel of HIV-1,
-2, and SIV isolates, of distinct coreceptor phenotypes. This assay allowed identification
of entry inhibitors, and characterization of an antagonist of a Rac guanine nucleotide
exchange factor, as an inhibitor of HIV-mediated fusion.
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Introduction
HIV infection is initiated by binding of envelope surface protein (SU or gp120) to CD4
and coreceptor, usually either chemokine receptor, CCR5 or CXCR4 (106). This results
in conformational changes in transmembrane envelope protein (TM or gp41), resulting in
insertion of the fusion peptide into the cell membrane, and subsequent fusion of viral and
cell membranes. HIV envelope acts as a chemokine mimic, stimulating responses such
as chemotaxis, gene transcription, and phosphorylation (107).
One target of this signaling pathway is the actin filament network (108).
Reorganization of the actin cytoskeleton is a critical feature of HIV-induced fusion (12).
This is mediated by activation of Rho family GTPases, especially Rac (27).

Rac

regulates diverse cellular processes, including intercellular adhesion, cytoskeletal
membrane ruffling and lamellipodia formation, proliferation, and gene transcription. The
active, GTP-bound form of Rac is negatively regulated by Rac GTPases (GAPs) and
positively regulated by Rac guanine nucleotide exchange factors (GEFs). Tiam1 is a
GEF specific for Rac, while others are more promiscuous in activating multiple Rho
GTPases.
In order to further elucidate the role of Rac activation in HIV fusion, we made use of a
novel virus-dependent fusion assay (12, 109-111). This is based on the ability of virus
particles to bridge at least two cells and allow transfer of cytoplasmic contents. In this
assay, we use U87 glioma cells expressing CD4 and CCR5 or CXCR4, as well as
vaccinia virus expressing T7 polymerase. The second population of U87 glioma cells,
with CD4 and CCR5 or CXCR4, is infected with a vaccinia virus with a β-galactosidase
gene under the regulation of the T7 promoter. A three hour incubation of these two cell
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populations in the presence of fusion-competent virus particles allows fusion, quantified
by β-galactosidase activity. Sensitivity of the assay was found to be enhanced by serum
starvation for 24-48 hrs prior to fusion. We show here that this assay is rapid, flexible,
and applicable to a wide range of lentivirus isolates. Moreover, this assay is useful for
examining the activity of inhibitors of receptor or co-receptor binding, fusion peptide
activity, as well as subsequent fusion activities, including Rac activation.
Results
Comparison of virus-dependent fusion and infection assays and the env-dependent
fusion assay
The virus-dependent fusion assay was directly compared to the env-dependent fusion
assay (Fig 1). For the env-dependent fusion assay, a macrophage-tropic virus, derived
from the YU2 envelope (WT), was compared to one with a mutation in gag, resulting in
substitution of L12E within the MA protein, resulting in a defect in envelope
incorporation in virus particles (112, 113).

Both proviral clones expressed similar

amount of cell-surface envelope, as demonstrated by the fusion assay (Fig 1, left-hand
bars). However, in the virus-dependent fusion assay the WT virus is capable of inducing
fusion, whereas the L12E virus, defective in envelope incorporation, fails to induce
fusion activity in this assay (Fig 1, right-hand bars).
The virus-dependent fusion and infection assays were also compared with isogenic
viruses that differed only in the sequence of their V3 envelope domain (Fig 2) (114).
Virus p2027 includes the V3 loop from R5 strain SF162. In contrast, virus IDI has a V3
loop derived from X4 strain HXB2, with the exception of substitutions at positions 27,
29, and 30 of the V3 loop that are found in SF162. Virus EIDI is identical to virus IDI
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with the exception of an additional substitution at position 25. Twenty or 50 ng of virus
was tested in the virus-dependent fusion assay, as described above. In contrast, 10 or 50
ng of virus was tested for infection of Magi.CD4.CCR5 cells (115).

The viruses

exhibited dose-dependent levels of infection and fusion in these assays, and the results
were quite similar.
The virus-dependent fusion and infection assays were also tested with a panel of 40
primary HIV isolates with differences in coreceptor tropism, as well as viruses derived
from 14 HIV-1 molecular clones, 2 HIV-2 molecular clones, and 2 SIV molecular clones
(Table 1, Fig 3). For this purpose, fusion assays were performed with U87.CD4.CCR5
and U87.CD4.CXCR4 cells, whereas infection assays were performed with Magi.CD4 or
Magi.CD4.CCR5 cells (which also express CXCR4). In each case, the virus-dependent
fusion and infection assays gave comparable results, demonstrating the utility of this
assay to screen a wide variety of laboratory and primary isolates.
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Table 1
Panel of Isolates Tested with Virus-Dependent Fusion Assay and Magi Assay
Coreceptor
Virus or Panel
Novel Properties
Usage
Primary Isolates
BaL, SF162

R5

LAI, 8 primary isolates

X4

89.6, MN

R5 X4

Sequential Isolates

R5→ X4

Isolates from diverse clades from NIH AIDS
Repository
27 longitudinal isolates from 6 HIV-infected
MACS subjects

Molecular Clones
ADA, BaL, SF162, YU2
(V3 mutant HXB2
Variable R5
chimeras)
HXB2

X4

HIV-2 (ES, ROD10)

R5 X4

SIV (mne, pbj)

R5 X4

Env chimeras and mutants that express V3 loop
or minimal sequence determinants for CCR5
usage in HXB2 backbone

Luciferase Reporters
ADA, SF162, YU2
chimeras

R5

HXB2

X4

SF2, 89.6

R5 X4

Multiple mutants with minimal sequence
determinants for R5 use

Use of virus-dependent fusion assay for studies of HIV entry inhibitors
The virus-dependent fusion and infection assays were compared in studies of entry
inhibitors that specifically block SU-mediated CD4 binding (Sim2) or CCR5 binding
(2D7), or TM-mediated fusion (T20, Fig 4). U87.CD4.CCR5 cells were pre-incubated
with antibody or drug, at the indicated concentrations for 12 hrs. For fusion assays, the
cells were also infected with either vaccinia viruses expressing β-galactosidase or T7
polymerase, as described above. The cells were then exposed to 100 ng of HIV-luc virus
(YU2-derived), for either 3 hrs for the fusion assay or 24 hrs for the infection assay (116).
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Fusion activity was determined by β-galactosidase activity, as described above.
Infectious virus was quantified by luciferase activity.

In each case, a similar

concentration-dependence was seen for inhibition, although the infection assay was
slightly less sensitive than the fusion assay at high concentrations of the anti-CCR5
antibody (2D7, Fig 4a). Similar assays were carried out with two different preparations
of T-20, a TM-fusion inhibitor, and inhibitory concentrations identified in the fusion
assay were similar to those reported previously using infection assays (Fig 4b) (117).
Identification of a Rac GEF inhibitor that blocks HIV entry
The virus-dependent fusion assay was utilized to identify novel HIV entry inhibitors.
Based on previous observations of a role of Rac activation during HIV fusion, we
examined an inhibitor of the Rac 1 GEFs, Trio and Tiam, NSC23766 (44). This drug
blocked HIV fusion, as measured by the Env-dependent fusion assay (Fig 5a,b), infection
(Fig 5c), or virus-dependent fusion (Fig 5d). The concentration range of HIV inhibitory
activity was similar to that required to block Rac activation (not shown).
In order to examine the specificity of the effects of the Rac GEF inhibitor, a
constitutively active Rac mutant, RacV12, was used to overcome the inhibitor effects by
activating the signaling pathway downstream of the Rac GEFs. RacV12 overcame the
effects on Rac activation as measured by the amount of Rac-GTP in cell lysates resulting
from HIV Env-mediated fusion (Fig 6a). No effects of RacV12 were seen on Rho
activation resulting from HIV Env mediated fusion (not shown). Moreover, RacV12
overcame the effects on Env-mediated fusion of the Rac GEF inhibitor (Fig 6b).
Conclusions
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The virus-dependent fusion assay provides a rapid, sensitive, flexible method to
examine the biological activity of laboratory or natural isolates of HIV-1, -2, or SIV, and
may have applications to many other viruses that mediate pH-independent fusion.

It

compares favorably with other assays of virus, such as one that depends upon transfer of
a virus core containing a Vpr-β-lactamase fusion protein into a target cell, which requires
a longer incubation time and FACS analyses (118, 119). It is likely that the virusdependent fusion assay can also examine pseudotyped HIV particles, to identify
inhibitors of other viral glycoproteins, as shown with the β-lactamase assay (120). This
assay has advantages over various env-dependent fusion assays, since it utilizes relevant
levels of virus-associated glycoprotein and does not require multiple receptor contacts for
initiating the activity (121).
The rapidity of the virus-dependent assay is ideal for screening panels of potential
HIV entry inhibitors, and is readily adaptable for high throughput screens. The assay is
effective at identifying inhibitory small molecules and antibodies.

It may have

applications for studies of neutralizing antibodies directed against HIV-1.

Lastly,

differences in results of virus-dependent fusion and infection assays may provide new
insights into biological differences between different virus isolates.
Rac activation is critical in other aspects of HIV biology besides entry. HIV-1 Nef
binds the DOCK-ELMO complex and p21-activated kinase 2 complex to initiate Rac
activation, inhibit lymphocyte chemotaxis, and induce merlin phosphorylation (122, 123).
Rac activation is also important for other viruses. Rho and cdc42 mediate adenovirus
endocytosis (124). Early steps in herpes simplex virus type 1 infection are dependent
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upon regulated Rac and Cdc42 signalling (125). In contrast, Rho activation facilities
Kaposi’s sarcoma herpesvirus entry (126).
The activity of the inhibitor of Rac GEF, Trio, further substantiates the role of Rac
activation in the fusion process. Additional studies of downstream mediators of Rac
activity in HIV fusion have shown no effects of chemical inhibitors of NADPH oxidase,
MEK, PI-3 kinase, or myosin light chain kinase, or dominant-negative inhibitors of Pak-2
or PI-3 kinase (our unpublished findings). It is quite possible that Rac activation through
the WAVE, Arp 2/3 complex is important for HIV fusion. Further studies of the entire
signaling pathway involved in HIV-fusion should be informative in developing new
strategies to block infection.
Materials and methods
Inhibitors
The CCR5 and CD4 monoclonal antibodies 2D7 and Sim.2, and T-20 drugs were
obtained through the AIDS Research and Reference Reagent Program, Division of AIDS,
National Institute of Allergy and Infectious Diseases (117, 127, 128).
Viruses
Recombinant vaccinia viruses expressing β-galactosidase (vCB21R), T7 polymerase
(vPT7-3), and CD4 (vCB-3) were obtained from the AIDS Research and Reference
Reagent Program, vaccinia viruses encoding an uncleaved HIV envelope (UNC; vCB16), ADA envelope (vCB-39), and HXB2 envelope (vSC60) as well as wild type vaccinia
virus (vWT) were gifts from Dr E Berger, vaccinia viruses encoding the YU2 envelope
(vSP-5) and constitutively active Rac GTPase (vRacV12) were gifts from Drs C Broder
and S Wei, respectively. HIV virus stocks were prepared by lipofection of plasmid DNA
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encoding full-length proviral molecular clones, with the Env gene of the R5 YU2, ADA,
or SF162 strains or the X4 HXB2 strain in the HIV NL4-3 backbone (12, 116), or with a
mutation in the Gag gene at residue 12 (L12E; our unpublished data). HIV Luc viruses
encode the firefly luciferase gene in place of Nef. Transfected 293T cell supernatants
were harvested after 48 hrs, filtered, and tittered for p24 antigen content by ELISA.
Twenty-seven low-passage isolates obtained at serial visits from participants in the
Baltimore site of the Multicenter AIDS Cohort Study (MACS) are also included (129).
Fusion and infection assays
The HIV-1 envelope-mediated fusion assay was modified from that developed by Dr
Berger (130). The U87 cell lines were serum-starved for 36 hrs, then infected overnight
at 37oC with vCB21R at MOI=10, and in some cases recombinant vaccinia virus
encoding the constitutively active GTPase RacV12 mutant (vRacV12). Fusion partner
BSC40 cells were infected overnight with vPT7-3 and vCB-39 encoding the ADA
envelope. Alternatively, in some experiments 106 BSC40 cells were transfected with 510 ug of proviral plasmids and infected after 1 hr with vPT7-3. Cells were then lightly
trypsinized, washed, and incubated with or without the Rac GEF inhibitor for 1 hr at
37oC. Cells (105) of each type are then mixed 1:1 in triplicate wells, incubated for 3 hrs
at 37oC, and fusion stopped by the addition of NP-40 to a final concentration of 1% and
freeze thawing at -20oC.

β galactosidase activity was determined using chlorophenol

red-β-d-galactopyoranoside (CPRG, Calbiochem) and the absorbance of each sample
determined at 579 nm (116).
The virus-dependent fusion assay was performed with free virus particles obtained 48
hrs after transfection of 293T cells (116). Virus was incubated in the presence of 20
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ug/ml DEAE-dextran with 105 U87.CD4.CCR5 cells infected for 18 hrs with vPT7-3 and
105 U87.CD4.CCR5 cells infected for 18 hrs with vCB21R. Assays were performed in
triplicate wells. Fusion activity was quantified as described above.
Infection assays were performed with Magi.CD4 or Magi.CD4.CCR5 cells and
number of blue foci determined 2 days post-infection (115). Alternatively, for some
assays, viruses with luciferase expressed in place of Nef were utilized, and luciferase
activity measured 1-2 days after infection.
Rac and Rho Activation Assays
These assays were performed with 2x106 serum starved U87.CD4.CCR5 cell mixed at
a ratio of 1:1 with BSC40 cells infected with vaccinia virus expressing Env or vWT. In
some cases, one population of U87.CD4.CCR5 cells was infected with vRacV12. Rac
GEF inhibitor was added at the indicated concentrations to the target cells 1 hr prior to
mixing and again at the time of mixing. Reactions were incubated at 37oC for 30 min,
washed two times with ice cold PBS, and cells lysed. Lysates were snap frozen and later
equal amounts of protein per well were analyzed using a G-LISA Rac activation or RhoA activation assay kit according to the manufacturer’s instructions (Cytoskeleton,
Denver, CO).
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Figures
Fig. 1. Comparison of Env-dependent and virus-dependent fusion assays, using an
Env packaging-defective mutant proviral clone (L12E). Virus particles from HIV-1
MA mutant L12E have diminished levels of envelope incorporation and demonstrate
little virus-dependent fusion activity. In contrast, transfection of these proviral clones
into BSC40 cells result in similar levels of Env-induced fusion when cells are mixed with
U87-CD4 cells.
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Fig. 2. Virus-dependent fusion assay results are comparable to levels of infection of
HeLa.CD4.CCR5 cells containing an LTR-lacZ reporter using viruses with Env V3
mutations. These viruses include amino acid substitutions in the V3 envelope domain
that affect their efficiency of use of CCR5 (114).

44

Fig. 3. Virus dependent fusion assay and infection results with HIV-2 and SIVmne.
Different amounts of virus produced from infectious molecular clones by transfection of
293T cells, were used in fusion assays with U87.CD4.CCR5 cells or infection assays with
Magi.CD4.CCR5 cells.
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Fig. 4. Inhibition of virus-dependent fusion with antibodies or peptide inhibitors. a)
Antibody neutralization studies were performed with anti-CCR5 antibody 2D7 or antiCD4 antibody Sim2.

Virus-dependent fusion assays (top) are compared to infection

assays performed for 24 hrs with U87.CD4.CCR5 cells (bottom). b) Dose-dependent
inhibition of virus-dependent fusion with T-20 was examined. Two different sources of
T-20 were obtained from the NIH AIDS Research and Reference Repository, derived
originally from DAIDS (with free N and C-terminal amino acids) and Trimeris (Nacetylated derivative). RLU, relative light units.
a
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b
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Fig. 5. Dose dependent inhibition of R5-Env dependent fusion or infection of
U87.CD4.CCR5 cells using a Rac GEF inhibitor. a) Rac GEF inhibitor was added at
the time of cell mixing or b) target U87 and/or HIV-1 ADA Env-expressing BSC40 cells
were pretreated for 1 hr, washed, and mixed prior to measuring fusion activity by βgalactosidase activity. c) Cells were infected with 10 ng p24 of HIVluc derived from
HIV-1 ADA, with drug added at the time of virus addition. Luciferase activity was
determined 16 hr post-infection, expressed as relative light units (RLU). d) Rac GEF
inhibitor was added at the time of virus in a virus-dependent fusion assay. Experiments
were repeated 3 times and representative data shown.
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Fig. 6. Constitutively active RacV12 overcomes the effects of the Rac GEF inhibitor.
a) Effects of RacV12 on the ability of the Rac GEF inhibitor to block the ability of HIV
ADA mediated fusion to activate Rac activation, as measured by the level of Rac-GTP in
the cells. b) Effects of RacV12 on the ability of the Rac GEF inhibitor to block HIV-1
ADA Env-dependent fusion.
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Chapter 3

HIV Envelope Induction of the Gαq Signaling Cascade
Is Required for Virus Entry
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Abstract
Binding of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env)
with the primary receptor CD4 and one of two coreceptors, CXCR4 or CCR5, activates a
signaling cascade resulting in Rac GTPase activation and stimulation of actin cytoskeletal
reorganizations critical for HIV-1 mediated membrane fusion. The mechanism by which
HIV-1 Env induces Rac activation and subsequent actin cytoskeleton rearrangement is
unknown. In this study, we show that Env-mediated Rac activation is dependent on the
activation of Gαq and its downstream targets. Fusion and Rac activation are mediated by
Gαq and phospholipase C (PLC), as shown by attenuation of fusion and Rac activation in
cells either expressing siRNA targeting Gαq or treated with the PLC inhibitor U73122.
Rac activation and fusion were also blocked by multiple protein kinase C (PKC)
inhibitors, by inhibitors of intracellular Ca2+ release, by Pyk2 targeted siRNA, and by the
Ras inhibitor S-trans,trans-farnesylthiosalicylic acid (FTS). Fusion was blocked without
altering cell viability or cell surface localization of CD4 and CCR5. Similar results were
obtained when cell fusion was induced by Env expressed on viral and cellular membranes
and when cell lines or primary cells were the target. Treatment with inhibitors and siRNA
specific for Gαi or Gαs signaling mediators had no effect on Env-mediated Rac activation
or cell fusion, indicating that the Gαq pathway alone is responsible. These results could
provide a new focus for therapeutic intervention, with drugs targeting host signaling
mediators, rather than viral molecules, a strategy which is less likely to result in
resistance.
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Introduction
Entry of HIV-1 is mediated by sequential binding of the trimeric HIV envelope
glycoprotein (Env) to CD4 and one of two primary chemokine coreceptors, CXCR4 or
CCR5. This binding triggers a series of conformational changes in Env that expose the
fusion peptide, which then induces the merger of viral or infected cell membranes with
target membranes (2, 4, 49). The HIV-1 Env interaction with CD4 and coreceptor also
stimulates various intracellular signaling events, similar to those initiated by their natural
ligands, such as phosphorylation of Pyk2, Ca2+ mobilization, activation of RhoGTPases,
and actin cytoskeleton rearrangements (12, 33, 49, 86, 87, 89, 99). Actin cytoskeletal
remodeling and RhoGTPases play a central role in regulating fusion of biological
membranes (24, 27). In the case of HIV-1-induced membrane fusion, activation of the
RhoGTPase Rac and subsequent actin cytoskeletal reorganizations are required for
efficient virus entry and infection (12, 25). The exact mechanism of Env-induced Rac
activation that mediates actin cytoskeletal rearrangements and induces membrane fusion
has not been investigated.
Binding of both CD4 and the coreceptors elicit signaling pathways that result in
Rac activation. However, previous results suggest that Env-induced Rac activation is
mediated via the coreceptor rather than CD4 (12). The coreceptor CCR5 is the principal
receptor for HIV-1 transmission, whereas CXCR4 binding viral isolates are primarily
found in late stages of disease (131). Coreceptors CCR5 and CXCR4 belong to a family
of seven-transmembrane-spanning receptors termed G-protein coupled receptors
(GPCRs). Ligand induced conformational changes in GPCRs leads to activation of
heterotrimeric (het) G proteins (40, 49, 67, 69). GPCRs associate with four classes of het
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G proteins, Gαi, which is sensitive to ADP ribosylation by pertussis toxin (PTX), Gαs,
Gαq, and Gα12/13 (49, 67). Most documented signaling through chemokine receptors goes
through the PTX sensitive Gαi, however fusion has been shown to be PTX insensitive
(78, 82-85). Additional studies have shown that mutation of the DRY domain of the
second intracellular loop of CCR5, the domain thought to interact with Gαi, also had no
effect on HIV-1 induced membrane fusion and entry (78, 79, 82-85). These results
suggest that Env-induced fusion is independent of signaling pathways mediated by Gαi.
However, GPCRs can induce PTX-insensitive pathways by activating other het G
proteins; by signaling independently of het G proteins through interactions with βarrestin, a scaffolding protein involved in internalization of GPCRs; or by direct binding
with the PDZ domain of guanine nucleotide exchange factors (GEFs), and various other
binding partners (67, 70).
The signaling method utilized depends on multiple factors, including cell type,
receptor, the activation state of the cell, and availability of signaling partners. In addition
to Gαi, CCR5 has been shown to couple to Gαs and Gαq and the interaction with Gαq has
been mapped to the third intracellular loop of CC chemokine receptors (49, 80, 132).
Signaling through Gαs leads to activation of adenylyl cyclase, calcium (Ca2+) channels
and cyclic AMP (cAMP)-dependent protein kinase A (PKA), whereas signaling though
Gαq results in activation of phospholipase Cβ (PLCβ), Ca2+channels, and protein kinase C
(PKC). Signaling components that participate in both Gαs and Gαq mediated pathways
and het G protein-independent pathways are activated by HIV-1 Env interaction with
CCR5 (87, 88, 133, 134). Since the likely domains involved in G protein dependent and
independent signaling pathways are also required for normal surface expression,
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generation of CCR5 molecules unable to couple with signaling intermediates was not
possible. In addition, similar signaling pathways are activated via CD4 and CCR5
suggesting that required signaling may occur through one receptor if the other is impaired
(49, 64, 89). In this study, we utilized small interfering RNA (siRNA) and various small
molecule inhibitors to determine which signaling processes are required for Rac
activation and subsequent membrane fusion (Fig. 1). The data presented demonstrate that
HIV-1 Env mediates activation of the Gαq pathway via CCR5 and this activation is
critical for HIV-1 induced cell-cell fusion.

Materials and Methods

Cell Lines. U87.CD4.CCR5 is an astroglioma cell line engineered to express CD4 and a
CCR5 construct that is tagged at its C terminus with green fluorescent protein (GFP). The
maintenance of BSC40 cells (African green monkey kidney cells), U87.CD4.CCR5 cell
lines and peripheral blood lymphocytes (PBLs) has been described (116). The TZM-BL
(also known as JC53-BL) reporter cell line was a gift from John C. Kappes. This is a
HeLa cell clone that expresses CD4, CCR5 and CXCR4 and was engineered to express
Escherichia coli β-galactosidase (β-Gal) and firefly luciferase under the transcriptional
control of the HIV-1 long terminal repeat (LTR) as described (135). TZM-BL cells were
maintained in Dulbecco's modified Eagle's medium (DMEM) containing 4 mM Lglutamine, 1 mM sodium pyruvate, 100 units of penicillin per ml, 100 µg of streptomycin
per ml (complete DMEM; Mediatech) supplemented with 15% fetal bovine serum
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(FCIII). Unless noted, tissue culture supplies were obtained from Mediatech, Manassas,
VA.

Reagents. The control siRNA constructs (non-targeting 20-25 nt siRNA designed as a
negative control), the siRNA contructs targeted to Gαq, Gαi Gαs Pyk2 and Rac and the
rabbit anti-Gαq/11, rabbit anti-Gαi, goat anti-Gαs, goat anti-Pyk2, goat anti-actin, and HRP
conjugated donkey anti-goat antibodies were obtained from Santa Cruz Biotechnology,
Inc (Santa Cruz, CA,). The siRNA constructs were transfected using GeneEraser siRNA
Transfection Reagent according to the manufacturer's instructions (Stratagene, La Jolla,
CA). The rabbit anti-Pyk2 antibody and thapsigargin were obtained from Sigma (St.
Louis, MO). The monoclonal anti-human CCR5 antibody (MAB182) was obtained from
R&D systems (Minneapolis, MN). The rabbit polyclonal anti-Pyk2 (pYpY579/580)
phosphospecific antibody and Cytochalasin D (CD) were obtained from Invitrogen
(Carlsbad, CA). 100X GDP, 100X GTPγS, and anti-Rac and anti-Ras antibodies were
obtained from Millipore (Billerica, MA). U73122 was obtained from Tocris Bioscience
(Ellisville, MO), U73343 and the cyclopiazonic acid were obtained from BioMol
International (Plymouth Meeting, PA), Xestospongin C was obtained from Cayman
Chemical (Ann Arbor, MI) dantrolene was obtained from Axxora (San Diego, CA), and
all other inhibitors were obtained from EMD Chemicals (San Diego, CA).

Viruses. Wild-type (WT) vaccinia (WR strain) and recombinant vaccinia viruses
expressing β-galactosidase (vCB21R), and T7 polymerase (vPT7-3) were obtained from
the AIDS Research and Reference Reagent Program . Vaccinia viruses encoding an
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uncleaved HIV envelope (UNC; vCB-16), ADA envelope (vCB-39), and HXB2 envelope
(vSC60), were gifts from Edward Berger, and the vaccinia virus encoding the HIV
envelope from the YU2 (vSP-5) strain and constitutively active Rac GTPase (vRacV12)
were gifts from Drs C Broder and S Wei, respectively (45). The HIV stocks used in the
following assays are prepared by the lipofection of plasmid DNA encoding full-length
proviral molecular clones, which contain the Env gene of the R5 YU2 strain in the
HIVNL4-3 backbone. To produce pseudotyped HIV-1, either amphotropic MLV (A-MLV)
envelope or vesicular stomatitis virus G (VSV-G) expressing plasmids were cotransfected
with the proviral DNA of HIV-1. Transfected 293T cell supernatants are harvested 48
hours postlipofection, filtered, and assayed for p24 antigen content by enzyme-linked
immunosorbent assay (116).

Envelope-dependent fusion assay. The HIV-1 envelope-mediated fusion assay used was
a modification of the assay developed by Dr. Berger's laboratory (130). The target cells
(PBMCs or U87.CD4.R5 cells) were serum starved for 36 hours (h) then infected
overnight with vCB21R or with recombinant vaccinia virus encoding the constitutively
active GTPase RacV12 mutant (vRacV12). Fusion partner BSC40 cells were co-infected
with vPT7-3 and vaccinia virus expressing HIV-1 Env. Cells were infected overnight
(multiplicity of infection [MOI], 10 for U87.CD4.R5 cells and BSC40 cells and MOI of
200 for PMBCs) at 37°C in complete media. The next day infected cells were lightly
trypsinized, and washed with PBS prior to mixing. Unless otherwise indicated inhibitors
were added at the indicated concentrations to U87.CD4.CCR5 cells 1 h prior to mixing
and again at the time of mixing. To allow fusion, 105 cells were mixed 1:1 with a fusion
partner in triplicate wells and incubated 3 h at 37°C. To account for any effect of
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inhibitors on vaccinia virus infection and/or on T7 polymerase function, vCB21R and
vPT7-3 co-infected cells were similarly treated with inhibitors. Concentration curves
were performed with all of the inhibitors to determine the concentration that resulted in
the maximum decrease in fusion without altering vaccinia virus infection or T7
polymerase activity. Cells were lysed by addition of NP-40 to a final concentration of 1%
and freeze thawing at -20°C. β-galactosidase activity of reaction lysates is determined
using chlorophenol red–β-d-galactopyranoside (CPRG, Calbiochem) and the absorbance
of each sample is determined at a wavelength of 570nm (12).

Western Blot Analysis. Cell lysates were prepared using mammalian cell lysis buffer
(50mM Tris-Cl, PH 8, 5mM EDTA, 100mM NaCl, 0.5% Triton X100 plus protease and
phosphatase inhibitors. Fifty micrograms of lysate was separated by 12% SDS-PAGE for
siRNA transfected samples and by 10% SDS-PAGE for Pyk2 samples and transferred to
PVDF membranes, blocked with 0.01% Tween 20 and 5% dry milk in TBS, and probed
overnight with rabbit polyclonal anti-Pyk2 (pYpY579/580) antibody (1:1,000) or for 2h
with anti-Gαq (1:500), anti- Gαi (1:500),anti-Gαs (1:500), anti-Pyk2 (1:500) or anti-Rac
(1:2,000) antibodies. After washing with 150 mM NaCl, 10 mM Tris-HCl, pH 7.5 (TBS),
horseradish peroxidase-labeled secondary antibody was added (1:1,000 donkey anti-goat
IgG; Santa Cruz, 1:2,000 dilution, goat anti-rabbit IgG; Pierce, or 1:10,000 dilution antimouse IgG; Amersham). Proteins were visualized in an Alpha Innotech (San Leandro,
CA) imager by using supersignal west femto sensitivity substrate (Pierce). The blots were
then stripped for 30 minutes at 50 degrees in stripping buffer (2% SDS, 6% Tris-Cl, PH
7.5, 0.7% β-mercaptoethanol in H2O), washed 3X in TBS, blocked and probed with anti-
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actin (1:500) or anti-Pyk2 (1:1,000) overnight, washed, and appropriate secondary
antibodies were added prior to visualization on Alpha Innotech imager.

Rac and Ras Activation Assay. Rac and Ras activation assays were performed with
2 × 106 serum-starved U87.CD4.CCR5 cells or 1 x 107 serum-starved U87.CD4.CCR5
cells per sample respectively. These cells were mixed at a ratio of 1:1 with BSC40 cells
which were infected with vCB-39 (HIVADA Env), vSC60 (HIVHXB2 Env), or WT vaccinia
virus (no Env) as described above. Inhibitors were added at the indicated concentrations
to the target cells 1 h prior to mixing and again at the time of mixing unless otherwise
noted. Reactions were incubated at 37 °C for 30 min, washed two times with ice cold
PBS, and cells were lysed. Lysates were snap frozen and later equal amounts of protein
per sample (determined by Bio-Rad Protein Assay, Bio-Rad Laboratories, Hercules, CA)
were analyzed using a G-LISA Rac activation assay kit (Cytoskeleton, Denver, CO) or
Ras activation assay kit according to the manufacturer's instructions (Cell Biolabs, San
Diego, CA), with equal amounts of protein for column loading (Bio-Rad).

Virus-dependent fusion assay. The virus-induced cell fusion assay was performed as
previously described (45). Briefly, U87.CD4.CCR5 cells were infected with vCB21R or
vPT7-3 cultured overnight, harvested by trypsin treatment, washed with PBS, and 105
cells were mixed (1:1) with DEAE-dextran (20ug/ml) and 100ng p24 HIVYU2. The assay
was performed in triplicate using a 96-well microtiter plate. Unless otherwise indicated
inhibitors were added at the indicated concentrations to both populations of
U87.CD4.CCR5 cells 1 h prior to virus addition and again at the time of virus addition.
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Fusion reactions were incubated for 3 h at 37°C and reactions were assayed for βgalactosidase activity as described (12).

JC53-BL assay. JC53BL cells were serum starved for 12h then plated overnight in
complete media in 96 well plate at 1X104 cells per well. Cells were treated for 1h with
indicated concentrations of inhibitors prior to addition of media alone or 150ng p24 of
HIVYU2 or VSVG or A-MLV-pseudotyped HIV in the presence of 20ug/ml DEAEdextran for 3h at 37°C. After 3h cells were washed 3 times with PBS and inhibitors were
added in fresh media. Following a 24h incubation cells were lysed and luciferase units
determined. Infected wells and uninfected wells with inhibitor were compared to wells
with no inhibitor.
cAMP assay. cAMP assay was performed with 5 x 106 serum-starved U87.CD4.CCR5
cells per condition. Half of the U87.CD4.CCR5 cells were pre-treated with 200ng/ml
pertussis toxin (PTX) for 18h prior to treatment with 1uM forskolin (EMD Chemicals)
and 500ng/ml CCL4 (PreproTech Inc., Rocky Hill, NJ), for 30 minutes and cAMP assay
was performed with equal amounts of protein per sample (Bio-Rad) according to
manufacturer’s instructions (Cayman Chemical, Ann Arbor, MI).

PKA assay. PepTag assay for nonradioactive detection of cAMP-dependent protein
kinase (Promega) was used with whole cell lysates prepared from U87.CD4.CCR5 cells
treated with indicated inhibitors for 1h. The assay was performed in the presence of
inhibitors with equal amounts of protein per sample (Bio-Rad) according to the
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manufacturer's protocol. PKA activity was quantitated by scanning densitometry of
phosphorylated peptide substrate resolved in 0.8% Tris · HCl agarose (pH 8.0).

Flow Cytometry and Confocal microscopy. U87.CD4.CCR5 cells were treated with
indicated concentrations of inhibitors for 3h. For detection of CD4 and CCR5,
Phycoerythrin (PE)-conjugated anti-CD4 (Q4120, Sigma), and monoclonal anti-human
CCR5 antibodies (MAB182, R&D systems, Minneapolis, MN) were used at 1:20 fold
dilution and 10ng/ml respectively. Cells were detached by incubation in 5 mM EDTA (in
PBS) for 5min at 37 °C. The incubation time for the primary and secondary (goat antimouse PE conjugated IgG F(ab)2, R&D systems) antibodies was 30 minutes on ice for
CCR5 and room temperature (RT) for CD4. Cells were then fixed with 1%
paraformaldehyde and analyzed using FACS Calibur flow cytometer (BD Biosciences)
with CellQuest software (BD Biosciences).

For confocal microscopy analysis, U87.CD4.CCR5 cells were plated on coverslips at
2X105 cells per well in 6 well plate. The next day cells were treated with indicated
concentrations of inhibitors for 3h and with CD for 15 minutes. Cells were fixed with 4%
paraformaldehyde for 30 minutes at RT, blocked with 5% BSA in PBS and stained with
anti-CD4-PE for 1h at RT (CCR5 has C-terminal GFP tag). Cells were washed with PBS
and incubated with 1:500 dilution of TO-PRO3 (Invitrogen) in permeabilization buffer
(0.2% saponin, 5% BSA in PBS) for 15 minutes. Cells were washed three times in PBS,
mounted on slides using Gold Anti-fade mounting media (Invitrogen), and 10 random
fields recorded for each condition. Cells were analyzed by confocal fluorescence
microscopy using a 510 Meta LSM confocal microscope (Zeiss, Thornwood, NY).
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Statistical Analysis. Raw data for fusion and infectivity assays were compared using
two-tailed t-test. P values are considered significant when they are <0.05, and very
significant when they are <0.01.
Results
HIV-1 Env induces Rac activation and membrane fusion via a PTX-insensitive and
PKA- independent pathway. In order to determine whether HIV-1 Env-dependent Rac
activation is mediated by Gαi/o family members, U87.CD4.CCR5 cells were pretreated
with 200ng/ml PTX, 18 hours prior to incubation with BSC40 cells expressing Env from
R5 HIVADA strain or cells lacking Env. Exposing cells to HIVADA Env in the presence or
absence of PTX resulted in a 2.25 fold increase in Rac activation as determined by
quantitation of levels of GTP-bound Rac1 purified by Rac-G-LISA (Fig. 2A). Activity of
PTX was confirmed by demonstrating that MIP-1β-mediated inhibition of forskolininduced cAMP formation was sensitive to PTX (not shown). In addition, Env-dependent
cell-cell fusion was also unaffected by treatment with PTX (78, 82-85). These results
indicate that HIV-1 stimulates Rac activity and Env-dependent cell-cell fusion by a
pathway that does not involve Gαi/o proteins.
Next, we investigated the importance of PTX-resistant G proteins Gαs and Gαq. The
major downstream effector of Gαs is adenylyl cyclase, which results in increased cellular
levels of cAMP and leads to activation of cAMP-dependent PKA. PKA is a likely
candidate for the pathway described in this study, because its activity is stimulated by
HIV-1 Env and PKA has been shown to be upstream of Rac activation and subsequent
cell migration (133). To test the role of PKA, U87.CD4.CCR5 cells were pre-treated with
two different inhibitors of PKA, inhibitory peptide PKA-I (14-22) and chemical inhibitor
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H89 and the effects were studied in a quantitative Env-dependent cell-cell fusion assay.
Although these PKA inhibitors effectively inhibited PKA activity, there was no effect on
Env-mediated cell fusion (Fig 2B). These data confirm a previous report that synthesis of
an early product of reverse transcription is not affected by PKA inhibition (136). In this
study none of the inhibitors had an effect on vaccinia virus infection or on T7 polymerase
activity at the concentrations described (not shown). In addition, H89 had no effect on
Env-dependent Rac activation (Fig 2C). In this experiment, controls included a mismatched X4 Env that did not induce Rac activation in U87.CD4.R5 cells, and a CCR5inhibitor, TAK-779, that completely inhibited Rac activation (12). These data suggest
that although the cAMP-dependent PKA pathway is activated by HIV-1 Env, it is not
required for Env-dependent Rac activation and cell-cell fusion.

HIV-1 Env mediates Rac activation and membrane fusion via G proteins from the
Gαq/11 family. In addition to Gαs, the Gαq/11 family of PTX-resistant G proteins are
known to associate with CCR5, (40, 49). To investigate the importance of the Gαq/11
family of G proteins, Gαq expression was down-regulated by RNAi in U87.CD4.CCR5
cells. Gαi and Gαs were also down-regulated to confirm that these proteins do not play a
role in Env-mediated fusion and to show that knockdown of irrelevant pathways has no
effect on Env-mediated fusion. siRNA expressing cells were then mixed with BSC40
cells expressing different Env subtypes. Maximal Rac activation was measured after 30
min, whereas maximal Env-dependent fusion was measured after 3 h (12). Transfection
of cells with Gαq-directed siRNAs decreased levels of Env-dependent cell-cell fusion by
an average of 73±3.6% for both HIV-1 R5 and Dual-tropic Env subtypes (Fig. 3A left
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panel). There was no significant fusion observed with cells expressing the X4 Env and
U87.CD4.R5 target cells with or without siRNA expression as was expected. Rac
activation was similarly decreased in cells transfected with Gαq-directed siRNAs (Fig
3C), whereas siRNA directed against Gαi and Gαs had no effect on Env-induced cell-cell
fusion or Rac activation (Fig 3A and 3C). The decrease in levels of fusion and Rac
activation correlated well with the decreased steady state level of Gαq and each siRNA
specifically downregulated its target protein with no effects on expression of the other Gα
proteins as detected by immunoblot (Fig. 3B). Vaccinia virus infection and T7
polymerase activity was also measured in siRNA transfected cells and Env-dependent
cell-cell fusion in these cells was normalized accordingly. In order to determine if Gαq
acts upstream of Rac in Env-mediated cell-cell fusion, a constitutively active Rac mutant,
RacV12, was used (Fig. 3A right panel). RacV12 overcame the effects on Env-mediated
fusion resulting from siRNA targeted to Gαq (Fig. 3A). These results show that the
effects of the siRNA are overcome by expression of a downstream signaling component.
Thus the Gαq/11 proteins are involved in HIV-1 Env-dependent cell-cell fusion upstream
of Rac activation.

HIV-1 Env-induced Rac activation and cell-cell fusion depends on PLC activation
Activation of the Gαq leads to activation of inositol phospholipid-specific
phospholipase C beta (PLCβ) which catalyzes the hydrolysis of phoshatidylinositol-4,5bisphosphate (PtdIns(4,5)P2) to produce the secondary messenger molecules
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (137). To test for the
involvement of PLC in HIV-1 induced fusion and Rac activation, U87.CD4.CCR5 cells
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were pretreated for 1h with 3µM of the PLC inhibitor U73122, or the inactive analog
U73343 prior to mixing with HIV-1 Env-expressing cells, and measurement of cell-cell
fusion and Rac activation (Fig. 4). This concentration of U73122 has previously been
shown to be specific for PLC (138), and does not increase intracellular Ca2+, whereas
higher concentrations of U73122 inhibit PLC and also lead to a release of Ca2+ from
intracellular stores (139). The PLC inhibitor U73122 suppressed Env-dependent cell-cell
fusion by an average of 73 ± 7.6% (Fig. 4A top panel) and Rac activation by 62 ± 1.5%
(Fig. 4B). The same concentration of the inactive analog U73343 had no significant
effect on fusion or Rac activation (Fig. 4). Inhibitory effects of U73122 were overcome
by expression of constitutively active RacV12 (Fig. 4A bottom panel). The
phosphatidylinositol-specific PLC inhibitor ET-18-OCH3 also suppressed Env-dependent
cell-cell fusion and Rac activation by approximately 45% (data not shown). To validate
the effects of U73122 and U73343 on Env-mediated fusion in a relevant HIV-1 target
cell, peripheral blood lymphocytes (PBLs) which express both CCR5 and CXCR4 were
used as the target cell in a quantitative Env-dependent cell-cell fusion assay. PBLs were
pretreated with U73122, U73343 and TAK-779 for 1h prior to mixing with BSC40 cells
expressing different HIV-1 Env subtypes and measurement of cell-cell fusion. The PLC
inhibitor U73122 suppressed Env-dependent cell-cell fusion in PBLs by an average of 74
± 12.8% and U73343 had no effect (Fig 4C). U73122 inhibited fusion mediated by HIV-1
R5 Envs, Dual-tropic Envs and X4 Envs suggesting that PLC is required for Env-induced
fusion mediated by both CCR5 and CXCR4. TAK-779, as expected completely inhibited
fusion mediated by HIV-1 R5 Env-expressing cells but inhibited fusion mediated by the
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Dual-tropic Env by only 59 ±5.4% and had no significant effect on fusion mediated by
X4 Env.

Intracellular Ca2+ release is required for Env-dependent cell-cell fusion and Rac
activation. The second messengers IP3 produced by hydrolysis of PtdIns(4,5)P2
activates the IP3 receptor (IP3R) on the membrane of the sarcoplasmic/endoplasmic
reticulum (SER) which opens a Ca2+ channel resulting in intracellular Ca2+ release. This
Ca2+ release leads to activation of the ryodine receptor (RyR)-operated Ca2+ channel
leading to a further increase in intracellular Ca2+. It has been shown previously that HIV1 Env interaction with chemokine receptors results in a PTX-insensitive elevation of
intracellular Ca2+ (89). However the role for intracellular Ca2+ release in HIV-1 Envmediated fusion is unknown. To test for the involvement of intracellular Ca2+ release,
multiple inhibitors of intracellular calcium release were utilized. These inhibitors include
xestospongin C (XC), which specifically blocks IP3R-induced Ca2+ release and
dantrolene, which blocks RyR-induced intracellular Ca2+ release. In addition,
thapsigargin (TG) and cyclopiazonic acid (CPA), irreversible and reversible inhibitors,
respectively, of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) pumps,
were used to deplete internal Ca2+ stores. Inhibition of the SERCA pumps prevents Ca2+
from being sequestered in the ER and it is gradually lost from the cell via passive leakage
into the cytosol and subsequent extrusion through the plasma membrane. TG and CPA
are structurally different and are unlikely to elicit similar cellular responses unless
specifically acting on SERCAs (140).
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Target cells were pretreated for 1hr with 100uM dantrolene, 10uM CPA, 2uM
TG, or 5uM XC. The cells were subsequently incubated with HIV-1 Env expressing cells
and cell-cell fusion and Rac activation were measured. Dantrolene, CPA, TG and XC
treatment reduced Env-mediated cell-cell fusion by an average of 93±2.2%, 79±2.5%,
97±2.6%, and 76±3.5% respectively in U87.CD4.CCR5 cells which is similar to the
inhibition observed in PBLs (Fig. 5A, left panel, Fig 5C). In the case of PBLs this
inhibition was observed with both CCR5 and CXCR4 tropic Envs. The effects of these
intracellular Ca2+ modulators on Env-induced Rac activation in U87.CD4.CCR5 cells
also correlate with their effects on Env-induced cell-cell fusion. Although all of these
intracellular Ca2+ modifiers inhibit Env-dependent Rac activation and cell-cell fusion to
similar degrees, the effects on cell-cell fusion were not completely reversed by
expression of RacV12 (Fig 5A, bottom panel). Env-dependent cell-cell fusion in cells
treated with dantrolene, CPA, TG, and XC and expressing RacV12 was 50±1.6%,
40±2.7%, 25±2.6%, and 32±6%, that of untreated cells, suggesting a role for intracellular
Ca2+ flux both upstream and downstream of Rac activation.

HIV-1 Env mediates Rac activation and cell-cell fusion via a PKC-dependent
pathway. Production of the second messenger DAG and the IP3 induced Ca2+ release
facilitate membrane translocation and activation of the serine/threonine kinase, PKC. To
investigate the role of PKC, U87.CD4.CCR5 cells were pre-treated for 1h with small
molecule inhibitors of PKC, Bisindolylmaleimide I (Bis I), Calphostin C, and
Chelerythrine Chloride (Ch Ch).

These cells were then incubated with HIV-1 Env

expressing cells, and cell-cell fusion was measured. The PKC inhibitors Calphostin C and
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Ch Ch reduced Env-mediated cell-cell fusion by 87±2% and 89±2% respectively whereas
Bis I only reduced fusion by 55±11% (Fig 6A, left panel). Concentration curves were
performed with all of the inhibitors used in this study to determine the concentration that
resulted in the maximum decrease in fusion without altering vaccinia virus infection or
T7 polymerase activity (data not shown). At higher concentrations Bis I had a greater
effect on Env-induced cell fusion, however at these concentrations Bis I is no longer
specific for PKC (141) (data not shown). Effects of PKC inhibition on fusion were
overcome with constitutively active RacV12 (Fig 6A, right panel).
To determine which isoform of PKC is involved in Env-mediated Rac activation
and cell-cell fusion, PKC inhibitors were used that are specific for conventional isoforms,
PKCα, PKCβ, and PKCγ, which depend on Ca2+ and DAG as well as a phospholipid for
activation. The specific PKC inhibitors used were Ro-32-0432 which is most specific for
PKCα, Go-6976 which specifically inhibits Ca2+ dependent PKC, particularly PKCα and
PKCβI, and the inhibitory peptide, PKC-I (20-28), which is a pseudosubstate that
specifically blocks PKCα and PKCβ activation. U87.CD4.CCR5 cells were pre-treated
with these inhibitors for 1h prior to mixing with HIV-1 Env-expressing cells, and
measurement of cell-cell fusion. Pretreatment with Ro-32-0432, Go-6976, and PKC-I
(20-28) decreased Env-mediated cell-cell fusion by 73±4.4%, 70±3.6% and 93±3.5%
respectively (Fig 6B, left panel). Expression of the constitutively active Rac mutant,
RacV12 overcame the effects of these PKC inhibitors on HIV-1 Env-mediated cell-cell
fusion (Fig 6B, right panel).
To determine the effects of PKC inhibitors on Rac activation U87.CD4.CCR5
cells were pre-treated with Calphostin C, Ch Ch, Go-6976 and PKC-I (20-28) for 1h prior
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to mixing with HIV-1 Env-expressing cells. Levels of suppression of Env-dependent Rac
activation correlated with levels of inhibition of Env-dependent cell-cell fusion (Fig. 6C).
In this experiment, controls included the CCR5-inhibitor, TAK-779 and a specific
RacGEF inhibitor, both of which inhibited Env-induced Rac activation (44, 45). In
addition to the data with RacV12, this suggests that PKCα and/or PKCβ is required
upstream of Rac in Env-mediated cell fusion.
To validate the effects of both general and specific PKC inhibitors on Envmediated fusion in a relevant HIV-1 target cell, PBLs were pretreated with Ch Ch and
Go-6976 for 1h prior to mixing with HIV-1 Env-expressing cells, and measurement of
cell-cell fusion. Pretreatment with Ch Ch and Go-6976 decreased Env-mediated cell-cell
fusion with HIV-1 R5 Envs, Dual-tropic Env and X4 Env by an average of 98±2.9%, and
75±2% respectively (Fig. 6D). As with the above experiments with the PLC inhibitor and
Ca2+ inhibitors these results suggest that PKC is required for Env-induced cell-cell fusion
in both cell lines and primary cells regardless of Env coreceptor preference.

HIV-1 Env-induced Pyk2 activation mediated by intracellular Ca2+ release is
required for Env-dependent cell-cell fusion and Rac activation. Previous studies have
shown that HIV-1 Env-induced intracellular Ca2+ release results in activation of the focaladhesion-related-kinase Pyk2, a downstream target of PKC (88, 89). Pyk2 is a nonreceptor tyrosine kinase that can be activated by growth factors, chemokines, and GPCR
ligands and provides a link between these ligands and multiple downstream cellular
events such as modulation of the cytoskeleton (88, 93, 142, 143). There are no available
inhibitors specific for Pyk2 so to test the role of Pyk2 in Env-induced Rac activation and
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cell-cell fusion, Pyk2 expression was down-regulated by RNAi in U87.CD4.CCR5 cells.
RNAi to Rac was used as a positive control for down-regulation of fusion. siRNA
expressing cells were then mixed with BSC40 cells expressing different Env subtypes.
Transfection of cells with Pyk2- and Rac-directed siRNAs decreased levels of Envdependent cell-cell fusion by an average of 77±5.4% and 73±2.3% respectively (Fig. 7A
left panel) and Rac activation by 83±2.5 and 81±0.6 respectively (Fig. 7C). The decrease
in levels of fusion and Rac activation correlated well with the decreased steady state level
of Pyk2 and Rac protein, and each siRNA was specific for its target protein as detected
by immunoblot (Fig. 7B). Vaccinia virus infection and T7 polymerase activity was also
measured in siRNA transfected cells and Env-dependent cell-cell fusion in these cells
was normalized accordingly. RacV12 overcame the effects on Env-mediated fusion
resulting from siRNA targeted to Pyk2 or Rac (Fig. 7A right panel) indicating that Pyk2
acts upstream of Rac in Env-mediated cell-cell fusion and that the effects of the siRNA
are overcome by Rac over-expression.

HIV-1 Env-induced Rac activation and cell-cell fusion depend on Ras activation.
Pyk2 can lead to Rac activation via multiple signaling partners; however previous data
suggests that Env-dependent Rac activation and cell-cell fusion are mediated by a Racspecific GEF (45). The Rac-specific GEF Tiam1 is directly activated by Ras and is
involved in actin cytoskeletal reorganization (42, 144). In addition, Pyk2 activates Ras
via Src downstream of Gαq providing a link between Pyk2 and Rac activation (142). To
test the role of Ras, U87.CD4.CCR5 cells were pretreated with the Ras inhibitor Strans,trans-farnesylthiosalicylic acid (FTS), which blocks membrane association of Ras,
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thus preventing Ras activation. FTS inhibition of Env-dependent cell-cell fusion was dose
dependent (Fig. 8A, left panel), and concentrations of FTS shown to abolish Envdependent cell-cell fusion in U87.CD4.CCR5 cells similarly inhibited Env-dependent
Rac activation and Env-dependent cell-cell fusion induced by BSC40 cells expressing all
HIV-1 Envs with target PBLs (Fig. 8B and Fig. 8C). However, FTS inhibition of cell-cell
fusion was not completely reversed by expression of RacV12, suggesting a role for Ras
both upstream and downstream of Rac activation (Fig. 8A, right panel).
Ras activation downstream of the chemokine receptor CCR5 has not been shown in
previous studies. To determine if Ras is activated via HIV-1 Env interaction with CCR5
and to determine if FTS inhibits this activity, U87.CD4.CCR5 cells were pretreated for
1hr with DMSO alone or with the indicated concentrations of FTS prior to mixing with
HIV-1 Env-expressing cells for 30 minutes, and measurement of Ras activation. The
activation state of Ras in cell lysates was determined by utilizing Raf-1 binding to
separate Ras-GTP from total Ras (Fig. 8D). There was a 3.6 fold increase in activated
Ras when U87.CD4.CCR5 cells were mixed with cells expressing Env from R5 HIVADA
strain (lane 6) versus U87.CD4.CCR5 cells mixed with cells expressing no HIV Env
(lane 3), or expressing Env from X4 HIVHXB2 strain (lane 4). The increase in levels of
activated Ras was prevented by TAK-779 (lane 5), suggesting that the Env interaction
with coreceptor, rather than CD4 alone, mediates Ras activation. Env-induced Ras
activation was inhibited by FTS in a dose dependent manner that correlates with
inhibition of Env-dependent cell-cell fusion (Fig. 8A, 8D lanes 7, 8, 9). These data
suggest that HIV-1 Env-induced Ras activation is required for Env-dependent Rac
activation and cell-cell fusion.
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HIV-1 Virus-dependent cell fusion and infection of TZM-BL cells is dependent on
the Gαq signaling pathway. The Env-induced cell fusion assay is a rapid, sensitive, and
flexible method used to solely study the HIV-1 Env-mediated fusion step of virus
infection. However, this assay involves over-expression of Env on the cell surface of
BSC40 cells and does not involve actual virus particles and may not reflect all the factors
that mediate fusion. Therefore, we used a virus-dependent fusion assay that is based on
the ability of virus particles to bridge two cells and allow transfer of cytoplasmic content
(45). This assay has advantages over the Env-induced cell fusion assay since it utilizes
relevant levels of virus-associated glycoprotein and is representative of virus-cell fusion
versus cell-cell fusion. In this assay we use two populations of U87.CD4.CCR5, one
population is infected with vaccinia virus expressing T7 polymerase and the second
population is infected with a vaccinia virus expressing the β-galactosidase gene under the
regulation of the T7 promoter. Both populations of U87.CD4.CCR5 cells were treated
with TAK-779, U73122, U73343, Ch Ch, Go-6976, PKC-I (20-28) dantrolene, CPA, TG,
XC, and FTS, for 1h prior to addition of fusion-competent R5 virus HIVYU2 for 3h. In this
experiment, controls included untreated and inhibitor treated cells that were not incubated
with virus (subtracted as background) and the CCR5-inhibitor, TAK-779, that completely
inhibited HIV-1 virus-dependent cell fusion. Like Env-dependent fusion, virus-induced
fusion was reduced by 73±5% in U73122 treated cells versus cells treated with DMSO
alone, and the inactive analog U73343 had no effect (Fig. 9A). The PKC inhibitors,
dantrolene, CPA, TG, XC and FTS also inhibited virus-dependent fusion at levels
comparable to inhibition seen with the Env-dependent fusion assay (Fig. 9A).
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The inhibitory effects of the various inhibitors to the downstream mediators of
Gαq on HIV-1 Env-induced cell-fusion and virus-dependent cell fusion suggest an
inhibition of virus entry. However, both the Env-dependent and virus-dependent fusion
assay only measure the initial step of virus infection, and do not look at the effect of
blocking the Gαq pathway, and subsequently fusion, on the entire virus life cycle. It is
also unknown whether the inhibitors used in this study specifically block fusion induced
by HIV-1 Env or if they block virus-induced membrane fusion and infection in general.
To test the specificity of these inhibitors for HIV-1 Env-induced entry and infection we
performed the following assay with wildtype HIVYU2 particles or with VSV-G and AMLV-pseudotyped HIV-1 virus particles. HIV-1 enters cells by inducing virus-cell
membrane fusion at the cell surface. When HIV-1 is pseudotyped with VSV-G or AMLV Env, the route of viral entry becomes clathrin-mediated or caveola-mediated
endocytosis (145, 146). To analyze the effects of these inhibitors on infection with each
of these viruses, we performed a single-cycle HIV-1 infection assay using TZM-BL
indicator cells (also known as JC53-BL cells), a derivative of HeLa cells, which express
surface levels of CD4, CCR5, and CXCR4 comparable to levels produced by peripheral
blood mononuclear cells (PBMC) (117). These cells have also been engineered to express
-galactosidase and luciferase under the control of the HIV-1 LTR, which allows
quantitative measurement of virus infectivity. TZM-BL cells were pretreated with TAK779, U73122, U73343, Ch Ch, Go-6976, dantrolene, CPA, TG, XC, and FTS, for 1hr
prior to incubation with R5 virus HIVYU2, VSV-G-pseudotyped HIV-1 or A-MLVpseudotyped HIV-1 for 3hrs. Ammonium chloride (NH4Cl) (inhibits clathrin mediated
endocytosis) and okadaic acid (OA) (inhibits caveola-mediated endocytosis) were
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included as controls for inhibition of VSV-G and A-MLV-mediated entry respectively.
After 3hrs virus was washed off, the same concentration of inhibitor was added back to
the wells, and the cells were incubated at 37° for 24hrs. Figure 9B shows that the
reduction in infection with HIVYU2 in the presence of PKC inhibitors, Ca2+ inhibitors, and
FTS was comparable to the reduction in Env-dependent and virus-dependent cell fusion
(Fig. 9B, upper left panel). The stronger inhibitory effect of U73122 seen in the reporter
gene virus infectivity assay, suggests that PLC could also play a role in post-fusion steps
in the virus life cycle (Fig. 9B, upper left panel). Interestingly, VSV-G HIV-1 infected
inhibitor-treated cells, with the exception of U73122 and NH4CL-treated cells, at
efficiencies equal to DMSO treated cells (Fig. 9B, right panel). Similarly, A-MLV HIV-1
infected inhibitor-treated cells, with the exception of U73122 and OA-treated cells, as
efficiently as it did DMSO-treated cells (Fig. 9B, lower left panel). These data indicated
that the PKC inhibitors, Ca2+ inhibitors and FTS were unable to block HIV-1 infection
when HIV-1 entered cells through VSV-G–mediated or A-MLV-mediated endocytosis. In
other words reverse transcription and nuclear import were able to proceed in the presence
of these inhibitors. VSV-G HIV-1 and A-MLV HIV-1 infection in U73122-treated cell
was inhibited by 57±8.9% and 64±3.6% respectively (Figure 9B). These results support
the suggestion PLC plays a role in post-fusion steps in the virus life cycle.
To analyze the effects of the siRNAs targeted to Gαq, Gαi ,Gαs, pyk2 and Rac on
HIV-1 infection and to show that the effects are not cell-type specific, we performed a
single-cycle HIV-1 infection assay using TZM-BL indicator cells transfected with control
siRNA and siRNA targeted to Gαq, Gαi ,Gαs, Pyk2 and Rac. Figure 9C shows that the
reduction in infection with HIVYU2 in cells expressing siRNA directed against Gαq, pyk2,

76

and Rac versus cells expressing control siRNA was comparable to the reduction in Envdependent cell-cell fusion and Rac activation (Fig. 3 and Fig. 7). Whereas, the siRNA
targeted to Gαi and Gαs had no effect (Fig. 9C). The decreased steady state level of Gαq,
Gαi ,Gαs, pyk2 and Rac protein in TZM-BL cells expressing targeted siRNA versus
control siRNA, was similar to that observed in U87.CD4.R5 cells (Fig. 3B and Fig. 7B),
and each siRNA was specific for its target protein, as detected by immunoblot (data not
shown).

Inhibitor treatment does not alter CD4/CCR5 receptor expression or surface
localization. Suppression of Env-dependent Rac activation and cell-cell fusion in the
presence of inhibitors could also be explained by a change in CD4/CCR5 receptor
localization or surface expression. To confirm that there were no changes in CD4/CCR5
receptor localization; U87.CD4.CCR5 cells were incubated with the inhibitors for 3h and
were analyzed by confocal microscopy. No gross differences in cell surface localizations
of CD4 or CCR5 were observed (Fig 10A). Blocking CCR5, with TAK-779 and Rac
activation with the RacGEF Inhibitor also had no effect on CD4/CCR5 localization. In
contrast, CD4 and CCR5 localization could be disrupted by treating cells with the actin
assembly inhibitor Cytochalasin D (CD). U87.CD4.CCR5 cells treated with inhibitors
reconstituted in DMSO were compared to DMSO treated cells, and the cells treated with
inhibitors reconstituted in H2O were compared to untreated cells.
To determine the effect of inhibitors on surface expression of the CD4/CCR5
receptors we used flow cytometric analysis (FACS). Incubation of U87.CD4.CCR5 cells
with U73122, U73343, Calphostin C, Ch Ch, PKC-I (20-28), dantrolene, FTS, and
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RacGEF Inhibitor for 3h had no effect on cell surface expression of CD4 or CCR5 (Fig.
9B). In this experiment, U87 cells that do not express CD4 or CCR5 were used as a
negative control and untreated cells were used as a positive control. TAK-779 a CCR5
inhibitor that interacts with the same domain as the anti-CCR5 antibody blocked CCR5
staining but had no effect on CD4 staining. These results confirm that at the
concentrations used in this study these inhibitors do not alter CD4/CCR5 cell surface
expression or localization.

Inhibitor treatment results in specific inhibition of target molecules.

Next we

examined whether the decrease in Env-dependent Rac activation and cell-cell fusion in
the presence of inhibitor is due to specific inhibition of the target molecule by
determining effects on PKA activity and Pyk2 phosphorylation. To measure the effect on
PKA activity, U87.CD4.CCR5 cells were pretreated for 1h with U73122, U73343,
Ch,Ch, Dantrolene, or FTS then lysed and total lysates were analyzed in the presence of
inhibitors using the PepTag assay for the non-radioactive detection of cAMP-dependent
protein. PKA activity in U73122, U73343, ChCh, and FTS-treated cells was similar to
that in untreated cells (Fig. 11A). PKC inhibitors Bis I, Calphostin C, Go-6976, and Ro32-0432 were also tested with similar results (data not shown). Treatment of
U87.CD4.CCR5 cells with dantrolene decreased PKA activity by 30% suggesting a role
for intracellular Ca2+ release in maintaining endogenous PKA activity. This decrease is
minimal compared to the 75% reduced PKA activity in cells treated with H89 (Fig. 10A).
In addition, dantrolene treated cells show a 90% decrease in Env-induced Rac activation
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and 98% decrease in cell-cell fusion whereas PKA inhibition has no effect (Fig. 6, Fig.
2B).
To determine the effect of inhibitors on HIV-1 Env-induced Pyk2 activation,
U87.CD4.CCR5 cells were pretreated with U73122, U73343, PKC inhibitors Calphostin
C, Ch Ch, Go-6976 and PKC-I (20-28), dantrolene, or FTS for 1h prior to mixing with
HIV-1 Env expressing cells for 5 min and measurement of Pyk2 phosphorylation. As
expected, inhibitors targeted to PLC, PKC and intracellular Ca2+ release that are required
upstream of Pyk2 decreased the amount of Env-induced Pyk2-phosphorylation whereas
FTS had no effect (Fig 11B).
Table 1 summarizes the effects of the PLC inhibitor, general and specific PKC
inhibitors, intracellular Ca2+ release inhibitors and FTS on Env-induced cell-cell fusion,
Rac activation, virus-dependent cell-cell fusion, infection of TZM-BL cells, PKA
activation and Pyk2 phosphorylation. These results confirm that at the concentrations
used in this study these inhibitors are specific for their target molecules.
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Table 1. Summary of studies with inhibitors
%
%
EDFb % Rac
%
% PKA
%
%Infection
EDFa with Activation VDFc
Activation Pyk2-P
RacV12

Reagent
(uM)

Target

H89 (10)

PKA

95±2

U73122 (3)

PLC

27±1 108±0.2

NTd

100±2

NT

NT

24±0.6

NT

27±2

28±5

0.8±1

105±5

19

Inactive
U73343 (3) analog for 95±1 105±0.4 104±4
U73122

99±14

96±10

111±4

97

NT

NT

NT

NT

NT

14±1

NT

NT

NT

16

17±0.4

7±4

10±2

99±4

14

27±1

24±6

33±3

NT

26

27±4 108±5

NT

NT

NT

NT

NT

7±3

114±5

6±1

0±3

2±0.2

NT

0

7±2.2 50±1.6

10±5

9±1.8

10±1.2

70±2.5

0

SERCA 21±2.5 40±1.6

19±1.2

14±3

13± 1.7

NT

NT

SERCA

21±2.2

9±1.1

0.6±0.5

NT

NT

3±0.5

NT

NT

0.3±2

92±24

97

Bis I (10)

PKC

45±11 107±8

Calphostin
C (0.5)

PKC

13±2

Ch Ch (50)

PKC

11±2 116±9

Ca2+
dependent
PKC
Ro-32- Specific for
0432 (10) PKC α & β
PKC-I (20- Specific for
28) (100) PKC α & β
RyRDantrolene Intracellular
Ca2+
(100)
release
Go 6976
(1)

CPA (10)
TG (2)
XC (5)

FTS (50)

21±4

97±7

99±3

3±2.6 25±1.6

IP3RIntracellular
24±3.5 32±1.6
Ca2+
release
Ras

0± 0.2 40 ±4

25±1.3 20±6.6

20±4

0±9

a. Values are percentages for treated reactions compared to those determined for
reactions with untreated controls.
b. EDF, Env-dependent fusion (percent fusion is the average of reactions from cells
incubated with HIVADA, HIVYU2, and HIV89.6 Env-expressing cells).
c. VDF, virus-dependent fusion
d. NT, not tested
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Discussion
Earlier studies using PTX and/or mutant CD4 and coreceptors supported the view
that signaling is not required for HIV-1 Env-mediated fusion (78, 82-85). However, it is
now apparent that signaling via CD4 and the coreceptors is far more intricate than was
thought previously. The studies suggesting that signaling is dispensable for HIV-1 entry
focused mostly on signaling through Gαi and did not show that Gαi-independent pathways
were similarly dispensable. A recent study reported that HIV-1 Env-mediated Rac
activation and subsequent reorganization of the actin filament network are required to
facilitate membrane fusion (12). Another study reported a block of entry and post-entry
events with the B oligomer of PTX, which modulates signaling independent of Gαi (147).
Additional studies reported that the tyrosine kinase inhibitor genistein blocks HIV-1
infection in primary macrophages and that RhoA and filamin A are required for the actindependent clustering of CD4 and coreceptor required for membrane fusion (11, 148,
149). These findings indicate that HIV-1 Env-induced signaling plays a crucial role in
Env-mediated membrane fusion.
In the current study, we elucidate that the signal transduction pathway of Envdependent Rac activation and membrane fusion is Gαq, PLC-β, PKC, Pyk2, and Ras
dependent (Fig 1). Env-mediated Rac activation and membrane fusion were attenuated in
cells expressing siRNA targeted to Gαq and Pyk2 and in cells treated with the PLC
inhibitor U73122 but not in cells treated with its inactive analog U73343 or in cells
expressing siRNA targeted to Gαi and Gαs. Rac activation and fusion were also blocked
by multiple PKC inhibitors, by inhibitors of intracellular Ca2+ release, and by the Ras
inhibitor FTS. The observation that siRNA and inhibitors targeting the Gαq pathway were
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inhibitory but inhibitors and siRNA targeting the Gαi or the Gαs pathway were not
indicates that this pathway is both necessary and sufficient to mediate membrane fusion.
Using a constitutively active Rac mutant, RacV12, we have shown that Gαq, PLC-β, PKC
and Pyk2, are necessary upstream of Rac whereas Ras activation and intracellular Ca2+
release are required for cell-cell fusion both upstream and downstream of Rac activation.
Importantly, the inhibitor concentrations employed in our experiments did not alter levels
of surface expression or localization of CD4 and CCR5 and also did not show any
nonspecific effects on vaccinia virus infection and T7 polymerase or on other signaling
pathways. Inhibitors to PKC, intracellular Ca2+ release and Ras suppressed Envdependent and virus-dependent fusion as well as HIVYU2 infection of TZM-BL cells to
comparable levels. On the other hand, VSV-G HIV-1 or A-MLV HIV-1 infection of
TZM-BL cells was not blocked by the PKC, intracellular Ca2+ release, and Ras inhibitors,
confirming that the block is specific to HIV-1 Env-mediated membrane fusion. The PLC
inhibitor U73122 had a greater effect on HIVYU2 infection of TZM-BL cells than on Envdependent and virus-dependent fusion and also decreased VSV-G HIV-1 or A-MLV
HIV-1 infection. Taken together this data suggests that while all the inhibitors suppress
fusion and therefore infection, U73122 can also suppress post-fusion steps in the virus
life-cycle.
It has been shown previously that binding of CCR5 by HIV-1 gp120 activates
several signaling pathways including those involving PLC and PKC activation, Ca2+
elevation, Pyk2 phosphorylation, and Rac activation (12, 90, 99). In the present study we
show that Env interaction with CCR5 also results in Ras activation. Env-induced Ras
activation is mediated specifically by CCR5, and not by CD4, because no increase in
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RasGTP was observed in U87.CD4.CCR5 stimulated with X4 Env or TAK-779 treated
cells stimulated with R5 Env. Env-dependent Ras activation provides a link between
CCR5 stimulation and Rac activation. We have shown previously that Env-mediated Rac
activation is dependent on a Rac specific GEF most likely Tiam-1 (45, 144), and Ras has
been shown to mediate Rac activation via a direct interaction with Tiam-1 or via
phospatidylinositol 3-OH kinase-mediated activation of Tiam-1 . The Env-mediated
activation of Ras upstream of Rac indicates that Tiam-1 is the RacGEF responsible for
Env-mediated Rac activation. Rac-GEFs and their interacting proteins play an important
role in selection of downstream effectors of Rac leading to regulation of different cellular
processes (150-152). Therefore, discovery of the Rac-GEF and of downstream targets of
Rac required for fusion will provide information on the mechanism of fusion and
additional targets for therapeutic intervention.
In summary, we provide evidence that siRNA and inhibitors targeted to Gαq and
its downstream effectors prevent HIV-1 infection of TZM-BL cells as well as Envdependent membrane fusion in U87.CD4.R5 cells and PBLs and virus-dependent
membrane fusion of U87.CD4.R5 cells. HIV-1 Env interaction with CCR5 stimulates a
signaling cascade involving Gαq, PLC, PKC, intracellular Ca2+ release, Pyk2 and Ras that
allows activation of Rac and subsequent actin cytoskeleton rearrangements necessary for
fusion. These results confirm and extend the implication of Rac in HIV-1 infection, and
point to new potential target molecules of HIV-1 inhibitory drugs. Multiple PKC
inhibitors are in clinical trials or are approved for clinical use to treat cancer and diabetes
including Go-6976 and Bis I used in this study (153). Multiple studies in mice with the
Ras inhibitor FTS have given promising results for the treatment of various types of
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cancer, neurofibromatosis, and kidney disease (154, 155). In addition, FTS is currently in
phase I clinical trials for hematologic malignancies (155, 156). The ability of these
inhibitors to specifically down-regulate their target molecules without adverse side
effects suggests that these inhibitors might be appropriate drugs for treatment of HIV-1
and other infectious microbes that manipulate this pathway. This strategy of using
inhibitors that disable host signaling proteins essential for pathogen survival may have a
general efficacy in developing drugs to combat pathogens that acquire drug resistance.
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Figures
Fig. 1. Model of signal transduction pathway elicited by Env interaction with CCR5
required for Rac activation and membrane fusion. This study establishes the role of
various signaling molecules during HIV-1-induced membrane fusion by examining the
effects of selective inhibitors and siRNA targeting the Gαq pathway using Rac activation,
virus entry and infection assays. Signaling molecules previously shown to be activated by
gp120 are shown in bold, and confirmed pathways are shown with a solid line (12, 87,
134, 141, 144). Suspected factors that may be involved are shown in normal font, and
potential pathways are shown with dotted lines. Ras is shown in black because it was
shown to be activated by Env in this study. Open boxes represent siRNA or selective
small molecule inhibitors used to inhibit Gαq and molecules downstream of Gαq.
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Fig. 2. Env-mediated Rac activation and cell-cell fusion are PTX-insensitive and
PKA independent. (A) U87.CD4.CCR5 cells were treated with 200ng/ml PTX for 18h
prior to and during 30 min incubation with BSC40 cells expressing no Env (grey) or Env
from HIV-1 strain ADA (black). Whole cell lysates were then analyzed by Rac specific
G-LISA activation assay (average A490 of duplicate wells ± standard deviation; data are
representative of results from three similar experiments). (B) Actin-dependent cell fusion.
Average fusion compared to untreated control reactions and detected by ß-galactosidase
activity ± standard deviation is shown. U87.CD4.CCR5 cells were infected with vaccinia
virus expressing ß-galactosidase (vCB21R) overnight, then these cells were pretreated
with DMSO alone (black) and the PKA inhibitors PKA 14-22 (grey) and H89 (black) at
indicated concentrations (uM) for 1h. A portion of these cells was mixed 1:1 with
HIVADA or HIVUNC Env-expressing cells (subtracted as background) for 3h in the
presence of inhibitors. Data are representative of results from three similar experiments
performed in triplicate. Cell fusion was normalized using untreated cells as incubated
with HIVADA Env as 100%. The rest of the cells were lysed and whole cell lysates were
analyzed for PKA activity in the presence of inhibitors. PKA (ng) based on standard
curve of A570nm of varying amounts of PKA. Results representative of three
independent experiments performed in duplicate. (C) U87.CD4.CCR5 cells were treated
for 1h with 1uM TAK-779 or 10uM H89 prior to and during 30 min incubation with
BSC40 cells expressing no Env (subtracted as background), HIVADA Env (open bars) or
HIVHXB2 Env (solid bars). Whole cell lysates were then analyzed by Rac specific G-LISA
activation assay. Average A490 of duplicate wells ± standard deviation; data are
representative of results from three similar experiments (*, P < 0.01).
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Fig. 3. Gαq down-regulation with siRNA reduces Env-mediated cell-cell fusion. (A)
Average fusion compared to untreated control reactions and detected by ß-galactosidase
activity ± standard deviation are shown. U87.CD4.CCR5 cells were transfected with
100nM control siRNA (control) or 100nM siRNA targeted against Gαq, Gαi or Gαs. 24h
post-transfection U87.CD4.CCR5 cells were serum starved. 48h post transfection the
cells were infected with vCB21R alone or with vaccinia virus encoding the constitutive active point mutant RacV12 (vRacV12) in complete media. 72 h post-transfection the
transfected U87.CD4.CCR5 were incubated with HIVUNC (subtracted as background)
HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are
representative of results from three similar experiments performed in triplicate (**, P <
0.05). Cell fusion was normalized using control siRNA transfected cells incubated with
HIVADA Env as 100%. (B) 2X105 of each population of transfected cells were lysed and
whole cell lysates were analyzed by western blot. There are three immunoblots, the lysate
from cells transfected with 100nM control siRNA (lane1) or 100nM siRNA targeted to
Gαq (lane 2), Gαi (lane 3), or Gαs (lane 4), were loaded on each immunoblot and were
initially probed with anti-Gαq (left), anti-Gαi (middle), or anti-Gαs (right), then all blots
were stripped and probed with anti-actin (bottom). The relative reduction index (RI) was
calculated as the quotient of the densitometry signal for the Gαq, Gαi or Gαs band and that
for actin (shown below), and then normalized by the ratio obtained with control siRNA
(defined as 1). Data represent results from 1of 3 experiments with similar results. (C)
U87.CD4.CCR5 cells were transfected with 100nM control siRNA (solid bars), 100nM
Gαq siRNA, Gαi siRNA, or Gαs siRNA (open bars) as described above. 72h posttransfection cells were incubated for 30 min with BSC40 cells expressing no Env
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(subtracted as background), or HIVADA Env. Whole cell lysates were then analyzed by
Rac specific G-LISA activation assay. Average A490 of duplicate wells ± standard
deviation; data are representative of results from three similar experiments (**, P < 0.05).
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Fig. 4. PLC-β is required for Env-mediated fusion upstream of Rac. Average fusion
compared to untreated control reactions and detected by ß-galactosidase activity ±
standard deviation are shown. (A) Serum starved U87.CD4.CCR5 cells were infected
with vCB21R alone, or with vRacV12 in complete media overnight. These cells were
then pretreated with DMSO alone, or 3uM of PLC-β inhibitor U73122 and its negative
analog U73343 for 1h and the inhibitors were also present during the incubation with
HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Envexpressing cells for 3h. Data are representative of results from three similar experiments
performed in triplicate (*, P < 0.01, **, P < 0.05). Cell fusion was normalized using
DMSO treated cells incubated with HIVADA Env as 100%. (B) U87.CD4.CCR5 cells
were treated for 1h with 1uM TAK-779, 3uM U73122, 3uM U73343 (open bars), or
DMSO alone (solid bars) prior to and during incubation for 30 min with BSC40 cells
expressing no Env (subtracted as background), or HIVADA Env. Whole cell lysates were
then analyzed by Rac specific G-LISA activation assay. Average A490 of duplicate wells
± standard deviation; data are representative of results from three similar experiments (*,
P< 0.01, **, P < 0.05). (C) Serum starved PBLs were infected with vCB21R in complete
media overnight. These cells were then pretreated with DMSO alone, 1uM TAK-779 or
3uM of PLC-β inhibitor U73122 and its negative analog U73343 for 1h and the inhibitors
were also present during the incubation with HIVUNC (subtracted as background)
HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are
representative of results from three similar experiments performed in triplicate (*, P <
0.01, **, P < 0.05). Cell fusion was normalized using DMSO treated cells incubated with
HIVADA Env as 100%.
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Fig. 5. Intracellular Ca2+ release is required for Env-mediated fusion upstream &
downstream of Rac. Average fusion compared to untreated control reactions and
detected by ß-galactosidase activity ± standard deviation are shown. (A) Serum starved
U87.CD4.CCR5 cells were infected with vCB21R alone, or with vRacV12 in complete
media overnight. These cells were then pretreated with DMSO alone or 100uM
dantrolene, 10uM cyclopiazonic acid (CPA), 2uM thapsigargin (TG), or 5uM
Xestospongin C (XC) for 1h and the inhibitors were also present during the incubation
with HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Envexpressing cells for 3h. Data are representative of results from three similar experiments
performed in triplicate (*, P < 0.01). Cell fusion was normalized using DMSO treated
cells incubated with HIVADA Env as 100%. (B) U87.CD4.CCR5 cells were treated for 1h
with DMSO alone (solid bars), 1uM TAK-779, 100uM dantrolene, 10uM CPA, 2uM TG,
5uM XC, or 100uM RacGEF inhibitor (open bars) prior to and during incubation for 30
min with BSC40 cells expressing no Env (subtracted as background), or Env from
HIVADA Env. Whole cell lysates were then analyzed by Rac specific G-LISA activation
assay. Average A490 of duplicate wells ± standard deviation; data are representative of
results from three similar experiments (*, P < 0.01). (C) Serum starved PBLs were
infected with vCB21R in complete media overnight. These cells were then pretreated
with DMSO alone or 100uM dantrolene, 10uM cyclopiazonic acid (CPA), 2uM
thapsigargin (TG), and 5uM Xestospongin C (XC) for 1h and the inhibitors were also
present during the incubation with HIVUNC (subtracted as background) HIVADA, HIVYU2,
HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are representative of results from
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three similar experiments performed in triplicate (*, P < 0.01). Cell fusion was
normalized using DMSO treated cells incubated with HIVADA Env as 100%.
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Fig. 6. PKC is required for Env-mediated fusion upstream of Rac. Average fusion
compared to untreated control reactions and detected by ß-galactosidase activity ±
standard deviation are shown. (A, B) Serum starved U87.CD4.CCR5 cells were infected
with vCB21R alone or with vRacV12 overnight in complete media. These cells were
then pretreated with DMSO alone or the PKC inhibitors Bisindolylmaleimide I (Bis I,
10uM), Calphostin C (0.5uM), and Chelerythrine Chloride (Ch Ch, 50uM) for 1h (A) or
pretreated with the specific PKC inhibitors Go-6976( Ca2+-dependent, 1uM), Ro-32-0432
(selective for α & β, 10uM), and PKC-I (20-28) (myristolated peptide inhibitor specific
for α & β, 100uM) for 1h (B). The inhibitors were also present during the incubation with
HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Envexpressing cells for 3h. Data are representative of results from three similar experiments
performed in triplicate (*, P<0.01, **, P < 0.05). Cell fusion was normalized using
DMSO treated cells incubated with HIVADA Env as 100%. (C) U87.CD4.CCR5 cells
were treated for 1h with DMSO alone (solid bars), 1uM TAK-779, 0.5uM Calphostin C,
50uM Ch Ch, 1uM Go 6976, 100uM PKC-I (22-28) and 100uM RacGEF inhibitor (open
bars) prior to and during incubation for 30 min with BSC40 cells expressing no Env
(subtracted as background), or HIVADA Env. Whole cell lysates were then analyzed by
Rac specific G-LISA activation assay. Average A490 of duplicate wells ± standard
deviation; data are representative of results from three similar experiments (*, P < 0.01).
(D) Serum starved PBLs were infected with vCB21R overnight in complete media.
These cells were then pretreated with DMSO alone or the PKC inhibitors Ch Ch, (50uM)
or Go-6976for 1h. The inhibitors were also present during the incubation with HIVUNC
(subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells
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for 3h. Data are representative of results from three similar experiments performed in
triplicate (*, P<0.01). Cell fusion was normalized using DMSO treated cells incubated
with HIVADA Env as 100%.
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Fig. 7. Env-induced fusion and Rac activation are dependent on Pyk2. (A) Average
fusion compared to untreated control reactions and detected by ß-galactosidase activity ±
standard deviation are shown. U87.CD4.CCR5 cells were transfected with 100nM control
siRNA (control) or 100nM siRNA targeted against Pyk2 or Rac. 24h post-transfection
U87.CD4.CCR5 cells were serum starved. 48h post transfection the cells were infected
with vCB21R alone or with vaccinia virus encoding the constitutive -active point mutant
RacV12 (vRacV12) in complete media. 72 h post-transfection the transfected
U87.CD4.CCR5 were incubated with HIVUNC (subtracted as background) HIVADA,
HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are representative of
results from three similar experiments performed in triplicate (*, P < 0.01). Cell fusion
was normalized using control siRNA transfected cells incubated with HIVADA Env as
100%. (B) 2X105 of the each population of transfected cells were lysed and whole cell
lysates were analyzed by western blot. There are two immunoblots, the lysate from cells
transfected with 100nM control siRNA (lane1) or 100nM siRNA targeted to Pyk2 (lane
2) or Rac (lane 3) were loaded on each immunoblot and were initially probed with antiPyk2 (left) or anti-Rac (right), then all blots were stripped and probed with anti-actin
(bottom). The relative reduction index (RI) was calculated as the quotient of the
densitometry signal for the Pyk2 or Rac band and that for actin (shown below), and then
normalized by the ratio obtained with control siRNA (considered 1). Data represent
results from 1of 3 experiments with similar results. (C) U87.CD4.CCR5 cells were
transfected with 100nM control siRNA (solid bars), 100nM Pyk2 or 100nM Rac siRNA
(open bars) as described above. 72h post-transfection cells were incubated for 30 min
with BSC40 cells expressing no Env (subtracted as background), or HIVADA Env. Whole
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cell lysates were then analyzed by Rac specific G-LISA activation assay. Average A490
of duplicate wells ± standard deviation; data are representative of results from 1 of 3
similar experiments (**, P < 0.05).
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Fig. 8. Ras is required for Env-mediated fusion upstream & downstream of Rac.
Average fusion compared to untreated control reactions and detected by ß-galactosidase
activity ± standard deviation are shown. (A) Serum starved U87.CD4.CCR5 cells were
infected with vCB21R alone, or with vRacV12 in complete media overnight. These cells
were then pretreated with DMSO alone or indicated concentrations of Ras inhibitor FTS
for 1h and inhibitor was also present during the incubation with HIVUNC (subtracted as
background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are
representative of results from three similar experiments performed in triplicate (*, P <
0.01). Cell fusion was normalized using DMSO treated cells incubated with HIVADA Env
as 100%. (B) U87.CD4.CCR5 cells were treated for 1h with DMSO alone (solid bars),
1uM TAK-779, 50uM FTS, and 100uM RacGEF inhibitor (open bars) prior to and during
incubation for 30 min with BSC40 cells expressing no Env (subtracted as background), or
Env from HIVADA Env. Whole cell lysates were then analyzed by Rac specific G-LISA
activation assay. Average A490 of duplicate wells ± standard deviation; data are
representative of results from three similar experiments (*, P < 0.01, **, P <0.05). (C)
Serum starved PBLs cells were infected with vCB21R in complete media overnight.
These cells were then pretreated with DMSO alone, 50uM Ras inhibitor FTS, or 100uM
RacGEF inhibitor for 1h and inhibitor was also present during the incubation with
HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Envexpressing cells for 3h. Data are representative of results from three similar experiments
performed in triplicate (*, P < 0.01). Cell fusion was normalized using DMSO treated
cells incubated with HIVADA Env as 100%. (D) Ras activation assay. Western blot
analysis of Raf-1 binding fractions from lysates of U87.CD4.CCR5 cells mixed with
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BSC40 cells expressing no Env (lane 3), HIVHXB2 Env (lane 4) or HIVADA Env (lanes 59). 1uM TAK-779 was included to inhibit CCR5-Env binding (lane 5). Cells were
pretreated with DMSO alone (lane 6) and indicated concentrations of FTS to inhibit Ras
(lane 7-9) for 1hr and during the 30 min incubation with Env-expressing cells. Positive
(lane 1) and negative (lane 2) controls were generated by GTPγS- and GDP-loading of
reaction lysates, respectively. Increases (n-fold) in the amount of Ras-GTP compared to
lane 3 were determined by densitometry (normalized to lysate loading control) and are
indicated below the blot. Data represent results from 1of 3 experiments with similar
results.
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Fig 9. Effect of inhibitors on virus-dependent cell fusion with HIV-1 R5 virus and
infection of TZM-BL cells with HIV-1 R5 virus or A-MLV- pseudotyped and VSVG pseudotyped HIV-1 virus. (A) Average fusion compared to untreated control
reactions and detected by ß-galactosidase activity ± standard deviation are shown. One
population of serum starved U87.CD4.CCR5 cells was infected with vCB21R and the
other population of U87.CD4.CCR5 cells was infected with vPT7-3 in complete media
overnight. These cells were then mixed (1:1) in triplicate wells of 96 well plate and
pretreated with DMSO alone, TAK-779 (1uM), U73122 and U73343 (3uM), Ch Ch
(50uM), Go-6976 (1uM), PKC-I (20-28) (100uM), dantrolene (100uM), CPA (10uM),
TG (2uM), XC (5uM) and FTS (50uM) for 1h. Inhibitors were also present during
incubation with 100ng of HIVYU2 per well for 3h at 37°C. Data are representative of
results from three similar experiments (*, P < 0.01). Cell fusion was normalized using
DMSO treated cells mixed with HIVYU2 as 100%. (B) JC53BL cells were pre-incubated
with DMSO alone, TAK-779 (1uM), U73122 and U73343 (3uM), Ch Ch (50uM), Go6976 (1uM), dantrolene (100uM), CPA (10uM), TG (2uM), XC (5uM), FTS (50uM),
NH4Cl (50mM), and OA (100nM) for 1h and inhibitors were also present during 3h
infection period with 150ng of HIVYU2, A-MLV-pseudotyped HIV-1 or VSV-Gpseudotyped HIV-1 per well. Virus and inhibitor were then washed off the cells and the
cells were incubated in the same concentration of inhibitor at 37°C overnight. Luciferase
activities in the infected cell lysates were measured at 24h post-infection and were used
to calculate virus infectivity relative to that of the control. Data are representative of
results from 1 of 3 similar experiments performed in triplicate (**, P < 0.05). Cell
infection was normalized using DMSO treated cells as 100%.
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Fig 10. Gαq inhibitors do not affect surface expression and localization of CD4 and
CCR5.GFP. (A) Confocal micrographs of U87.CD4.CCR5 cells untreated, treated with
DMSO alone, TAK-779 (1uM), U73122 (3uM), U73343 (3uM), Calphostin C (0.5uM),
Chelerythrine Chloride (50uM), PKC-I 20-28 (100uM), dantrolene (100uM), FTS
(50uM) and RacGEF Inhibitor (100uM) for 3h, and CD (1uM) for 15 min, fixed and
stained with anti-CD4-PE antibodies (red) and counterstained with TO-PRO3 (blue). The
green GFP signal and red PE signal have been merged to show areas of colocalization
(yellow). Data are representative of results from 3 experiments. Images were collected
using an oil objective (magnification X63). (B) U87.CD4.CCR5 cells were incubated
with all the inhibitors listed in (A) except CD for 3h and detached by treatment with
5mM EDTA. U87 cells and untreated and treated U87.CD4.CCR5 cells were labeled for
surface expression of CD4 and CCR5 and analyzed by flow cytometry. Unlabeled
U87.CD4.CCR5 cells were used to compensate for GFP. Data are expressed as
percentage of surface expression based on DMSO treated cells as 100%.
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Fig 11. Pretreatment with inhibitors results in specific effects on target molecules.
(A) U87.CD4.CCR5 cells were treated with the PKA inhibitor H89 (10uM), PLC
inhibitor U73122 and its negative analog U73343 (10uM), PKC inhibitor Ch Ch (50uM),
Intracellular Ca2+ inhibitor dantrolene (100uM) and Ras inhibitor FTS (50uM) for 1h.
Whole cell lysates were then analyzed for PKA activity in the presence of inhibitors.
PKA (ng) based on standard curve of densitometry of varying amounts of PKA. Results
representative of two independent experiments performed in duplicate (*, P < 0.01, **, P
<0.05). (B) Western blot analysis of phosphorylated Pyk2 from lysates of
U87.CD4.CCR5 cells mixed with BSC40 cells expressing no Env (lane 1) or Env from
HIV-1 strains HXB2 (lane 3), or ADA (lanes 2, 4-12) at 37°C for 5 min. Cells were
pretreated with DMSO alone (NI, lane 1-3), 1uM TAK-779 (lane 4), 3uM U73122 and
U73343 (lane 5-6), 0.5uM Calphostin C (lane 7), 50uM Ch Ch (lane 8), 1uM Go-6976
(lane 9), 100uM PKC-I (20-28) (lane 10), 100uM dantrolene (lane 11) and 50uM FTS
(lane 12) for 1hr and during the 5 min incubation with Env-expressing cells. Cell lysates
were resolved by 10% SDS-PAGE, transferred to a nitrocellulose membrane, and probed
with anti-Pyk2 phosphospecific [pY579/580] antibody (upper panel, P-Pyk2). The same
blot was then stripped and reprobed with an antibody specific for total Pyk2 (lower
panel). Blots shown are representative of 3 independent experiments.
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Chapter 4

Role of Abl Kinase and the Wave2 Signaling Complex
in HIV-1 Entry at a Post-Hemifusion Step
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Preface to Chapter 4
Chapter 4 has been prepared as a manuscript for submission to PNAS by Brooke Harmon
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Harmon.
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Abstract
Entry of human immunodeficiency virus type 1 (HIV-1) commences with binding of the
envelope glycoprotein (Env) to the receptor CD4, and one of two coreceptors, CXCR4 or
CCR5. Env-mediated signaling through coreceptor results in Gαq-mediated Rac
activation and actin cytoskeleton rearrangements necessary for fusion. In this study, we
show that the mechanism of Env-induced Rac activation is mediated by the Rac guanine
nucleotide exchange factor Tiam-1, which associates with the adaptor protein IRSp53 to
link Rac to the Wave2 complex and activates the actin polymerization complex Arp2/3.
Env-mediated fusion and HIV-1 infection are dependent on Tiam-1, IRSp53, Wave2, and
Arp3 as shown by attenuation of fusion and infection in cells expressing siRNA targeted
to these signaling components. Env-dependent cell fusion and HIV-1 infection were also
inhibited by siRNA to Abl and Abl kinase activity inhibitors, imatinib, nilotinib, and
dasatinib. Fusion was blocked by these inhibitors without altering cell viability or surface
expression of CD4 and CCR5. Similar results were obtained when cell-cell fusion was
induced by Env expressed on viral or cellular membranes and when cell lines or primary
cells were the target. Using membrane curving agents and fluorescence microscopy, we
showed that inhibition of Abl kinase activity arrests fusion at the hemifusion step,
suggesting a role for actin remodeling in pore formation and expansion. These results
also suggest a potential use of Abl kinase inhibitors to treat HIV-1 infected patients.
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Introduction
HIV-1 enters cells by fusion at the plasma membrane and endocytosis (1-3). HIV-1
entry requires multiple conformational changes in the HIV-1 glycoprotein, and
rearrangement of the actin cytoskeleton. These events are triggered by binding of the
viral envelope (Env) surface subunit gp120 to the primary receptor, CD4, and one of two
chemokine coreceptors, CCR5 or CXCR4 (2, 12). This interaction activates signaling
events similar to those initiated by natural ligands, such as Ca2+ mobilization, activation
of RhoGTPases, and phosphorylation of tyrosine kinases, pyk2, Zap70 and p56lck (12,
49, 73). The Rho GTPase sub-family stimulates myosin based contractility and drives
the formation of stress fibers and focal adhesions. The Rac GTPase sub-family stimulates
lamellipodia and membrane ruffles, and the Cdc42 subfamily stimulates the formation of
filopodia (26, 27, 157). We showed that HIV-1 Env binding to target cells activates Rac,
stimulates membrane ruffles and lamellipodia, and fusion is inhibited by dominant
negative Rac (12, 45). Furthermore, HIV-1 Env-induced Rac activation depends on
activation of Gαq, phospholipase C (PLC), Ca2+ mobilization, protein kinase C (PKC),
pyk2 and Ras (73). In the current study we identified the fusion-specific effectors of Rac
required for actin cytoskeleton rearrangements that mediate membrane fusion and entry.
Rac GTPase is regulated by guanine nucleotide exchange factors (GEFs) (26, 27,
157). HIV-Env induced Rac activation is mediated by a Rac-specific GEF, either Tiam-1
or Trio (44, 45). GEFs not only facilitate the GDP to GTP switch for their targeted
GTPase, but they also select downstream effector proteins by participating in scaffold
protein complexes that organize components of a specific signaling pathway.
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There are multiple effectors of Rac, including serine/threonine kinases, lipid kinases,
actin-binding proteins, and adaptor/scaffold molecules (27, 158). PAK is a downstream
effector of Rac and Cdc42 that promotes stabilization of actin networks. Another
downstream effector of Rac that nucleates actin polymerization is the Arp2/3 complex.
The Arp2/3 complex is activated by the Wave2 complex through IRSp53, an adaptor
protein that binds Rac and Wave2 (27). The Wave2 complex includes Rac-associated
protein 1, Nck-associated protein, Abl-interacting protein 2, and heat shock protein C300.
Wave2 also associates with Abl, which promotes Wave2 phosphorylation and activation
(159). In addition to determining which Rac effectors are critical for membrane fusion,
we studied the steps in the membrane fusion process affected by these signaling
molecules. These data demonstrate that the Wave2 signaling complex and Abl are
required for Env-mediated membrane fusion, entry, and infection and that inhibition of
Abl kinase arrests the fusion process at hemifusion.
Results
HIV-1 Env-mediated fusion depends on the Wave2 signaling complex.
To determine whether Abl, Trio, or Tiam-1 are required for HIV-1 Env-mediated cell
fusion, expression of these proteins was downregulated by RNA interference (RNAi) in
U87.CD4.CCR5 cells. Cells expressing siRNAs were mixed with BSC40 cells expressing
different Env subtypes and Env-dependent fusion was measured. Transfection of target
cells with siRNA to Tiam-1 and Abl decreased levels of Env-mediated cell-cell fusion by
an average of 79 ± 5% and 74 ± 5% respectively for both HIV-1 R5 and dual-tropic Envsubtypes (Fig 1A, left). There was no significant fusion observed with CCR5 expressing
target cells and X4 Env expressing cells, as expected. The decrease in the levels of fusion
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correlated well with the decreased steady-state level of Tiam-1, and Abl as detected by
immunoblot (Fig. 1C). The siRNA directed against Trio had no effect on Env-induced
cell-cell fusion despite a 70% reduction in expression of the Trio protein (Fig 1A, C). To
determine whether Tiam-1 and Abl are acting exclusively upstream of Rac, a
constitutively active Rac mutant, RacV12 was expressed in siRNA transfected cells.
Expression of RacV12 reversed the effects on fusion of siRNA to Tiam-1, suggesting that
Tiam-1 is functioning upstream of Rac (Fig 1A, right). In contrast, levels of fusion in
cells expressing RacV12 and siRNA to Abl were only 53 ± 1% that of cells expressing
RacV12 and control siRNA, suggesting a role for Abl upstream and downstream of Rac.
Tiam1 binds to the Rac and Cdc42 effector IRSp53, enhancing IRSp53 binding to Rac
and the Wave2 scaffolding complex (150). To determine the role of these Rac effectors in
Env-mediated membrane fusion, their expression was downregulated by RNAi in
U87.CD4.CCR5 cells. The siRNA expressing cells were mixed with Env-expressing cells
and fusion measured. Expression of siRNAs to Irsp53, Wave2, and Arp3 decreased
fusion by 74 ± 5% 77 ± 4% and 78 ± 4%, respectively, and this decrease was not
overcome by expression of RacV12, suggesting that these proteins are required
downstream of Rac (Fig 1B). The decrease in fusion correlated with the downreguation in
protein expression as seen by immunoblot (Fig. 1C), and each siRNA was specific for its
target protein (Fig S1A). Treatment of cells stably expressing siRNA resistant Arp3, with
Arp3 targeted siRNA had no effect on Env-mediated cell-cell fusion. (Fig. 1D). However,
treatment of untransfected cells and cells stably expressing siRNA resistant Arp3 with
siRac decreased fusion by 75 ± 5% and 76 ± 3% respectively (Fig. 1D). These results
show that the effect of RNAi on fusion is specific to inhibition of target molecules.
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Small molecule inhibitors of Abl kinase activity inhibit HIV-1 entry.
Since treatment of cells with Abl targeted siRNA led to a decrease in fusion, we
determined whether treatment with Abl kinase inhibitors, imatinib (IMB), nilotinib
(NIL), and dasatinib (DAS), block fusion and infection. IMB is a relatively specific
inhibitor of Bcr-Abl, Abl, Arg, and class III receptor tyrosine kinases. NIL is a kinase
inhibitor 20-50 fold more potent than IMB at inhibiting Abl. DAS, originally designed as
a Src family kinase inhibitor, also inhibits ephrin and platelet-derived growth factor
receptor kinases, and kit. DAS is 300 fold more potent than IMB at inhibiting Abl (160,
161). To determine the concentrations of these Abl kinase inhibitors that inhibit Envmediated fusion without non-specific effects, trypan blue analysis, vaccinia virus
infection, and T7 polymerase activity were measured in addition to Env-dependent cell
fusion (Fig. S2). Treatment of U87.CD4.CCR5 cells with 10uM IMB, 500nM NIL, and
300nM DAS for 1h prior to and during 3h incubation with Env-expressing cells
decreased Env-mediated fusion by an average of 95 ± 2%, 92 ± 5%, and 92 ± 6%,
respectively, and Abl kinase activity by 85-87% (Fig. 2A, S1B). There was no decrease
in T7 polymerase activity, or localization of CD4 and CCR5 on the cell surface (Fig. S2,
S3). Expression of RacV12 in cells treated with IMB, NIL and DAS increased the level
of fusion by an average of 3.5-fold (**, P < 0.05) compared to treated cells without
RacV12, suggesting a role of Abl kinase activity upstream of Rac (Fig. 2B). To
determine the effect of these Abl kinase inhibitors on Env-induced Rac activation,
U87.CD4.CCR5 cells were treated with inhibitors for 1h prior to mixing with BSC40
cells expressing no HIV-1 Env, HIV-1 X4 Env, or HIV-1 R5 Env for 30 minutes in the
presence of inhibitor. The mismatched X4 Env, that does not induce Rac activation in
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CCR5 expressing cells, and the CCR5 inhibitor TAK-779, which completely blocks Envmediated Rac activation in CCR5 expressing cells, were included as controls. Envinduced Rac activation was abolished in cells treated with TAK-779 and all three of the
Abl kinase inhibitors (Fig. 2C). To validate these effects in a relevant HIV-1 target cell,
PBLs which express CD4, CCR5 and CXCR4, were used as the target cell in an Envdependent cell fusion assay. Treatment of PBLs with IMB, NIL, and DAS decreased
fusion by an average of 92 ± 1%, 92 ± 3%, and 99.5 ± 1%, respectively, for HIV-1 R5,
dual-tropic and X4 Env subtypes (Fig. 2D). In addition, infection of CD4, CCR5 and
CXCR4-expressing cells with R5 and X4 HIV-1 was inhibited by treatment with IMB in
a dose dependent manner (Fig. S2C). These results suggest that Abl is required for Envinduced fusion mediated by both CCR5 and CXCR4. The CCR5 inhibitor TAK-779, as
expected, completely blocked fusion and infection mediated by R5 Env-expressing cells,
inhibited fusion mediated by dual-tropic Env by 56 ± 2%, and had no effect on fusion or
infection mediated by X4 Env (Fig. 2D, S2C).
To confirm these results using virus particles with relevant levels of virus-associated
glycoprotein, we used a virus-dependent cell fusion assay based on the ability of virus
particles to bridge two cells and allow transfer of cytoplasmic contents (12, 45). For this
assay we used two populations of U87.CD4.CCR5 cells, one expressing the T7
polymerase and the other expressing the β-galactosidase (β-gal) gene under the T7
promoter. Both populations were incubated with inhibitors for 1h prior to 3h incubation
with R5 virus HIVYU2. In this assay controls included untreated and inhibitor treated cells
that were not incubated with virus, TAK-779, and T-20, which blocks entry by inhibiting
the conformational change in HIV-1 gp41 required for fusion (135). Virus-dependent cell
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fusion was reduced by an average of 94 ± 3% in cells treated with IMB, DAS, and NIL
compared to cells treated with DMSO alone, and treatment with TAK-779 and T-20
completely inhibited fusion (Fig. 2E). To confirm the specificity of these effects, we
performed an Env-dependent fusion assay with cells stably expressing two different drug
resistant Bcr-Abl mutants (Y253F and T315I), or expressing wildtype (WT) Bcr-Abl
(162). Expression of the drug resistant Bcr-Abl mutants but not WT Bcr-Abl resulted in
recovery of fusion (Fig. 2F), demonstrating that the effects of these inhibitors on Envdependent fusion are specific to inhibition of Abl.
Infection of TZM-BL cells with HIV-1 particles but not particles pseudotyped with
Amphotropic Murine Leukemia Virus (A-MLV) Env or Vesicular Stomatitis Virus
Glycoprotein (VSV-G) depend on Abl and the Wave2 signaling complex
To determine whether the Wave2 signaling complex and Abl are required exclusively
for HIV-1 entry, or virus-induced fusion and infection in general, we examined infection
with HIV-1 versus A-MLV Env (A-MLV-HIV-1) or VSV-G pseudotyped HIV-1 (VSVG HIV-1) using the TZM-BL assay. HIV-1 Env induces virus-cell fusion at the cell
surface to facilitate entry, whereas viruses pseudotyped with VSV-G or A-MLV Env
induce clathrin- or caveola-mediated endocytosis, respectively (145). TZM-BL cells, a
derivative of HeLa cells that express physiological levels of CD4, CCR5, CXCR4, and
luciferase (luc) under the control of the HIV-1 LTR, were pretreated with the Abl kinase
inhibitors for 1h prior to incubation with virus for 3h, and a subsequent 24h incubation
with inhibitor only (117, 135). Ammonium chloride (NH4Cl) which inhibits clathrin
mediated endocytosis, and okadaic acid (OA), which inhibits caveola-mediated
endocytosis, were included as controls. Fig. 3A shows that treatment with IMB, NIL, and
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DAS decreased infection with HIVYU2 virus by 93 ± 10%, 94 ± 0.5%, and 92 ± 14%,
respectively, comparable to the reductions in Env-dependent and virus-dependent cell
fusion . The Abl kinase inhibitors had no effect on infection with A-MLV HIV-1 or
VSV-G HIV-1, but treatment with NH4Cl blocked infection with VSV-G HIV-1, and
treatment with OA blocked infection with A-MLV HIV-1 (Fig. 3A, middle and bottom).
These data show that Abl kinase inhibitors were able to block HIV-1 Env-mediated
fusion specifically, had no effect on infection via clathrin-mediated or caveola-mediated
endocytosis, and do not affect post-entry steps.
To test the effect of Wave2 complex targeted siRNAs on infection, TZM-BL cells
were transfected with 200nM control or siRNA directed towards Tiam-1, Trio, Abl,
Irsp53, Wave2 and Arp3. These cells were incubated with virus for 3h, and media alone
for 24h. The decreased levels of HIV-1YU2 infection of TZM-BL cells expressing siRNA
targeted to Tiam-1, Abl, Irsp53, Wave2, and Arp3 was comparable to levels of Envmediated cell fusion with U87.CD4.CCR5 cells expressing these siRNAs, whereas the
siRNA to Trio had no effect (Fig. 3B, 1A, 1B). Steady state levels of target proteins in
cells expressing targeted siRNAs were decreased to similar levels as in U87 cells (Fig.
1C). Infection of TZM-BL cells with A-MLV HIV-1 or VSV-G HIV-1 was not affected
by expression of the targeted siRNAs (Fig 3B), suggesting that Tiam-1, Abl, Irsp53,
Wave2, and Arp3 are not necessary for post-fusion steps in the virus life cycle.
The Abl kinase inhibitors block fusion and infection at a post-hemifusion step
HIV-1 Env-induced fusion and release of the viral capsid into the cytosol is a
multistep process. 1) The surface subunit gp120 binds CD4, and undergoes a
conformational change, and actin cytoskeletal rearrangements in the target membrane
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bring the coreceptor CCR5 or CXCR4 into close proximity. 2) Coreceptor binding to
gp120 triggers conformational changes in gp41 to produce a prebundle conformation that
inserts into the target cell membrane, allowing lipid mixing or hemifusion, and pore
formation. 3) Additional conformational changes induce formation of the gp41 6-helixbundle which prevents pore closure and facilitates pore enlargement and full fusion (4, 7,
163). To determine which step(s) in the membrane fusion process are blocked by the Abl
kinase inhibitors, we examined the effect of membrane curving agents on fusion and
infection. Oleic acid (OLA), chlorpromazine (CPZ), dibucaine (DB), and trifluoperazine
(TFP) are lipid analogs that insert into the inner leaflet of the cell membrane. OLA
induces curvature in the membrane that promotes formation of a hemifusion intermediate
but cannot induce pore formation if there is a block at hemifusion. CPZ, DB, and TFP are
membrane-permeable weak bases that partition into inner leaflets of cell membranes and
induce curvature and relieve a block at hemifusion (164, 165). To determine the effect of
inhibitors and lipid analogs on virus-dependent cell fusion, U87.CD4.CCR5 cells were
treated with TAK-779, IMB, NIL, and DAS for 1h, prior to 30 minute incubation with
HIVYU2, and treatment with CPZ, DB, and TFP for 1 min or OLA for 5 min. The lipid
analogs were washed off, inhibitor and virus were added back, and fusion was measured
after 3h. Cells were also incubated with the lipid analogs in the absence of HIVYU2 to
account for the effects of these agents on the cells and on T7 polymerase activity. TAK779 mediated inhibition of fusion was not affected by these lipid analogs. The average
level of fusion for CPZ treated cells, treated with IMB, NIL, and DAS, versus DMSO
alone was 78 ± 3% versus 5 ± 3% in the absence of any lipid analog (Fig. 4A). Addition
of the lipid analogs DB and TFP increased levels of fusion in cells treated with Abl

118

kinase inhibitors to 52 ± 3% and 55 ± 2% respectively, in comparison to cells treated
with DMSO alone. Addition of OLA did not increase fusion in cells treated with any of
the inhibitors.
To confirm these results with another cell type and to show the effect of lipid analogs
on HIV-1 infection, TZM-BL cells were similarly treated with inhibitors and lipid
analogs but after the 3h incubation with HIV-1YU2, virus was washed off, inhibitors were
added back and cells incubated for 24h. Addition of CPZ and TFP to TZM-BL cells
treated with Abl kinase inhibitors increased average infection to 56 ± 5% and 59 ± 4%
respectively, versus DMSO treated cells (Fig. 4B). Infection of TZM-BL cells treated
with Abl kinase inhibitors in the absence of lipid analogs was only 11 ± 5% that of
DMSO treated cells. OLA had no effect on infection (Fig. 4B). These results suggest that
inhibition of Abl kinase arrests fusion at a hemifusion step, preventing pore formation,
pore enlargement and content mixing.
To confirm that Abl kinase inhibitors cause arrest at hemifusion, we used a
modification of a fusion assay described previously (166). CHO-K1 cells, that lack
expression of the lipid ganglioside GM1, were engineered to express GFP and the HIV1ADA (R5) Env protein. U87.CD4.CCR5 cells were used as the target cell, and lipid
mixing was detected when GM1, detected by a TRITC-conjugated form of cholera toxin
β-subunit (CTX-β), was transferred from the target cell to CHO-K1-GFP cells. Complete
fusion is detected when cells express GM1, GFP, and are multinucleated. Quantification
was performed for three independent experiments and percentage of hemifused GFP+,
GM1+ cells with single nuclei and the percentage of multinucleated fully fused cells was
enumerated for 68 cells from each condition (Fig. 4C, S4, Table S1). There were 83.1
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±10.9% hemifused cells with IMB-treated cells mixed with HIVADA-expressing CHO-K1
cells, compared to DMSO treated cells with 22.3 ± 4.9% hemifused cells and 75.5 ± 6.2%
fully fused cells (Fig 4C). With no HIV-1 Env or with the addition of TAK-779 there was
little or no hemifusion or full fusion. These results confirm that Abl kinase activity is
required at a post-hemifusion step.
Discussion
Dynamic regulation of the actin cytoskeleton is required for fusion of biological
membranes. For Env-mediated membrane fusion actin rearrangements in the target cell
are critical for formation of the gp120-CD4-coreceptor complex, as well as post-binding
steps (11, 12, 25, 33, 44, 45, 73). Our previous data demonstrated that Env-induced Rac
activation is mediated by Gαq and its downstream effectors, including Ras. We showed
that a small molecule inhibitor of Rac GEFs, Trio and Tiam-1 eliminated Env-dependent
fusion (44, 45). Other studies showed that Ras promotes Rac activation via direct
interaction with Tiam1, or by phosphatidylinositol 3-kinase (PI3K)-mediated activation
of Tiam-1 (144). Env-dependent Rac activation likely occurs through the first
mechanism, since treatment of target cells with PI3K inhibitors had no effect on Envdependent cell fusion (167).
The non-receptor tyrosine kinase, Abl, modulates actin upstream and downstream of
Rac (168, 169). In the current study, we show that the activity of Abl kinases is required
both upstream and downstream of Rac for Env-induced membrane fusion. Env-mediated
fusion and Rac activation were attenuated in cells treated with siRNA targeted to Abl, or
Abl kinase inhibitors, IMB, NIL, and DAS, which was only partially overcome by
expression of RacV12. This inhibition was observed with Env expressed on viral or

120

cellular membranes, and when cell lines or primary cells were the target. The inhibitor
concentrations employed did not alter levels of CD4 or CCR5 expression or localization
on the surface of cells nor did they result in nonspecific effects on vaccinia virus
infection or T7 polymerase activity. The effects of these inhibitors on Env-mediated
fusion were specific to inhibition of Abl as demonstrated by reversal of inhibition in cells
expressing drug resistant Abl mutants.
Abl kinase has been shown to modulate actin reorganization downstream of Rac by
phosphorylation and activation of the Wave2 complex. Abl interactor adaptors associate
with Wave2, and promote membrane translocation and phosphorylation of Wave2 (159,
170). Wave2 mediates signaling downstream of Rac, through Arp2/3-mediated actin
polymerization. Tiam1 binds to the adaptor protein IRSp53, and promotes the interaction
of activated Rac and Wave2. In the current study we demonstrated that IRSp53, Wave2,
and Arp3 are required downstream of Rac for HIV-1 entry and infection. Env-mediated
fusion was attenuated in cells expressing siRNA targeted to IRSp53, Wave2 and Arp3
and this inhibition was not overcome by expression of RacV12. The decrease in fusion
observed with Arp3 targeted siRNA was overcome by expression of siRNA resistant
Arp3 suggesting that the effects observed with RNAi were specific. Infection of TZM-BL
cells with HIV-1 was similarly inhibited in cells expressing Tiam-1, Abl, IRSp53, Wave2
and Arp3 directed siRNA. HIV-1 infection was also inhibited in cells treated with Abl
kinase inhibitors. The inhibition of HIV-1 infection by targeted siRNA or Abl kinase
inhibitors was overcome when virus was pseudotyped with VSV-G or A-MLV Env.
These results suggest that these signaling mediators are important for HIV-1 Env

121

mediated entry and are not necessary for clathrin or caveola-mediated endocytosis, and
they are not required at post-entry steps in the virus life cycle.
The current study also showed that the block in fusion caused by inhibition of Abl
kinase occurs after hemifusion and before cytoplasmic mixing. This conclusion was
based on the 1) confocal microscopy demonstration that addition of IMB to the fusion
reaction allowed membrane but not cytoplasmic mixing, and 2) observation that lipid
analogs that overcome a block at hemifusion overcame Abl kinase inhibition of HIV-1
virus dependent cell fusion and infection. These results support a model whereby HIV-1
Env binding to CCR5 stimulates activation of Gαq resulting in activation of Ras, via
pyk2 and Abl phosphorylation of the Ras GEF complex. Activated Ras then mediates
Rac activation via the Rac GEF Tiam-1, and activated Rac interacts with IRSp53. IRSp53
promotes Rac activation of the Wave2 complex, which is also activated by Abl, and
activated Wave2 induces subsequent activation of Arp2/3-mediated actin rearrangements
which facilitate pore formation, pore enlargement, and entry of HIV-1.
Many microbial pathogens depend on Abl family kinases to mediate efficient infection
of their targeted host, including Shigella flexneri, enteropathogenic Escherichia coli,
Heliobacter pylori, Anaplama phagocytophilum, coxsackievirus, poxvirus, and murine
AIDS virus. Abl kinases are involved in pathogen entry, intracellular movement, and exit
from target cells; proliferation of target cells; and phosphorylation of microbial effectors.
Many of these processes involve reorganization of the target cell actin cytoskeleton and
depend on the same signaling pathways as HIV-1 (12, 73, 171). Discovery of these
signaling mediators as fundamental components of microbial pathogenesis provides new
targets for therapeutic intervention. The clinical application of IMB, NIL, and DAS,
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which block deregulated Abl kinases in leukemia patients, demonstrate that inhibition in
vivo is possible with manageable side effects (160, 161, 172). In addition IMB has been
shown to be an effective inhibitor of anti-apoptotic pathways induced by HIV-1 in
macrophages (173). Most current antiviral therapies target viral proteins and mutation of
the virus leads to therapy resistance. Therefore, using inhibitors that target host signaling
proteins essential for HIV-1 entry may be an efficient new strategy for treatment of
infected patients.
Materials and Methods
Reagents & Cell Lines. U87.CD4.CCR5 cells are astroglioma cells expressing CD4,
CCR5-GFP or HA-CCR5. CHO-K1 cells (ATCC) were grown in F-12K media with 10%
serum and other cells maintained as described (116). pMSCVneo-WT, Y253F, and T315I
Bcr-Abl were gifts from Dr. R. Van Etten (162). The siRNA resistant mutations were
generated in Arp3 based on sequences obtained from Santa Cruz Biotechnology Inc
(SCBT), by PCR-mediated mutagenesis. WT and mutant cDNAs were cloned in
pcDNA3.1+zeo. IMB, NIL, and DAS were from LC Laboratories and were used at 10uM,
500nM, and 300nM respectively unless indicated; CPZ (0.5mM), DB (5mM), TFP
(0.3mM), OA (100nM), OLA (50uM) and NH4Cl (50mM) were from Sigma; TAK-779
(1uM), and T-20 (10ug/ml) were from the AIDS Research and Reference Reagent
Program; and siRNA constructs were from SCBT and used at 200nM (73).
Viruses. WT vaccinia (WR strain) and recombinant vaccinia viruses expressing β-gal
(vCB21R), T7 polymerase (vPT7-3), constitutively active Rac GTPase (vRacV12), or
HIV-1 Env proteins were described (116). HIV with R5 YU2 or X4 HXB2 Env in
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HIVNL4-3 backbone were generated from 293T cells; some were pseudotyped with AMLV) or VSV glycoproteins (73). TZM-BL assays were performed as described (73).
Fusion and hemifusion assays. Envelope-mediated and virus-dependent fusion assays
were described. Average fusion compared to untreated control reactions were detected by
ß-gal activity ± standard deviation (73). Hemifusion assays were performed with 2x106
CHO-K1 cells nucleofected with a GFP expression plasmid, and after 24h infected with
vaccinia virus expressing HIVADA Env or no Env. After 16h, 4x105 U87.CD4.CCR5.HA
cells were added for 3h, fixed with paraformaldehyde, stained with TRITC-conjugated
CTX-β (CTX-555, EMD), and analyzed on a 510 Meta LSM confocal microscope.
Statistical Analysis. Fusion and infectivity results were compared using a two-tailed ttest. All p values, unless indicated, were <0.03.
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Figures
Fig. 1. Downregulation of Wave2 signaling complex with siRNA reduces HIV-1 Envmediated cell fusion and infection. U87.CD4.CCR5 cells were transfected with control
siRNA (control) or siRNA targeted against (A) Trio, Tiam-1, Abl, Rac, (B) Irsp53,
Wave2, and Arp3. Cells were serum starved 24h post-transfection (pt), infected with
vCB21R alone or with vRacV12 48h pt, and 72h pt cells were incubated for 3h with
HIVUNC (subtracted as background), HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Envexpressing cells and β-gal activity was measured (C) Each population of transfected cells
were analyzed by western blot with antibodies to the designated protein or actin. The
relative reduction index (RI) is the quotient of the densitometry signal for the target band
and that for actin, normalized by the ratio obtained with control siRNA. (D)
U87.CD4.CCR5 cells engineered to express a siRNA resistant clone of Arp3 were
transfected with control siRNA, or siRNA targeted against Arp3 or Rac. Cell fusion was
measured by β-gal activity, and was normalized using control siRNA transfected cells
incubated with HIVADA Env as 100%. All data are representative of results from three
similar experiments performed in triplicate.
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Fig 2. Abl kinase is required upstream and downstream of Rac. (A) Serum starved
U87.CD4.CCR5 cells were infected with vCB21R alone, or with (B) vRacV12 overnight,
then treated with DMSO alone, TAK-779, IMB, NIL, or DAS for 1h and the inhibitors
were also present during 3h incubation with HIV-1 Env-expressing cells and β-gal
activity as measured. (C) U87.CD4.CCR5 cells were treated for 1h with TAK-779, IMB,
NIL, or DAS and during 30 min incubation with BSC40 cells expressing no Env
(subtracted as background), HIVADA Env or HIVHXB2 Env. Whole cell lysates were
analyzed by Rac specific G-LISA activation assay. Average A490 of triplicate wells ±
standard deviation are shown. (D) Serum starved PBLs were infected with vCB21R in
complete media overnight, treated with DMSO, TAK-779, IMB, NIL, or DAS for 1h
prior to addition of HIV-1 Env-expressing cells and β-gal activity was measured. (E)
U87.CD4.CCR5 cells were infected overnight with vCB21R or vPT7-3, then mixed (1:1)
in triplicate wells, treated for 1h with DMSO, TAK-779, T20, IMB, NIL, DAS, and with
100ng of HIVYU2 for 3h at 37°C. β-gal activity was measured and cell fusion was
normalized using DMSO treated cells mixed with HIVYU2 as 100%(F) U87.CD4.CCR5
cells engineered to express indicated clones of Bcr-Abl were treated with Abl inhibitors
and HIVUNC or HIVADA Env as described above or analyzed by western blot with antiAbl or anti-actin antibody (inset). All data are representative of results from three similar
experiments performed in triplicate.
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Fig. 3. Infection with HIV-1 particles but not particles pseudotyped with MLV Env
or VSV-G is dependent on Abl and the Wave2 signaling complex. (A) TZM-BL cells
were incubated for 1h with DMSO, NH4Cl , OA, IMB, NIL, or DAS and 150ng of
HIVYU2, A-MLV-or VSV-G-HIV-1 per well was added for 3h, washed, and cells were
incubated with inhibitors overnight and luc activity was measured. (B) TZM-BL cells
were transfected with control siRNA or siRNA directed against indicated target proteins
and 48h later infected with 150ng of HIVYU2, A-MLV- or VSV-G-HIV-1 for 3h, cells
were washed and incubated overnight, and luc activity measured. Cell infection was
normalized using (A) DMSO treated cells or (B) cells transfected with control siRNA as
100%. All data are representative of results from three similar experiments performed in
triplicate.
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Fig. 4. Abl kinase inhibitors block virus-dependent fusion and infection at a posthemifusion step. (A) Serum starved U87.CD4.CCR5 cells were infected with vCB21R
or vPT7-3 overnight, then mixed (1:1) in triplicate wells of 96 well plate, and these cells
or (B) TZM-BL cells were treated with DMSO, TAK-779, IMB, NIL, or DAS for 1h, (A)
100ng or (B) or 150ng of HIVYU2 added for 30 min with indicated lipid analogs for 1-5
min (A) Cells were washed, and virus and inhibitors were added back for 3h and β-gal
activity was measured or (B) cells were then washed and incubated in inhibitor overnight
and luc activities were measured. Data are representative of results from three similar
experiments. Cell fusion and infection were normalized using DMSO treated cells
infected with HIVYU2 as 100%. (C) CHO-K1 cells that do not express GM1 were
transfected with a GFP expressing plasmid (green), and 24h later infected with WT
vaccinia virus or vaccinia virus expressing HIVADA Env. After another 24h, CHO-K1
cells were overlayed for 3h with U87.CD4.CCR5 cells pre-treated for 1h with DMSO,
TAK-779, or IMB. Cells were fixed and stained with CTX-555 (red), and counterstained
with TO-PRO 3 (blue). Images were collected using an oil objective (magnification X63).
The upper panels are a consolidation of three different images and the lower panels are a
consolidation of two different images. Images were cropped but relative cell size was
maintained. The percentage of hemifused cells is listed.
.
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Supporting Imformation
Fig. S1. Abl is activated by HIV-1 Env and Pretreatment with inhibitors and siRNA
results in specific effects on target molecule. (A) U87.CD4.CCR5 cells were
transfected with 200nM control siRNA or siRNA directed against Trio, Tiam-1, Abl,
IRSp53, Wave2, Arp3 and Rac and 48 h later each population of transfected cells was
lysed and analyzed by western blot with antibodies to the designated protein or actin. The
relative reduction index (RI) is the quotient of the densitometry signal for the target band
and that for actin, normalized by the ratio obtained with control siRNA. Data are from 1
of 3 experiments with similar results. The bottom blot depicting Rac levels in cells
transfected with the labeled siRNA demonstrates that the siRNAs have no effect on Rac
expression. (B) Abl kinase activity was measured using PAthScan Bcr/Abl activity assay
from Cell Signaling. Depicted is western blot analysis of a downstream target of activated
Abl kinase, phosphorylated CrkL, and loading control eIF4E from lysates of
U87.CD4.CCR5 cells mixed 1:1 with BSC40 cells expressing no Env (lane 1) or Env
from HIV-1 strain ADA (lanes 2-5) at 37°C for 20 min. Cells were pretreated with
DMSO alone (NI, lane 1-2), 1uM TAK-779 (lane 3), 10uM IMB (lane 4), 500nM NIL
(lane 5), 300nM DAS (lane 6), 100uM Rac GEF Inhibitor (lane 8), for 1hr and during the
20min incubation with Env-expressing cells. Cell lysates were resolved by 10% SDSPAGE, transferred to a nitrocellulose membrane, and probed with phosphospecific
primary antibody cocktail and anti-rabbit or anti-biotin secondary. Blots shown are
representative of 3 independent experiments.
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Fig. S2. Abl kinase inhibitors decrease Env-induced fusion, virus-dependent fusion
and infection of TZM-BL cells with R5 and X4 virus in a concentration dependent
manner. Average fusion compared to untreated control reactions was detected by ß-gal
activity ± standard deviation. (A) Serum starved U87.CD4.CCR5 cells were infected with
vCB21R alone, or with vRacV12 overnight, then treated with DMSO alone, 1uM TAK779 or 1uM, 5uM and 10uM IMB, for 1h and the inhibitors were also present during the
3h incubation with HIVUNC (subtracted as background) HIVADA, HIVYU2, HIV89.6 or
HIVHXB2 Env-expressing cells. (B) U87.CD4.CCR5 cells were infected overnight with
vCB21R or vPT7-3, then mixed (1:1) in triplicate wells, treated for 1h with DMSO, 1uM
TAK-779, or 1uM, 5uM and 10uM IMB, and 100ng of HIVYU2 added for 3h at 37°C.
Cell fusion was normalized using DMSO treated cells mixed with HIVYU2 as 100%. (C)
TZM-BL cells were incubated for 1 h with DMSO, 1uM TAK-779, 1, 5 and 10uM IMB,
and 150ng of HIVYU2 or 150ng HIVHXB2 per well was added for 3h, washed, and cells
were incubated with inhibitors at 37°C overnight. (D) Serum starved U87.CD4.CCR5
cells were infected with vCB21R alone, or with vRacV12 overnight, then treated with
DMSO alone, 125, 250 and 500nM NIL, or (E) DMSO alone, 75, 150 and 300nM DAS,
for 1h and the inhibitors were also present during the 3h incubation with HIVUNC
(subtracted as background) HIVADA, HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells.
Data are representative of results from three similar experiments.
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Fig. S3. Abl kinase inhibitors do not affect surface expression and localization of
CD4 and CCR5.GFP. (A) Confocal micrographs of U87.CD4.CCR5 cells treated with
DMSO alone, TAK-779 (1uM), IMB (10uM), NIL (500nM), Dasatinb (300nM) and
RacGEF Inhibitor (100uM) for 3h, and CD (1uM) for 15 min, fixed and stained with antiCD4-PE antibodies (Sigma, red) and counterstained with TO-PRO3 (blue). The green
GFP signal and red PE signal have been merged to show areas of colocalization (yellow).
Data are representative of results from 3 experiments. Images were collected using an oil
objective (magnification X63). The NIL panel is a consolidation of 2 separate images.
(B) U87.CD4.CCR5 cells were incubated with no inhibitor, DMSO alone, TAK-779
(1uM), IMB (10uM), NIL (500nM), Dasatinb (300nM) and RacGEF Inhibitor (100uM)
for 3h and detached by treatment with 5mM EDTA. U87 cells, and untreated and treated
U87.CD4.CCR5 cells, were stained with anti-CCR5 (R&D) or anti-CD4 antibodies
(Sigma), and goat anti-mouse PE conjugated antibody. Cells were analyzed on a FACS
Calibur flow cytometer. Unlabeled U87.CD4.CCR5 cells were used to compensate for
GFP. Data are expressed as percentage of surface expression based on DMSO treated
cells as 100%.
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Fig. S4. Abl kinase inhibitors block fusion at a post-hemifusion step. (A) CHO-K1
cells that do not express GM1 were transfected with a GFP expressing plasmid, and 24h
later infected with wildtype vaccinia virus or vaccinia virus expressing HIVADA. After
another 24h, CHO-K1 cells were overlayed for 3h with U87.CD4.CCR5.HA cells pretreated for 1h with DMSO, 1uM TAK-779, or 10 uM IMB. Cells were fixed and stained
with TRITC-conjugated CTX (CTX-555), and counterstained with TO-PRO 3 (blue).
Images were collected using an oil objective (magnification X63). The upper right middle
panel (ADA DMSO) is a consolidation of two different images. Images were cropped but
relative cell size was maintained.

138

SI Table 1. Quantification of cell-cell hemifusion assay
HIV Env

Inhibitor

% hemifusion ± SD

% fusion ± SD

None

DMSO

0

0

DMSO

22.3 ± 4.9

75.5 ± 6.2

TAK-779

7 ± 4.8

0

Imatinib

83.1 ±10.9

14.3 ± 5.1

(n=68)
ADA (R5)
(n=68)
ADA (R5)
(n=68)
ADA (R5)
(n=68)
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Chapter 5
Discussion and Conclusions
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Introduction:
Substantial insights into the mechanism used by HIV-1 viral proteins to promote
fusion have come from numerous studies using cell fusion assays, techniques that
monitor viral core-associated enzymes into the host cell, and time-resolved imaging of
single viral particles. The current model for viral protein-mediated fusion has emerged
from extensive biochemical and functional data using these systems (7, 174-182). Fusion
commences with binding of trimeric gp120 to CD4 which induces a structural change in
gp120 that creates the binding site for coreceptor. Upon binding to coreceptor the
gp120/gp41 complex undergoes additional conformational changes that results in
dissociation of gp120 and gp41 and insertion of the hydrophobic TM domain of gp41 into
the target cell membrane (4, 7, 183). In addition to anchoring the viral proteins to the
target membrane, the fusion peptide also destabilizes lipid bilayers, by reducing the free
energy barrier required to pass through curved fusion intermediates (182, 184). Next the
extended trimeric conformation of gp41 that is bridging the viral and target membrane
folds back on itself forming a hairpin structure and driving membrane merger
(hemifusion) (7). The energy from the final folding of gp41 into the 6HB conformation is
thought to facilitate pore formation and enlargement and the 6HB, which forms after pore
formation, is though to prevent pore closure (7).
Dilation of fusion pores to a size that is large enough for nucleocapsid delivery
(~50nm) is required for infection but the mechanism of pore enlargement in not well
understood. However evidence from our lab demonstrates a role for actin remodeling in
HIV-1 entry post binding that would support the idea of HIV-1 hijacking cellular
machinery to create and expand the fusion pore (7, 12). In Chapters 2-4 we sought to
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determine the mechanism used by Env to mediate actin cytoskeleton rearrangements and
to establish what role these rearrangements are playing in fusion.
A previous study from our lab looked at the role of the actin filament network
during HIV-1 Env-dependent entry and virus dependent syncytium formation, utilizing
the actin cytoskeleton disrupting drugs JP, LA, and CD (7, 12). Previous studies showed
that formation of the Env-CD4-coreceptor complexes was inhibited by treatment of target
cells with the actin filament capping drug CD but the effect of other actin-targeted drugs
and the role of actin at later stages in entry was not investigated (25, 185). The study
from our lab went on to show that the actin filament stabilizing drug, JP and the actin
monomer sequestering drug, LA inhibited cell fusion mediated by X4 and R5 Env by 80
to 100% whether added before or after incubation at 25°C. As was shown previously CD
was only inhibitory when the drug was added before the 25°C incubation (12, 25, 185).
These results indicate that modulation of the actin cytoskeleton is necessary for HIV-1
entry both prior to and after formation of Env-CD4-coreceptor complexes.
This study then went on to support the role for actin-based structures in HIV-1
Env-mediated syncytium formation by confocal imaging. Membrane ruffles,
lamellipodia, and filopodial extensions were observed in target cells mixed with Envexpressing cells by time-lapse confocal microscopy (12). These actin structures are
mediated by Rac and Cdc42, while Rho stimulates formation of stress fibers which were
not observed in the target cell (12, 31). This study went on to show that Rac was
activated in target cells exposed to Env and that this activation was required for fusion
and dependent on Env ligation of CCR5. The results from this study indicate that HIV-1
Env-coreceptor interactions stimulate an intracellular signaling cascade that promotes
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Rac mediated reorganization of the actin filament network necessary to facilitate
membrane fusion (12, 25, 185).
Results
The data presented in Chapter 2 further substantiated a role for Rac activation in
membrane fusion. Treatment of target cells with a Rac GEF inhibitor blocked HIV-1
fusion as measured by the Env-dependent fusion assay, infection, or the virus-dependent
fusion assay (45). The concentration of Rac GEF inhibitor that blocked HIV fusion was
similar to that required to block Env-induced Rac activation. The specificity of the
inhibitor was examined by expressing a constitutively active Rac mutant, RacV12 in
target cells treated with inhibitor. Expression of RacV12 overcame the effects of the Rac
GEF inhibitor on Env-dependent fusion and on Env-dependent Rac activation (45). In
addition the Rac GEF inhibitor had no effect on Env-dependent Rho activation (data not
shown). This study also gave insight into the Rac GEF(s) required for Env-mediated Rac
activation, as Tiam-1 and Trio are the only Rac GEFs known to be sensitive to this
inhibitor (44). Additional studies looking at the role of downstream mediators of Rac in
HIV Env-mediated fusion showed no effects of chemical inhibitors of NADPH oxidase,
MEK, or myosin light chain. Expression of DN PAK-2 and PI3-K in target cells also had
no effect on Env-mediated fusion (unpublished findings). In addition, a study looking at
IL-17-mediated HIV permissiveness in quiescent T cells showed that DN PI3Kp110 and
the PI3-K inhibitor wortmannin had no effect on fusion or infection of cells with HIV
(186).
In an effort to identify the role of CCR5-mediated signaling in Env-induced Rac
activation and membrane fusion we made various mutations in the domains of the
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intracellular loops (ICLs) and cytoplasmic tail of CCR5 thought to associate with
different signaling effectors. It has been shown previously that certain intracellular
domains of CCR5 and CXCR4 can be mutated without affecting HIV-induced membrane
fusion (78-85, 187-189). It has also been shown that specific domains of CCR5 associate
with different Gα proteins and scaffolding molecules such as β-arrestin (40, 49, 80, 132).
To determine which CCR5 domains and subsequently which signaling molecules were
required for Env signaling to Rac, U87 CD4 cell lines were established that expressed
mutations in the ICL2, ICL3 or the cytoplasmic tail of CCR5. The ICL3 mutations made
in CCR5 were previously made in CCR1, which has 100% sequence homology to CCR5
in this region. These mutations in ICL3 of CCR1 disrupted CCR1 coupling to Gαq (80).
The mutations made in ICL2 replaced the arginine (R) and tyrosine (Y), from the
conserved DRY motif thought to associate with Gαi and β-arrestin, with glycine (G) and
alanine (A) (85). The mutation in the C terminus of CCR5 was a truncation of the
cytoplasmic tail engineered to end with amino acid (aa) 313. This mutation had been
shown previously to disrupt β-arrestin association and Ca+ flux (83-85).
After these cell lines were established they were sorted by GFP for CCR5
expression equal to that of U87 CD4 cells expressing wildtype CCR5 (wt cells). Upon
examination of surface expression by flow cytometry with a CCR5 monoclonal antibody
the mutants were observed to have a drastic reduction in the amount of surface expression
compared to wt cells. These results were then confirmed by confocal microscope
analysis. Next these cells were sorted for CCR5 surface expression similar to wt cells
using a monoclonal antibody to CCR5. However upon examining surface expression of
CCR5 on these newly sorted cell lines by flow cytometry and confocal microscopy, it
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became apparent that there was still little to no surface expression of mutant CCR5
(figure 1). The sequences for all of the mutants were double checked and are the same as
the CCR5 expressed in wt cells except for the targeted mutations. These results together
with the confocal analysis lead to the conclusion that these mutations prevent proper
surface trafficking of CCR5, as similar levels of CCR5 are synthesized (figure 1B).
Although these mutations were all made previously in other studies, further investigation
of the literature confirmed that the mutations do in fact affect surface expression of
CCR5. (84, 85, 190, 191)
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Fig 1. Mutations in the ICL2, ICL3, and a deletion in the C-terminus of CCR5.GFP
prevent its surface expression. (A) Confocal micrographs of U87.CD4.CCR5.GFP cells
(wildtype

CCR5,

far

left),

U87.CD4.CCR5.ICL3.GFP

(middle

left),

U87.CD4.CCR5.ICL2.GFP (right center), and U87.CD4.CCR5∆C.GFP (far right), fixed
and stained with anti-CD4-PE antibodies (red). The green GFP signal and red PE signal
have been merged to show areas of colocalization (yellow). (B) The mutant CCR5
constructs were transiently transfected into 293T cells and 48hr post transfection
untransfected (not shown but used to determine R1) and transfected 293T cells were
labeled for surface expression of CCR5 (anti-CCR5 primary and anti-mouse PEconjugated secondary) and analyzed by flow cytometry. The lower left quadrant are cells
that do not express CCR5 (R1), the lower right quadrant are cells that express CCR5 as
determined by expression of GFP but it is not on the surface (R2), and the upper right
quadrant are cells that express CCR5 at the surface (R4, PE staining).

Green: CCR5-GFP

Red: CD4

Yellow: Colocalization
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Since generation of CCR5 molecules unable to couple with signaling
intermediates was not possible, we looked for alternative methods to determine the
signaling pathway that regulates Env-mediated Rac activation and membrane fusion. In
chapter 3 we utilized small interfering RNA (siRNA) and various small molecule
inhibitors to determine the Env-induced signaling pathway required for Rac activation
and fusion. The results from this study demonstrate that HIV-1 Env mediates activation
of the Gαq pathway via CCR5 and this activation is critical for HIV-1 induced membrane
fusion. Expression of Gαq, Gαi, and Gαs was downregulated by siRNA, and Env-mediated
Rac activation and fusion were measured. Env-induced Rac activation and cell fusion
were attenuated in cells expressing siRNA targeted to Gαq but not in cells expressing
siRNA targeted to Gαi, or Gαs (73). Treatment of cells with inhibitors to the Gαq
downstream effectors, PLCβ, PKC, intracellular Ca2+ release, and Ras, also blocked Envmediated Rac activation and membrane fusion. Whereas inhibitors specific for PKA, the
downstream effector of Gαs, and PTX which blocks signaling via Gαi had no effect on
Env-dependent Rac activation and cell fusion (73). In addition, Env-dependent Rac
activation and cell fusion was also attenuated in cells expressing siRNA targeted to pyk2
which is activated downstream of PKC and intracellular Ca2+ release, and is a mediator of
Ras activation. Expression of RacV12 overcame the effects of Gαq and pyk2 siRNA as
well as the effects of inhibitors of PLCβ and PKC on Env-dependent cell fusion,
suggesting that these signaling mediators are acting upstream of Rac. Whereas levels of
Env-induced fusion were only partially recovered by expression of RacV12 in cells
treated with inhibitors to intracellular Ca2+ release and Ras, suggesting they play a role
both upstream and downstream of Rac (73).
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Similar results were obtained when cell fusion was induced by Env-expressed on
viral or cellular membranes and when cell lines or primary cells were the target.
Furthermore, single cycle infection of HIV-1 was also attenuated when Gαq and its
downstream signaling mediators were blocked. On the other hand, infection of cells with
A-MLV Env or VSV-G pseudotyped HIV-1 was not blocked by inhibitors to PKC,
intracellular Ca2+ release and Ras, suggesting that these signaling mediators are
specifically required for HIV-1 mediated fusion (73). The PLC inhibitor had a greater
effect on HIV-1 infection than on Env-dependent fusion and also slightly decreased
infection of cells with A-MLV-HIV-1 and VSV-G-HIV-1, suggesting that PLC is
required at a post-fusion step in the virus life cycle (73).
In summary, chapter 3 provides evidence that HIV-1 Env interaction with CCR5
stimulates a signaling cascade involving Gαq, PLC, PKC, intracellular Ca2+ release, Pyk2
and Ras that allows activation of Rac and subsequent actin cytoskeleton rearrangements
necessary for fusion. These results confirm and extend the implication of Rac in HIV-1
infection, and elucidate new potential target molecules of HIV-1 inhibitory drugs.
The data presented in chapter 4 builds upon this pathway and demonstrates the
role of the Rac GEF Tiam-1, the src tyrosine kinase Abl, and the Wave2 complex in
mediating Env-induced reorganization of the actin cytoskeleton necessary for membrane
fusion. This chapter also demonstrates that Abl kinase is required for membrane fusion
after the hemifusion step, supporting the hypothesis that the virus hijacks cellular
machinery to facilitate pore formation and enlargement (7). In this study we used siRNA
to downregulate expression of the Rac GEFs Tiam-1 and Trio. We also used siRNA to
downregulate expression of the src tyrosine kinase Abl. Abl has been shown previously
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to modulate the actin cytoskeleton both upstream and downstream of Rac (157, 168-170,
192-199). Env-mediated cell fusion and HIV-1 infection of TZM-BL cells was attenuated
in cells expressing siRNA targeted to Tiam-1 and Abl but not in cells expressing siRNA
targeted to Trio, despite a 70% reduction in protein levels of Trio. Expression of RacV12
in cells completely overcame the effect of Tiam-1 directed siRNA, but only partially
recovered levels of fusion in cells expressing Abl directed siRNA. These results support
the idea that Tiam-1 is required upstream of Rac to facilitate its activation and Abl is
functioning upstream and downstream of Rac in Env-mediated cell fusion. As mentioned
previously, different GEFs are induced by specific signaling components and act not only
as activators of Rac but also control the effectors activated. GEFs participate in
subsequent signaling by directing localization of the activated Rac GDP to GTP exchange
and by interacting in scaffold complexes that organize specific downstream signaling
mediators (27, 28, 31, 42, 44, 144, 150).
Theses results demonstrate a role for Tiam-1 and Abl, but not Trio, in Envmediated Rac activation and membrane fusion suggesting that the downstream effector of
Rac is the Arp2/3 actin nucleating complex. Arp2/3 is activated downstream of Rac by
the Wave2 complex which includes five main proteins, Wave2, Sra-1, Nap-1, Abi2, and
HSP C300. The tyrosine kinase Abl has been shown to associate with the Wave2
complex via the Abi2 protein and and has been shown to phosphorylate Wave2
enhancing the ability of Wave2 to activate the Arp2/3 complex. In addition, the adaptor
protein IRSp53 has been shown to interact with Tiam-1, and this interaction links Rac to
Wave2 mediated Arp2/3 activation (150). In this study we observed a decrease in Envmediated fusion and HIV-1 infection with cells expressing Irsp53, Wave2 and Arp3
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directed siRNA. This decrease was not overcome by expression of RacV12,
demonstrating a role for these proteins downstream of Rac in Env-mediated fusion.
However expression of siRNA reistant Arp3 did overcome the decrease in fusion in cells
expressing siRNA to Arp3 but not siRNA to Rac, suggesting that the effects observed
with RNAi were specific. The decrease in fusion and infection observed with siRNA
targeted to Abl, Tiam-1, IRSp53, Wave2 and Arp3 directly correlated with the decrease
in protein expression as seen by immunoblot.
Since treatment of cells with Abl targeted siRNA attenuated Env-dependent
fusion and HIV-1 infection, we next sought to determine the effects of commercially
available Abl kinase inhibitors, IMB, NIL and DAS, on fusion and infection. The
inhibitor concentrations employed did not alter levels of CD4 or CCR5 expression or
localization on the surface of cells nor did they result in nonspecific effects on vaccinia
virus infection or T7 polymerase activity. These inhibitors were used in multiple assays
including Env-dependent cell fusion with cell lines and primary cells as the target, virusdependent cell fusion, Infection of TZM-BL cells with both R5 and X4 virus and Rac
activation assays. The Abl kinase inhibitors completely abolished fusion and infection
mediated by both R5 and X4 Env. Env-mediated Rac activation and virus dependent cell
fusion were similarly abolished. Expression of RacV12 partially overcame the inhibitor
effects on Env-mediated fusion similar to the effects of RacV12 expression seen in cells
expressing Abl targeted siRNA. Treatment of cells expressing drug resistant clones of
Bcr-Abl with Abl kinase inhibitors had no effect on Env-mediated fusion suggesting that
the effects of these drugs on fusion were specific to inhibition of Abl. The inhibition of
infection of TZM-BL cells expressing Abl, Tiam-1, IRSp53, Wave2 and Arp3 directed
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siRNA or treated with Abl kinase inhibitors was overcome when HIV-1 virions were
psuedotyped with VSV-G or A-MLV Env. These results suggest that these signaling
mediators are necessary for HIV-1 Env mediated fusion and entry but are not necessary
for clathrin or caveloa-mediated endocytosis, and they are not required at post-entry steps
in the virus life cycle. An Abl kinase assay was also performed and demonstrated that
incubation of target cells with HIV-1 Env-expressing cells resulted in a 2 fold increase in
Abl kinase activity (measured by an increase in phosphorylated CrkL, a downstream
target of active Abl kinase) and Abl kinase activity is inhibited by IMB, NIL, and DAS.
To determine what step in the fusion process is dependent on Abl kinase-mediated
actin cytoskeleton rearrangements we used the membrane-permeable, cationic
amphipaths, CPZ, DB, and TFP that induce positive spontaneous curvature of the plasma
membrane, which in turn disrupts the hemifusion intermediate and promotes pore
formation (176, 200, 201). We also tested the effect of the exogenous cone shaped lipid
OLA that promotes negative spontaneous curvature of the membrane and lipid mixing
(165, 202). Brief exposure of Abl kinase inhibitor treated cells to CPZ, DB, and TFP 30
min after incubation with virus increased fusion by ten to fifteen fold above the fusion
observed with inhibitor treated cells not treated with membrane curving agents. Brief
exposure of TAK-779 treated cells to CPZ, DB, and TFP did not lead to an increase in
fusion as was expected. Infection of TZM-BL cells was similarly increased for Abl
kinase inhibitor treated cells upon exposure to CPZ and TFP. OLA did not increase virusdependent membrane fusion or infection of HIV-1 in cells treated with Abl kinase
inhibitors. No increase was observed in cells lacking exposure to virus, or in CCR5 cells
exposed to X4 virus, indicating that the increase in fusion and infection was dependent on
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Env. The block was not overcome by the exogenous lipid OLA, which promotes lipid
mixing and hemifusion suggesting that the inhibitor treated cells are not arrested prior to
hemifusion. Another assay utilizing confocal microscopy demonstrated that addition of
IMB to the fusion reaction allowed lipid but not cytoplasmic mixing, confirming that
inhibition of Abl kinase arrests fusion at the hemifusion stage and that Abl kinases are
required for pore formation.
In conclusion the data from chapters 2, 3, and 4 support the role of Env-mediated
signaling to the actin cytoskeleton in membrane fusion and virus entry. Chapter 2
confirmed the requirement for Rac activation in membrane fusion and gave clues to the
Rac GEF mediating Env-dependent Rac activation (45). Chapter 3 demonstrated that the
signaling pathway activated by Env binding to coreceptor required for Rac activation and
membrane fusion was the Gαq pathway. This pathway involves multiple signaling
components including PLCβ, PKC, pyk2 and Ras. Chapter 4 established a role for the
Rac GEF Tiam-1 and Abl in Env-dependent Rac activation and membrane fusion and
showed that signaling from Rac to the actin cytoskeleton is dependent on Abl, IRSp53,
Wave2 and Arp3. Data present in chapter 4 also suggested that Abl kinase-mediated actin
cytoskeleton rearrangements are required at a post-hemifusion step in the fusion process
and that HIV-1 membrane fusion and infection can be inhibited by IMB, NIL and DAS.

Future Directions
The Rac-Wave2-Arp2/3 pathway described in Chapter 4 mediates actin
polymerization, however actin rearrangement is a dynamic process that not only requires
actin nucleation but also requires release of monomeric actin, and exposure of barbed
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ends. In addition to activating Arp2/3, Rac has been shown to regulate actin dynamics by
activating ADF/cofilin to accelerate actin turnover, and by regulating proteins such as
gelsolin that promote the uncapping of actin at filament ends, leading to exposure of
barbed ends (30, 35). The signaling mediators necessary for release of capping proteins
and actin monomers in Env-mediated actin cytoskeletal rearrangements are unknown,
and could provide additional targets for therapeutic intervention.
A recent study demonstrated a requirement for phosphatidylinositol 4-phosphate
5-kinase (PI4P5-K) activity, which mediates production of phosphatidylinositol (4,5)bisphosphate (PIP2), in HIV-1 membrane fusion and entry (203). The production of PIP2
is triggered by Env-CD4 interactions and localizes at sites of Env-target cell contact
along with F-actin. PI4P5-K is a downstream effector of Rac where it mediates focal
complex assembly and is involved in release of actin capping proteins from barbed ends
of actin filaments. PI4P5-K is also a downstream effector of Rho and is involved in focal
adhesion assembly (30). Another protein implicated in cell motility and Rac-mediated
actin structures is profilin. When actin barbed ends are free to polymerize, profilin
promotes actin filament dynamics by catalyzing nucleotide exchange on actin from ADPto ATP, thereby contributing to actin polymerization at the leading edge of lamellipodia
(204). A role for profilin in HIV-1 cell fusion has recently been demonstrated in
macrophages (204). Another protein that regulates actin cytoskeletal dynamics
downstream of Rho GTPases is actin depolymerizing factor ADF/cofilin. ADF/cofilins
bind to actin-GDP at the ends of aged filaments and promote actin monomer dissociation.
ADF/coflin can also bind to actin monomers and prevent GDP to GTP exchange. The
role of ADF/cofilin in HIV-1 entry is slightly ambiguous since some studies suggest that
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it is phosphorylated and inactivated by Env-mediated ROCK activation (11), and other
studies suggest that ADF/cofilin is dephosphorylated and activated by Env signaling
through CXCR4 (205). The role of various downstream effectors of Rho and Rac that
mediate actin turnover and uncapping of barbed ends in Env-dependent fusion should be
tested with available siRNA and small molecule inhibitors.
Future studies should also address the role of CD4 in Env-induced actin
cytoskeleton rearrangements necessary for fusion. It is clear based on many published
articles that gp120 mediates actin-dependent recruitment of CD4 and CXCR4 to sites of
gp120 binding (10, 11, 25, 77, 104, 206, 207). However it is unclear whether Env
signaling through CD4 alone or signaling through CD4 and coreceptor is required for
Env, CD4 and coreceptor clustering. In addition the mechanism of actin-mediated
clustering of receptors is unclear. Some studies have shown a requirement for CD4
mediated activation of Ezrin-radixin-moesin (ERM) proteins that is not dependent on the
Rho effector ROCK or PKC (77). However, Rho could still play a role in ERM activation
through PIP2 and another unknown mediator (27). Other studies have shown a role for
CD4 and coreceptor-mediated filamin-A interactions in receptor clustering that is
dependent on RhoA and ROCK mediated phosphorylation of ADF/cofilin (11).
In a previous study our lab demonstrated that expression of DN Rac completely
attenuated Env-dependent fusion whereas expression of DN RhoA decreased fusion by
40% (18). Based on results showing a role for Rho activation in HIV-1 entry (11, 12, 33),
I hypothesize that CD4-mediated RhoA activation is responsible for Env-CD4-coreceptor
clustering required for binding, and subsequent signaling through coreceptor to Rac is
necessary for pore formation and enlargement. (35). Rac and Rho have been shown to
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actively antagonize one another and mediate different processes (27, 36, 37). The C
terminus of gp41 interacts with and inhibits p115 Rho GEF, suggesting that Rho is turned
off and unnecessary for fusion events after gp41 insertion (38). Therefore it seems likely
that Rho is only involved in the initial steps of Env-induced fusion prior to hemifusion
and is subsequently inactivated by Rac and/or the C terminus of gp41.
On the other hand, Env-mediated signaling to Rac and the actin cytoskeleton
could occur through CD4 or coreceptor or both resulting in enhanced signaling (43, 49,
64, 89). No studies have been performed in cells expressing mutant CD4 and mutant
coreceptor incapable of signaling. A signaling pathway similar to the Gαq pathway is
elicited by activation of CD4 suggesting that signaling necessary for fusion could occur
through either receptor. The presence of CD4 could also play role in determining the
signaling pathway elicited and the amount of activation (101, 102).
We are currently testing these hypotheses by expressing multiple CD4 mutants
incapable of signaling in target cells and performing assays with lipid analogs and the
hemifusion assay described in chapter 4.

Preliminary Results:
U87 cell lines expressing CCR5.GFP alone (U87 CCR5) and U87 cell lines
expressing CCR5.GFP and tailless CD4 (U87 CD4.401 CCR5) have been established.
U87 cell lines expressing CD4 mutants that cannot bind to filamin A or p56lck are being
established. The cell lines expressing CCR5 alone were used in an Env-dependent cell
fusion assay where they were infected with a vaccinia virus expressing CD4. These cells
showed similar amounts of fusion to U87 cells expressing wt CD4 and wt CCR5.GFP (wt
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cells). In addition the surface expression of CCR5 was determined to be equal to
expression in wt cells via FACS. When this cell line was used in a Rac activation assay a
significant decrease in the amount of Rac activation was observed in comparison to wt
cells. These results suggest that CD4 is required for total Env-induced Rac activation.
Based on these experiments it is still unknown whether CD4 is only required to induce
the conformational change required for efficient binding to CCR5 or whether its
cytoplasmic domain is involved in the signaling pathway leading to optimal Rac
activation.
To address this question U87 CD4.401.CCR5 cells were engineered and sorted
for surface expression of CD4 and CCR5 that is similar to wt cells. These cells as well as
U87.CD4.CCR5, U87.CCR5 and U87.CD4 cells were studied in a quantitative Env- and
virus- dependent cell fusion assay and Rac activation assay. Although these cells express
similar levels of receptor at the surface, cell fusion and Rac activation with U87.CD4.401
CCR5 cells were reduced by 61 ± 7% and 64 ± 2% respectively compared to cells
expressing wt CD4 and CCR5 (Fig. 2).
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Fig. 2. Deletion of CD4 C-terminus attenuates Env-dependent fusion and Rac
activation and virus-dependent fusion. (A) Average fusion compared to untreated
control reactions and detected by ß-galactosidase activity ± standard deviation are shown.
U87.CD4.CCR5, U87.CD4, U87.CCR5 and U87.CD4.401.CCR5 were infected with
vCB21R overnight then incubated with HIVUNC (subtracted as background) HIVADA,
HIVYU2, HIV89.6 or HIVHXB2 Env-expressing cells for 3h. Data are representative of
results from three similar experiments performed in triplicate. Cell fusion was normalized
using U87.CD4.CCR5 cells incubated with HIVADA Env as 100%. (B) Cells were
incubated for 30 min with BSC40 cells expressing no Env (subtracted as background), or
HIVADA Env. Whole cell lysates were then analyzed by Rac specific G-LISA activation
assay. Average A490 of duplicate wells ± standard deviation; data are representative of
results from three similar experiments. (C) One population of U87.CD4.CCR5 or
U87.CD4.401.CCR5 cells was infected with vCB21R and the other population of cells
was infected with vPT7-3 in complete media overnight. These cells were then mixed
(1:1) in triplicate wells of 96 well plate and incubated with 75, 100, and 150ng of HIVYU2
per well for 3h at 37°C. Data are representative of results from three similar experiments
(*, P < 0.01). Cell fusion was normalized using U87.CD4.CCR5 cells mixed with 150ng
HIVYU2 as 100%.
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Future studies will include Env- and virus-dependent fusion assays, and Rac and Rho
activation assays with mutant CD4 cell lines. Kinetic assays and temperature assays will
also be performed to determine whether the observed attenuation in fusion is at the
binding step and if allowing increasing amounts of time for binding before raising the
temperature will increase the levels of fusion with these mutants. Mutant CD4 and CCR5
localization should also be determined before and after treatment with Env to see if
disrupting signaling through CD4 is effecting the recruitment of coreceptor to the site of
Env-CD4 complexes. This can be done by confocal microscopy analysis and by coimmunoprecipitation assays with antibodies to CD4, coreceptor, and gp120 (Env) (208).
Cells will also be treated with the small molecule inhibitors damnacanthal (blocks lck
activity) and piceatannol (blocks syk kinase ZAP-70) and the effects on Env-dependent
fusion will be measured (205). We will also test Env-dependent fusion with Jurkat cells,
which like T cells have Lck, or Jurkat derivatives deficient in Lck, ZAP70, or LAT.
Finally, assays to determine the fusion steps dependent on CD4 will be performed, using
mutants and inhibitor treated cells in hemifusion assays with lipid analogs and with
CHO-K1 cells.

Therapeutic Implications and Conclusions
As mentioned previously the current anti-retroviral therapy, HAART, has
important limitations, including rapid virus replication rebound after withdrawal, the
increasing emergence and transmission of multi-resistant viral strains, difficulties in
patient compliance, severe side effects and high cost that prevents delivery to
undeveloped countries (2, 57). These considerations underscore the need for further
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progress in drug discovery. Blocking HIV entry, versus blocking other steps in the virus
life cycle is an attractive strategy since this would lock HIV outside the cell and thereby
prevent the virus from replenishing its latent cellular reservoirs, the last hurdle in HIV
eradication (57). However there are caveats to targeting the Env glycoprotein, as it one of
the most variable HIV proteins, making evolution of drug resistance likely.
Drugs that antagonize CD4, CXCR4, or CCR5 are also risky because they could
interfere with their normal immune signaling functions in the cell. In addition, use of
inhibitors that block both CCR5 and CXCR4 would be necessary to prevent promiscuous
coreceptor usage. Although CCR5 and CXCR4 are the only chemokine receptors thought
to be targeted by HIV in vivo, multiple other chemokine receptors have been shown to be
functional coreceptors in vitro, suggesting that under selective pressure HIV-1 could
evolve to use other chemokine receptors (50). An additional concern with the use of
coreceptor inhibitors is the risk of interfering with the physiology of other GPCRs which
are widespread. Cross reaction of inhibitors with other GPCRs would cause side effects
unrelated to interference with the chemokine system (57).
The discovery of a role for Abl kinase in HIV-1 Env-mediated entry is a
particularly encouraging result as the development and clinical application of IMB, DAS,
and NIL that block deregulated Bcr-Abl in chronic myeloid leukemia patients clearly
shows that inhibition of Abl kinases is possible in vivo with clinically manageable side
effects (160, 171, 193). The next step will be to test IMB (Gleevac) in individuals
infected with HIV-1 that have failed HAART therapy. Patients should be treated and the
effect of the drug should be monitored by viral loads. In addition viral samples should be
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taken to monitor resistance of virus to IMB. PBMC and CD4+ T cells should also be
monitored for virus induced-changes in susceptibility to infection in the presence of IMB.
Studies should also been done prior to patient treatment to test for emergence of
drug resistance. PBMCs should be infected with R5 and X4 viruses in the presence of 3
different concentrations of IMB, for example 0.1uM, 1uM, and 10uM. These cells should
be cultured for several weeks and used in entry and infection assays in the presence of
IMB to test for new susceptibility to infection and fusion. Virus will be retitered on
MAGI-5 cells in the presence or absence of IMB to test for resistance.
The Env-mediated signaling pathway to Rac contains multiple factors that could
be potential drug targets. There are multiple PKC inhibitors in clinical trials or approved
for clinical use to treat cancer and diabetes (153). Studies with the Ras inhibitor FTS in
mice have given encouraging results for the treatment of various types of cancer,
neurofibromatosis, and kidney disease (154-156). In addition, FTS is currently in phase I
clinical trials for hematologic malignancies (155). The ability of these inhibitors and the
Abl kinase inhibitors to specifically down-regulate their target molecules without adverse
side effects suggests that these inhibitors might be appropriate drugs for treatment of
HIV-1 and other infectious microbes that manipulate this pathway. In addition,
determining the other signaling effectors of Rho and Rac that mediate Env-dependent
fusion could provide additional targets for therapeutic intervention. This strategy of using
inhibitors that disable host signaling proteins rather than viral proteins, essential for
pathogen survival, may have a general efficacy in developing drugs to combat HIV-1 and
other pathogens that acquire drug resistance.

161

REFERENCES

1.
2.
3.
4.
5.
6.

7.
8.
9.
10.

11.
12.

13.

14.

15.

16.

17.

Fauci AS (2003) HIV and AIDS: 20 years of science. Nature Med 9: 839-843.
Greene WC, Peterlin BM (2002) Charting HIV's remarkable voyage through the
cell: Basic science as a passport to future therapy. Nature Med 8: 673-680.
Flint SJ, et al. (2000) Principles of Virology, Molecular Biology, Pathogenesis,
and Control (ASM Press.
Gallo SA, et al. (2003) The HIV Env-mediated fusion reaction. Biochim Biophys
Acta 1614: 36-50.
Le Rouzic E, Benichou S (2005) The Vpr protein from HIV-1: distinct roles along
the viral life cycle. Retrovirology 2: 11.
Bergamaschi A, et al. (2009) The human immunodeficiency virus type 2 Vpx
protein usurps the CUL4A-DDB1DCAF1 ubiquitin ligase to overcome a
postentry block in macrophage infection. J Virol 83: 4854-4860.
Melikyan G (2008) Common principles and intermediates of viral proteinmediated fusion: the HIV-1 paradigm. Retrovirology 5: 111.
Miyauchi K, et al. (2009) HIV enters cells via endocytosis and dynamindependent fusion with endosomes. Cell 137: 1-12.
Keduo Qian SLM-N, Kuo-Hsiung Lee, (2009) HIV entry inhibitors and their
potential in HIV therapy. Medicinal Research Reviews 29: 369-393.
Nguyen DH, Giri B, Collins G, Taub DD (2005) Dynamic reorganization of
chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of
CD4 engagement. Exp Cell Res 304: 559-69.
Jimenez-Baranda S, et al. (2007) Filamin-A regulates actin-dependent clustering
of HIV receptors. Nat Cell Biol 9: 838-846.
Pontow S, Heyden N, Wei S, Ratner L (2004) Actin cytoskeletal reorganizations
and coreceptor-mediated activation of Rac during human immunodeficiency
virus-induced cell fusion. J Virol 78: 7138 - 7147.
Finnegan C, Berg W, Lewis G, DeVico A (2002) Antigenic properties of the
human immunodeficiency virus transmembrane glycoprotein during cell-cell
fusion. J Virol 76: 12123 - 12134.
Dimitrov A, et al. (2005) Conformational changes in HIV-1 gp41 in the course of
HIV-1 envelope glycoprotein-mediated fusion and inactivation. Biochemistry 44:
12471 - 12479.
Dimitrov A, et al. (2007) Exposure of the membrane-proximal external region of
HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion.
Biochemistry 46: 1398 - 1401.
Abrahamyan L, et al. (2005) The cytoplasmic tail slows the folding of human
immunodeficiency virus type 1 Env from a late prebundle configuration into the
six-helix bundle. J Virol 79: 106 - 115.
Gallo S, et al. (2004) Temperature-dependent intermediates in HIV-1 envelope
glycoprotein-mediated fusion revealed by inhibitors that target N- and C-terminal
helical regions of HIV-1 gp41. Biochemistry 43: 8230 - 8233.

162

18.

19.
20.

21.

22.

23.

24.
25.

26.
27.
28.
29.
30.
31.
32.
33.
34.

35.

36.
37.

Golding H, et al. (2002) Dissection of human immunodeficiency virus type 1
entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 76: 6780 6790.
Koshiba T, Chan D (2002) The prefusogenic intermediate of HIV-1 gp41 contains
exposed C-peptide regions. J Biol Chem 278: 7573 - 7579.
Markosyan R, Cohen F, Melikyan G (2003) HIV-1 envelope proteins complete
their folding into six-helix bundles immediately after fusion pore formation. Mol
Biol Cell 14: 926 - 938.
Mkrtchyan S, et al. (2005) Ternary complex formation of human
immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an
intermediate of membrane fusion. J Virol 79: 11161 - 11169.
Melikyan G, et al. (2000) Evidence that the transition of HIV-1 gp41 into a sixhelix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol
151: 413 - 424.
Melikyan G, et al. (2005) Imaging individual retroviral fusion events: from
hemifusion to pore formation and growth. Proc Natl Acad Sci USA 102: 8728 8733.
Eitzen G (2003) Actin remodeling to facilitate membrane fusion. Biochim
Biophys Acta 1641: 175-81.
Iyengar S, Hildreth J, Schwartz D (1998) Actin-dependent receptor colocalization
required for human immunodeficiency virus entry into host cells. J Virol 72: 5251
- 5255.
Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420:
629-35.
Burridge K, Wennerberg K (2004) Rho and Rac take center stage. Cell 116: 16779.
Bourne HR (2005) Rac and cell migration: CDM proteins integrate signals.
Nature Cell Biology 7: 777-778.
Ridley AJ, et al. (1992) The small GTP-binding protein Rac regulates growth
factor-induced membrane ruffling. Cell 70: 401-10.
Ridley AJ (2001) Rho GTPases and cell migration. Journal of Cell Science 114:
2713-2722.
Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279: 509-514.
Kjoller L, Hall A (1999) Signaling to Rho GTPases. Exp Cell Res 253: 166-79.
del Real G, et al. (2004) Statins inhibit HIV-1 infection by down-regulating Rho
activity. J Exp Med 200: 541 - 547.
Bader MF, et al. (2004) Coupling actin and membrane dynamics during calciumregulated exocytosis: a role for Rho and ARF GTPases. Biochim Biophys Acta
1742: 37-49.
Disanza A, et al. (2005) Actin polymerization machinery: the finish line of
signaling networks, the starting point of cellular movement. Cell Mol Life Sci 62:
955-70.
Caron E (2003) Rac signalling: a radical view. 5: 185-187.
Ohta Y, Hartwig JH, Stossel TP (2006) FilGAP, a Rho- and ROCK-regulated
GAP for Rac binds filamin A to control actin remodelling. 8: 803-814.

163

38.
39.
40.
41.

42.
43.
44.
45.

46.

47.
48.
49.

50.
51.

52.
53.

54.
55.

56.

Zhang H, et al. (1999) Functional interaction between the cytoplasmic leucinezipper domain of HIV-1 gp41 and p115-RhoGEF. Curr Biol 9: 1271-4.
Raftopoulou M, Hall A (2004) Cell migration: Rho GTPases lead the way. Dev
Biol 265: 23-32.
Oppermann M (2004) Chemokine receptor CCR5: insights into structure,
function, and regulation. Cell Signal 16: 1201-10.
Naor Z, Benard O, Seger R (2000) Activation of MAPK cascades by G-proteincoupled receptors: the case of gonadotropin-releasing hormone receptor. Trends
Endocrinol Metab 11: 91-9.
Mertens AE, Roovers RC, Collard JG (2003) Regulation of Tiam1-Rac signalling.
FEBS Lett 546: 11-6.
Huang Y, Wange RL (2004) T cell receptor signaling: beyond complex
complexes. J Biol Chem 279: 28827-28830.
Gao Y, et al. (2004) Rational design and characterization of a Rac GTPasespecific small molecule inhibitor. Proc Natl Acad Sci USA 101: 7618-7623.
Pontow S, Harmon B, Campbell N, Ratner L (2007) Antiviral activity of a Rac
GEF inhibitor characterized with a sensitive HIV/SIV fusion assay. Virology 368:
1-6.
Santy LC, Ravichandran KS, Casanova JE (2005) The DOCK180/Elmo complex
couples ARNO-mediated Arf6 activation to the downstream activation of Rac1.
Curr Biol 15: 1749-54.
Sanui T, et al. (2003) DOCK2 regulates Rac activation and cytoskeletal
reorganization through interaction with ELMO1. Blood 102: 2948-2950.
Fukui Y, et al. (2001) Haematopoietic cell-specific CDM family protein DOCK2
is essential for lymphocyte migration. Nature 412: 826-31.
Stantchev TS, Broder CC (2001) Human immunodeficiency virus type-1 and
chemokines: beyond competition for common cellular receptors. Cytokine Growth
Factor Rev 12: 219-43.
Broder C, Collman R (1997) Chemokine receptors and HIV. J Leukoc Biol 62:
20-29.
Otsuka S, Bebb G (2008) The CXCR4/SDF-1 chemokine receptor axis: a new
therapeutic target for non-small cell lung cancer. Journal of Thoracic Oncology 3:
1379-1383.
Mueller A, Strange PG (2004) The chemokine receptor, CCR5. The International
Journal of Biochemistry & Cell Biology 36: 35-38.
Lim JK, Glass WG, McDermott DH, Murphy PM (2006) CCR5: no longer a
‘good for nothing’ gene – chemokine control of west nile virus infection. Trends
in Immunology 27: 308-312.
Klein RAS (2008) A moving target: the multiple roles of CCR5 in infectious
diseases. The Journal of Infectious Diseases 197: 183-186.
Lim JK, et al. (2008) Genetic deficiency of chemokine receptor CCR5 is a strong
risk factor for symptomatic west nile virus infection: an analysis of 4 cohorts in
the US epidemic. The Journal of Infectious Diseases 197: 262-265.
Pope M, Haase AT (2003) Transmission, acute HIV-1 infection and the quest for
strategies to prevent infection. 9: 847-852.

164

57.
58.
59.
60.

61.
62.
63.

64.

65.

66.
67.
68.

69.
70.
71.
72.

73.

74.
75.

Lusso P (2006) HIV and the chemokine system: 10 years later. Embo J 25: 447456.
Kuritzkes DR (2009) HIV-1 entry inhibitors: an overview. Current Opinion in
HIV and AIDS 4: 82-87.
Esté JA, Telenti A (2007) HIV entry inhibitors. The Lancet 370: 81-88.
Toth PT, Ren D, Miller RJ (2004) Regulation of CXCR4 receptor dimerization by
the chemokine SDF-1{alpha} and the HIV-1 coat protein gp120: a fluorescence
resonance energy transfer (FRET) study. J Pharmacol Exp Ther 310: 8-17.
van Buul JD, et al. (2003) Leukocyte-endothelium interaction promotes SDF-1dependent polarization of CXCR4. J Biol Chem 278: 30302-30310.
Konig R (2002) Interactions between MHC molecules and co-receptors of the
TCR. Curr Opin Immunol 14: 75-83.
Bour S, Geleziunas R, Wainberg M (1995) The human immunodeficiency virus
type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.
Microbiol Rev 59: 63-93.
Graziani-Bowering GM, Filion LG, Thibault P, Kozlowski M (2002) CD4 is
active as a signaling molecule on the human monocytic cell line Thp-1.
Experimental Cell Research 279: 141-152.
Kristiansen K (2004) Molecuar mechanisms of ligand binding, signaling, and
regulation within the superfamily of G-protein coupled receptors: molecular
modeling and mutagenesis approaches to receptor structure and function.
Pharmacol Ther 103: 21-80.
Bhattacharya M, Babwah AV, Ferguson SSG (2004) Small GTP-binding proteincoupled receptors. Biochem Soc Trans 32: 1040-1044.
Brady AE, Limbird LE (2002) G protein-coupled receptor interacting proteins:
emerging roles in localization and signal transduction. Cell Signal 14: 297-309.
Gudermann T, Schaneberg T, Schultz G (1997) Functional and structural
complexity of signal transduction via G-protein-coupled receptors. Annual Review
of Neuroscience 20: 399-427.
Hermans E (2003) Biochemical and pharmacological control of the multiplicity of
coupling at G-protein-coupled receptors. Pharmacol Ther 99: 25-44.
Heuss C, Gerber U (2000) G-protein-independent signaling by G-protein-coupled
receptors. Trends Neurosci 23: 469-75.
Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling
networks: emerging paradigms. Trends in Pharmacological Sciences 22: 368-376.
Gomez-Mouton C, et al. (2004) Dynamic redistribution of raft domains as an
organizing platform for signaling during cell chemotaxis. J Cell Biol 164: 759768.
Harmon B, Ratner L (2008) Induction of the G{alpha}q signaling cascade by the
human immunodeficiency virus envelope is required for virus entry. J Virol 82:
9191-9205.
Jolly C, Kashefi K, Hollinshead M, Sattentau QJ (2004) HIV-1 cell to cell transfer
across an Env-induced, actin-dependent synapse. J Exp Med 199: 283-293.
Bedinger P, et al. (1988) Internalization of the human immunodeficiency virus
does not require the cytoplasmic domain of CD4. 334: 162-165.

165

76.
77.

78.
79.

80.
81.

82.
83.

84.

85.

86.

87.
88.

89.

90.

Berger E, Murphy P, Farber J (1999) Chemokine receptors as HIV-1 coreceptors:
roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657 - 700.
Barrero-Villar M CJ, Gordón-Alonso M, Barroso-González J, Alvarez-Losada S,
Muñoz-Fernández MA, Sánchez-Madrid F, Valenzuela-Fernández A. (2009)
Moesin is required for HIV-1-induced CD4-CXCR4 interaction, F-actin
redistribution, membrane fusion and viral infection in lymphocytes. Journal of
Cell Science 122: 103-113.
Davis CB, et al. (1997) Signal transduction due to HIV-1 envelope interactions
with chemokine receptors CXCR4 or CCR5. J Exp Med 186: 1793-1798.
Amara A, et al. (2003) G protein-dependent CCR5 signaling is not required for
efficient infection of primary T lymphocytes and macrophages by R5 human
immunodeficiency virus type 1 isolates. J Virol 77: 2550-2558.
Arai H, Charo I (1996) Differential regulation of G-protein-mediated signaling by
chemokine receptors. J Biol Chem 271: 21814-21819.
Aramori I, et al. (1997) Molecular mechanism of desensitization of the chemokine
receptor CCR-5: receptor signaling and internalization are dissociable from its
role as an HIV-1 co-receptor. Embo J 16: 4606-4616.
Atchison RE, et al. (1996) Multiple extracellular elements of CCR5 and HIV-1
entry: dissociation from response to chemokines. Science 274: 1924-6.
Alkhatib G, et al. (1997) CC chemokine receptor 5-mediated signaling and HIV-1
co-receptor activity share common structural determinants. Critical residues in the
third extracellular loop support HIV-1 fusion. J Biol Chem 272: 19771-19776.
Farzan M, et al. (1997) HIV-1 entry and macrophage inflammatory protein-1beta
-mediated signaling are independent functions of the chemokine receptor CCR5. J
Biol Chem 272: 6854-6857.
Gosling J, et al. (1997) Molecular uncoupling of C-C chemokine receptor 5induced chemotaxis and signal transduction from HIV-1 coreceptor activity.
PNAS 94: 5061-5066.
Liu Q-H, et al. (2000) HIV-1 gp120 and chemokines activate ion channels in
primary macrophages through CCR5 and CXCR4 stimulation. PNAS 97: 48324837.
Lee C, et al. (2003) Macrophage activation through CCR5- and CXCR4-mediated
gp120-elicited signaling pathways. J Leukoc Biol 74: 676-682.
Del Corno M, et al. (2001) HIV-1 gp120 and chemokine activation of Pyk2 and
mitogen-activated protein kinases in primary macrophages mediated by calciumdependent, pertussis toxin-insensitive chemokine receptor signaling. Blood 98:
2909-2916.
Cicala C, et al. (1999) Induction of phosphorylation and intracellular association
of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T
cells by macrophage-tropic HIV envelope. J Immunol 163: 420-426.
Popik W, Hesselgesser JE, Pitha PM (1998) Binding of human immunodeficiency
virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of
inflammatory genes and activates the MEK/ERK signaling pathway. J Virol 72:
6406-6413.

166

91.

92.
93.

94.

95.

96.

97.

98.

99.
100.

101.
102.
103.
104.
105.

106.
107.

108.

Wang JM, et al. (1998) HIV-1 Envelope gp120 inhibits the monocyte response to
chemokines through CD4 signal-dependent chemokine receptor down-regulation.
J Immunol 161: 4309-4317.
Weissman D, et al. Macrophage-tropic HIV and SIV envelope proteins induce a
signal through the CCR5 chemokine receptor.
Yi Y, et al. (2004) Chemokine receptor utilization and macrophage signaling by
human immunodeficiency virus type 1 gp120: implications for
neuropathogenesis. J Neurovirol 10 Suppl 1: 91-6.
Badr G, et al. (2005) HIV Type 1 glycoprotein 120 inhibits human B cell
chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand
(CCL)20, and CCL21. J Immunol 175: 302-310.
Van Drenth C, et al. (2000) Desensitization of CXC chemokine receptor 4,
mediated by IL-16/CD4, is independent of p56lck enzymatic activity. J Immunol
165: 6356-6363.
Vlahakis SR, et al. (2001) Chemokine-receptor activation by env determines the
mechanism of death in HIV-infected and uninfected T lymphocytes. J Clin Invest
107: 207-215.
Madani N, Kozak SL, Kavanaugh MP, Kabat D (1998) gp120 envelope
glycoproteins of human immunodeficiency viruses competitively antagonize
signaling by coreceptors CXCR4 and CCR5. PNAS 95: 8005-8010.
Liu Q-H, et al. (2000) HIV-1 gp120 and chemokines activate ion channels in
primary macrophages through CCR5 and CXCR4 stimulation. Proc Natl Acad Sci
U S A 97: 4832-4837.
Popik W, Pitha PM (2000) Exploitation of cellular signaling by HIV-1:
unwelcome guests with master keys that signal their entry. Virology 276: 1-6.
Kinter A, Arthos J, Cicala C, Fauci AS (2000) Chemokines, cytokines and HIV: a
complex network of interactions that influence HIV pathogenesis. Immunol Rev
177: 88-98.
Staudinger R, et al. (2003) Evidence for CD4-enchanced signaling through the
chemokine receptor CCR5. J Biol Chem 278: 10389-10392.
Xiao X, et al. (1999) Constitutive cell surface association between CD4 and
CCR5. PNAS 96: 7496-7501.
Viard M, et al. (2002) Role of cholesterol in human immunodeficiency virus type
1 envelope protein-mediated fusion with host cells. J Virol 76: 11584 - 11595.
Lapham CK, et al. (1996) Evidence for cell-surface association between fusin and
the CD4-gp120 complex in human cell lines. Science 274: 602-605.
Mashikian MV, et al. (1999) Reciprocal desensitization of CCR5 and CD4 is
mediated by IL-16 and macrophage-inflammatory protein-1{beta}, respectively. J
Immunol 163: 3123-3130.
Pierson TC, Doms RW (2003) HIV-1 entry and its inhibition. Current Topics in
Microbiology & Immunology 281: 1-27.
Sodhi A, Montaner S, Gutkind JS (2004) Viral hijacking of G-protein-coupledreceptor signalling networks. Nature Reviews in Molecular Cell Biology 5: 9981012.
Matarrese P, Malorni W (2005) Human immunodeficiency virus (HIV)-1 proteins
and cytoskeleton: partners in viral life and host cell death. 12: 932-941.

167

109.

110.
111.

112.
113.

114.

115.

116.

117.

118.

119.
120.

121.

122.
123.

Esser MT, et al. (1999) Cyanovirin-N Binds to gp120 to interfere with CD4dependent human immunodeficiency virus type 1 virion binding, fusion, and
infectivity but does not affect the CD4 binding site on gp120 or soluble CD4induced conformational changes in gp120. J Virol 73: 4360-4371.
Clavel F, Charneau P (1994) Fusion from without directed by human
immunodeficiency virus particles. J Virol 68: 1179-1185.
Murakami T, Ablan S, Freed EO, Tanaka Y (2004) Regulation of human
immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease
activity. Journal of Virology 78: 1026-1031.
Kaushik R, Ratner L (2004) Role of HIV-1 matrix phosphorylation in an early
post-entry step of virus replication. Journal of Virology 78: 2319-2326.
Freed EO, Martin MA (1996) Domains of the human immunodeficiency virus
type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into
virions. Journal of Virology 70: 341-351.
Hung C-S, Heyden NV, Ratner L (1999) Analysis of the critical domain in the V3
loop of human immunodeficiency virus type 1 gp120 involved in CCR5
utilization. Journal of Virology 73: 8216-8226.
Pirounaki M, vanderHeyden NA, Arens M, Ratner L (2000) Rapid phenotypic
drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line.
Journal of Virologic Methods 85: 151-162.
Pontow S, Ratner L (2001) Evidence for common structural determinants of
human immunodeficiency virus type 1 coreceptor activity provided through
functional analysis of CCR5/CXCR4 chimeric coreceptors. J Virol 75: 1150311514.
Derdeyn CA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to
the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3
Loop of gp120. J Virol 74: 8358-8367.
Cavrois M, Noronha CD, Greene WC (2002) A sensitive and specific enzymebased assay detecting HIV-1 virion fusion in primary T lymphocytes. Nature
Biotechnology 20: 1151-1154.
Cavrois M, et al. (2004) HIV-1 virion fusion assay: uncoating not required and no
effect of Nef on fusion. Virology 328: 36-44.
Yonezawa A, Cavrois M, Greene WC (2005) Studies of Ebola virus glycoproteinmediated entry and fusion by using pseudotyped human immunodeficiency virus
type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor
necrosis factor alpha. J Virol 79: 918-926.
Saeed MF, Kolokoltsov AA, Davey RA (2006) Novel, rapid assay for measuring
entry of diverse enveloped viruses, including HIV and rabies. Journal of
Virological Methods 135: 143-150.
Janardhan A, et al. (2004) HIV-1 Nef binds the DOCK2-ELMO1 complex to
activate rac and inhibit lymphocyte chemotaxis. PLOS Biology 2.
Lakhe-Reddy S, et al. (2006) Beta8 integrin binds Rho GDP dissociation
inhibitor-1 and activates Rac1 to inhibit mesangial cell myofibroblast
differentiation. Journal of Biological Chemistry 281: 19688-19699.

168

124.

125.

126.

127.

128.

129.

130.

131.
132.

133.

134.

135.

136.

137.

Li E, Stupack D, Bokoch GM, Nemerow GR (1998) Adenovirus endocytosis
requires actin cytoskeleton reorganization mediated by Rho family GTPases.
Journal of Virology 72: 8806-8812.
Hoppe S, et al. (2006) Early herpes simplex virus type 1 infection is dependent on
regulated Rac1/Cdc42 signalling in epithelial MDCKII cells. Journal of General
Virology 87: 3483-3494.
Veettil MV, et al. (2006) RhoA-GTPase facilitates entry of Kaposi's sarcomaassociated herpesvirus into adherent target cells in a Src-dependent manner.
Journal of Virology 80: 11432-11446.
Wu L, et al. (1997) Interaction of chemokine receptor CCR5 with its ligands:
multiple domains for HIV-1 gp120 binding and a single domain for chemokine
binding. J Exp Med 186: 1373-1381.
Pravecz T, Norcross MA (1993) Costimulatory properties of the human CD4
molecule: enhancement of CD3-induced T cell activation by human
immunodeficiency virus type 1 through viral envelope glycoprotein gp120. AIDS
Research and Human Retroviruses 9: 945-955.
Kaslow RA, et al. (1987) he Multicenter AIDS Cohort Study: rationale,
organization, and selected characteristics of the participants. American Journal of
Epidemiology 126: 310-318.
Nussbaum O, Broder CC, Berger EA (1994) Fusogenic mechanisms of
enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virusbased assay quantitating cell fusion-dependent reporter gene activation. J Virol
68: 5411-22.
Scarlatti G, et al. (1997) In vivo evolution of HIV-1 co-receptor usage and
sensitivity to chemokine-mediated suppression. 3: 1259-1265.
Maghazachi AA, Al-aoukaty A (1998) Chemokines activate natural killer cells
through heterotrimeric G-proteins: implications for the treatment of AIDS and
cancer. FASEB J 12: 913-924.
Masci AM, et al. (2003) HIV-1 gp120 induces anergy in naive T lymphocytes
through CD4-independent protein kinase-A-mediated signaling. J Leukoc Biol 74:
1117-1124.
Kanmogne GD, et al. (2006) HIV-1 gp120 compromises blood-brain barrier
integrity and enhance monocyte migration across blood-brain barrier: implication
for viral neuropathogenesis. 27: 123-134.
Wei X, et al. (2002) Emergence of resistant human immunodeficiency virus type
1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents
Chemother 46: 1896-1905.
Amella C-A, Sherry B, Shepp DH, Schmidtmayerova H (2005) Macrophage
inflammatory protein 1{alpha} inhibits postentry steps of human
immunodeficiency virus type 1 infection via suppression of intracellular cyclic
AMP. J Virol 79: 5625-5631.
Wu D, Jiang H, Katz A, Simon M (1993) Identification of critical regions on
phospholipase C-beta 1 required for activation by G-proteins. J Biol Chem 268:
3704-3709.

169

138.

139.

140.

141.
142.

143.

144.
145.
146.
147.

148.

149.
150.

151.

152.

153.
154.

Suh B-C, Hille B (2002) Recovery from Muscarinic Modulation of M Current
Channels Requires Phosphatidylinositol 4,5-Bisphosphate Synthesis. Neuron 35:
507-520.
Jan C-R, Ho C-M, Wu S-N, Tseng C-J (1998) The phospholipase C inhibitor
U73122 increases cytosolic calcium in MDCK cells by activating calcium influx
and releasing stored calcium. Life Sciences 63: 895-908.
Treiman M CC, Christensen SB. (1998) A tool coming of age: thapsigargin as an
inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases. Trends Pharmacol Sci
19: 131-135.
Toullec D, et al. (1991) The bisindolylmaleimide GF 109203X is a potent and
selective inhibitor of protein kinase C. J Biol Chem 266: 15771-15781.
Blaukat A, et al. (1999) Adaptor proteins Grb2 and Crk couple pyk2 with
activation of specific mitogen-activated protein kinase cascades. J Biol Chem 274:
14893-14901.
Sajan MP, et al. (2002) Sorbitol activates atypical protein kinase C and GLUT4
glucose transporter translocation/glucose transport through proline-rich tyrosine
kinase-2, the extracellular signal-regulated kinase pathway and phospholipase D.
Biochem J 362: 665-74.
Lambert JM, et al. (2002) Tiam1 mediates Ras activation of Rac by a PI(3)Kindependent mechanism. Nat Cell Biol 4: 621-625.
Beer C, Andersen DS, Rojek A, Pedersen L (2005) Caveola-dependent endocytic
entry of amphotropic murine leukemia virus. J Virol 79: 10776-10787.
Maddon P, et al. (1988) HIV infection does not require endocytosis of its
receptor, CD4. Cell 54: 865-874.
Alfano M, et al. (1999) The B-Oligomer of pertussis toxin deactivates CC
chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains. J Exp Med 190:
597-606.
Stantchev TS MI, Telford WG, Clouse KA, Broder CC. (2007) The tyrosine
kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages.
Virus Res 123: 178-189.
Alfano M, Guido P (2004) Role of cytokines and chemokines in the regulation of
innate immunity and HIV infection. Molecular Immunology 42: 161-182.
Connolly BA, Rice J, Feig LA, Buchsbaum RJ (2005) Tiam1-IRSp53 complex
formation directs specificity of Rac-mediated actin cytoskeleton regulation. Mol
Cell Biol 25: 4602-4614.
Price MO, Atkinson SJ, Knaus UG, Dinauer MC (2002) Rac activation induces
NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide
production is exchange factor-dependent. J Biol Chem 277: 19220-19228.
Zhou K WY, Gorski JL, Nomura N, Collard J, Bokoch GM (1998) Guanine
nucleotide exchange factors regulate specificity of downstream signaling from
Rac and Cdc42. J Biol Chem 273: 16782-16786.
Mackay HJ, Twelves CJ Targeting the protein kinase C family: are we there yet?
Borthakur G, et al. (2007) Phase I study of s-trans, trans-farnesylthiosalicylic acid
(FTS), a novel oral Ras inhibitor, in patients with refractory hematologic
malignancies. J Clin Oncol (Meeting Abstracts) 25: 7071-.

170

155.
156.
157.

158.

159.
160.
161.

162.

163.
164.

165.

166.

167.
168.

169.
170.

171.
172.

Barkan B, et al. (2006) The Ras inhibitor farnesylthiosalicylic acid as a potential
therapy for neurofibromatosis type 1. Clin Cancer Res 12: 5533-5542.
Khwaja A, et al. (2005) The inhibition of human mesangial cell proliferation by
S-trans, trans-farnesylthiosalicylic acid. Kidney International 68: 474-486.
Debreceni B, et al. (2004) Mechanisms of guanine nucleotide exchange and Racmediated signaling revealed by a dominant negative Trio mutant. J Biol Chem
279: 3777-3786.
Sun D, Xu D, Zhang B (2006) Rac signaling in tumorigenesis and as target for
anticancer drug development. Drug resistance updates: reviews and
commentaries in antimicrobial and anticancer chemotherapy 9: 274-287.
Soderling SH, Scott JD (2006) Wave signaling: from biochemistry to biology.
Biochem Soc Trans 34: 73-76.
Melo JV, Chuah C (2008) Novel agents in CML therapy: tyrosine kinase
inhibitors and beyond. Hematology 2008: 427-435.
Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J (2007) Important
therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 13: 10891097.
Roumiantsev S, et al. (2002) Clinical resistance to the kinase inhibitor STI-571 in
chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain Ploop. Proc Natl Acad Sci USA 99: 10700-10705.
Gallo S, et al. (2006) Kinetic studies of HIV-1 and HIV-2 envelope glycoproteinmediated fusion. Retrovirology 3: 90.
Melikyan G, Egelhofer M, von Laer D (2006) Membrane-anchored inhibitory
peptides capture human immunodeficiency virus type 1 gp41 conformations that
engage the target membrane prior to fusion. J Virol 80: 3249 - 3258.
Chernomordik L, et al. (1998) The pathway of membrane fusion catalyzed by
influenza hemagglutinin: restriction of lipids, hemifusion, and lipidic fusion pore
formation. J Cell Biol 140: 1369 - 1382.
Subramanian RP, Geraghty RJ (2007) Herpes simplex virus type 1 mediates
fusion through a hemifusion intermediate by sequential activity of glycoproteins
D, H, L, and B. Proc Natl Acad Sci USA 104: 2903-2908.
Viard M, et al. (2004) The role of glycosphingolipids in HIV signaling, entry and
pathogenesis. Glycoconj J 20: 213 - 222.
Zandy NL, Pendergast AM (2008) Abl tyrosine kinases modulate cadherindependent adhesion upstream and downstream of Rho family GTPases. Cell
Cycle 7: 444-448.
Zandy NL, Playford M, Pendergast AM (2007) Abl tyrosine kinases regulate cellcell adhesion through Rho GTPases. Proc Natl Acad Sci USA 104: 17686-17691.
Leng Y, et al. (2005) Abelson-interactor-1 promotes Wave2 membrane
translocation and Abelson-mediated tyrosine phosphorylation required for Wave2
activation. Proc Natl Acad Sci USA 102: 1098-1103.
Backert S, Feller SM, Wessler S (2008) Emerging roles of Abl family tyrosine
kinases in microbial pathogenesis. Trends in Biochemical Sciences 33: 80-90.
Rix U, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors
imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood
110: 4055-4063.

171

173.
174.
175.
176.
177.

178.

179.
180.

181.
182.
183.
184.
185.

186.

187.

188.
189.

190.

Swingler S, et al. (2007) Apoptotic killing of HIV-1 infected macrophages is
subverted by the viral envelope glycoprotein. PLoS Pathog 3: e134.
Cohen F, Markosyan R, Melikyan G (2002) The process of membrane fusion:
nipples, hemifusion, pores, and pore growth. Curr Top Membranes 52: 501 - 529.
Blumenthal R, Clague M, Durell S, Epand R (2003) Membrane fusion. Chem Rev
103: 53 - 69.
Chernomordik L, Zimmerberg J, Kozlov M (2006) Membranes of the world
unite! J Cell Biol 175: 201 - 207.
Daecke J, Fackler O, Dittmar M, Krausslich H (2005) Involvement of clathrinmediated endocytosis in human immunodeficiency virus type 1 entry. J Virol 79:
1581 - 1594.
Cavrois M, De Noronha C, Greene W (2002) A sensitive and specific enzymebased assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat
Biotechnol 20: 1151 - 1154.
Kolokoltsov A, Davey R (2004) Rapid and sensitive detection of retrovirus entry
by using a novel luciferase-based content-mixing assay. J Virol 78: 5124 - 5132.
Saeed M, Kolokoltsov A, Davey R (2006) Novel, rapid assay for measuring entry
of diverse enveloped viruses, including HIV and rabies. J Virol Methods 135: 143
- 150.
Tobiume M, et al. (2003) Nef does not affect the efficiency of human
immunodeficiency virus type 1 fusion with target cells. J Virol 77: 10645 - 10650.
Brandenburg B, Zhuang X (2007) Virus trafficking - learning from single-virus
tracking. Nat Rev Microbiol 5: 197 - 208.
Sougrat R, et al. (2007) Electron tomography of the contact between T cells and
SIV/HIV-1: implications for viral entry. PLoS Pathog 3: e63.
Tristram-Nagle S, Nagle J (2007) HIV-1 fusion peptide decreases bending energy
and promotes curved fusion intermediates. Biophys J 93: 2048 - 2055.
Gallo S, Puri A, Blumenthal R (2001) HIV-1 gp41 six-helix bundle formation
occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Envmediated fusion process. Biochemistry 40: 12231 - 12236.
Ducrey-Rundquist O, Guyader M, Trono D (2002) Modalities of interleukin-7induced human immunodeficiency virus permissiveness in quiescent T
lymphocytes. J Virol 76: 9103-9111.
Brelot A, Heveker N, Montes M, Alizon M (2000) Identification of residues of
CXCR4 critical for human immunodeficiency virus coreceptor and chemokine
receptor activities. J Biol Chem 275: 23736-23744.
Doranz BJ, et al. (1999) Identification of CXCR4 domains that support coreceptor
and chemokine receptor functions. J Virol 73: 2752-2761.
Hesselgesser J, et al. (1997) CD4-independent association between HIV-1 gp120
and CXCR4: functional chemokine receptors are expressed in human neurons.
Curr Biol 7: 112-21.
Venkatesan S, et al. (2001) A membrane-proximal basic domain and cysteine
cluster in the C-terminal tail of CCR5 constitute a bipartite motif critical for cell
surface expression. J Biol Chem 276: 40133-40145.

172

191.

192.
193.
194.
195.
196.

197.

198.
199.
200.

201.

202.

203.
204.
205.
206.

207.
208.

Venkatesan S, et al. (2002) Reduced cell surface expression of CCR5 in CCR5
{delta}32 heterozygotes is mediated by gene dosage, rather than by receptor
sequestration. J Biol Chem 277: 2287-2301.
Goga A, et al. (1995) Alternative signals to RAS for hematopoietic transformation
by the BCR-ABL oncogene. 82: 981-988.
Lin J, Arlinghaus R (2008) Activated c-Abl tyrosine kinase in malignant solid
umors. 27: 4385-4391.
Parmar K, Rosenberg N (1996) Ras complements the carboxyl terminus of v-Abl
protein in lymphoid transformation. J Virol 70: 1009-1015.
Ren R YZ, Baltimore D. (1994) Abl protein-tyrosine kinase selects the Crk
adapter as a substrate using SH3-binding sites. Genes Dev 8: 783-795.
Raffel GD, Parmar K, Rosenberg N (1996) In vivo association of v-Abl with shc
mediated by a non-phosphotyrosine-dependent SH2 interaction. J Biol Chem 271:
4640-4645.
Renshaw MW LJ, Schwartz MA. (2000) The c-Abl tyrosine kinase contributes to
the transient activation of MAP kinase in cells plated on fibronectin. Oncogene
19: 3216-3219.
Sini P, et al. (2004) Abl-dependent tyrosine phosphorylation of Sos-1 mediates
growth-factor-induced Rac activation. 6: 268-274.
Sirvent A, et al. (2007) The tyrosine kinase Abl is required for Src-transforming
activity in mouse fibroblasts and human breast cancer cells. 26: 7313-7323.
Melikyan GB, Brener SA, Ok DC, Cohen FS (1997) Inner but not outer
membrane leaflets control the transition from glycosylphosphatidylinositolanchored influenza hemagglutinin-induced hemifusion to full fusion. J Cell Biol
136: 995-1005.
Zavorotinskaya T, Qian Z, Franks J, Albritton LM (2004) A point mutation in the
binding subunit of a retroviral envelope protein arrests virus entry at hemifusion.
J Virol 78: 473-481.
Chernomordik LV, et al. (1997) An early stage of membrane fusion mediated by
the low pH conformation of influenza hemagglutinin depends upon membrane
lipids. J Cell Biol 136: 81-93.
Barrero-Villar M, et al. (2008) PI4P5-kinase I{alpha} is required for efficient
HIV-1 entry and infection of T cells. J Immunol 181: 6882-6888.
Syriani E, et al. (2008) Profilin induces lamellipodia by growth factorindependent mechanism. FASEB J 22: 1581-1596.
Yoder A, et al. (2008) HIV envelope-CXCR4 signaling activates cofilin to
overcome cortical actin restriction in resting CD4 T cells. 134: 782-792.
Popik W, Alce TM, Au W-C (2002) Human immunodeficiency virus type 1 uses
lipid raft-colocalized CD4 and chemokine receptors for productive entry into
CD4+ T cells. J Virol 76: 4709-4722.
Manes S, et al. (2000) Membrane raft microdomains mediate lateral assemblies
required for HIV-1 infection. Embo J 1: 190-196.
Stantchev T, et al. (2007) The tyrosine kinase inhibitor genistein blocks HIV-1
infection in primary human macrophages. Virus Res 123: 178 - 189.

173

